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Cancer is one of the leading causes of mortality worldwide, with around 14 
million new cases in 2012 
1
. It is expected that this number will increase up to 
20 million around 2025, which means that the cumulative risk factor of people 
who will be afflicted with a form of cancer, which is now already 18.5%, will 
increase further over the upcoming years. The common goal of many research 






Cancer can be defined as the rapid creation of abnormal cells that have the 
ability to divide and grow uncontrollably beyond their usual boundaries, after 
which they can spread and invade in other organs 
3
. Although this definition is 
clear, a tumor is more complex than a mass of proliferating cancer cells. It is a 
heterogeneous and complex disease regulated by genomic alterations. The 
complexity is due to the different locations and number of alterations or 
mutations between cancer types and between patients with the same type of 
cancer. Some mutations will create oncogenes which will work in favor of the 
tumor and others will lead to a loss of function of tumor suppressor genes. In 
addition, the transformation from a normal cellular environment into a 
malignant tumor environment, tumorigenesis, is a multi-step process. This 
process is reflected by genetic alterations in the regulatory circuits of cells 
which normally would maintain homeostasis. Although a lot of processes are 
involved, some molecular, biochemical, and cellular characteristics are shared 
by most tumors. Those alterations are rationalized by the well-known cancer 




Figure 1: Cancer Treatment  
IGS= image-guided surgery (figure is adapted from 
4
). 
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nowadays, these molecular alterations do not play a major role in the 
treatment decision process. 
 
Cancer treatment 
There is no doubt that cancer will remain a significant healthcare problem for 
the years to come. Fortunately, early diagnosis and improvements in therapy, 
including neo-adjuvant treatments, have led to serious improvements in 
survival rates and quality of life. However, due to the fact that there are more 
survivors, there is also an increase in late toxic side effects which will influence 
the quality of life in a negative manner 
8,9
. Surgical interventions, systemic 
treatments and radiotherapy or a combination thereof, are the main 
treatment modalities for cancer 
10
. Whenever possible, surgery is the first 
choice to treat localized disease (Figure 1) 4,11. In case of locally advanced 
disease, patients can be offered neo-adjuvant treatment before surgery (as 
shown in Figure 1). The goal of this therapy is to reduce tumor invasion and 
size of the primary tumor allowing radical or more organ sparing surgery and 







With the aim of improving the clinical outcome of cancer patients, cancer 
research is directed towards developing personalized and targeted treatments 
to increase the specificity in eradicating the cancer cells and sparing healthy 
tissue 
10
. Diagnosis, staging and treatment planning are determined by several 
techniques, and imaging is indispensable to provide information about the 
tumor biology and anatomical structures. Frequently used imaging modalities 
to gain information about the anatomical structures involved are computed 
tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) and 
conventional radiography. Although anatomical imaging provides information 
about tumor morphology, it does not always give functional information about 
the tumor. Molecular imaging techniques can provide valuable functional 
information. In general, with molecular imaging it is possible to non-invasively 
visualize, characterize and measure biological processes of the tumor and the 
tumor micro-environment at a molecular level 
14
. The most well-known and 
clinical used molecular imaging techniques are single photon emission 
tomography (SPECT) and positron emission tomography (PET).  
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For intra-operative imaging, the use of optical imaging is gaining interest and 
is nowadays widely used in both clinical and pre-clinical research 
15
. The 
additional value of near-infrared fluorescence in the range of 700-900 nm over 
lower wavelength fluorescence is a higher tissue penetration of up to a 
centimeter and low auto fluorescence 
16
. The drawbacks are the lack of whole 
body overview and still the limited penetration depth. Therefore, combining 
techniques like optical and nuclear imaging can have synergistic effects (Figure 
2). The same is true for the introduction of PET-CT as hybrid imaging modality. 
Both single modalities, PET as molecular modality and CT as morphological 
modality, lack the requirements for an accurate and complete in vivo 
assessment. However, together providing anatomical, physiological, biological 
and molecular information this problem will be solved 
5,15
. The specifications 
of several imaging techniques and the use of hybrid techniques are discussed 
more in depth in Chapter 2. 
 
Targets 
For molecular imaging the use of a-specific contrast agent the so-called 
molecular imaging agent is required as the goal is to assess the expression or 
function of a dedicated molecular target 
14,17
. There are two main approaches 
of developing a targeting agent by conjugation or by structure-mimicking. The 
first is the most widely used method in which a contrast agent consists out of 
a targeting moiety associated with the molecule of interest, a contrast-
enhancing agent dependent on the type of imaging modality and a linker to 
connect those two parts. The other approach is to chemically modify a 
molecule that naturally interacts with the molecule of interest. With this 






Figure 2: Information of content visualized. 
Green is capable of visualizing this type of information, red is not. (figure is adapted from 
5
). 
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Using a targeted contrast agent is called active targeting, however, passive 
targeting is also possible via the enhanced permeability and retention effect 
(EPR) by which molecules leak into the tumor 
19
. The drawback of passive 
targeting in combination with surgery is that the targeting is a-specific and, as 
discriminating the boundary of a tumor is essential during surgery, agents that 
leak into the core of the tumor are not the best candidates 
19-21
.  
In general, targets can be divided in a genetic and a mechanistic class. The first 
represents genes or gene products that carry mutations or that lead to a 
higher disease risk. In our genome, which consists out of 25.000 genes, around 
1800 genes are involved in diseases such as cancer. This means, including 
post-translational modifications, over 40.000 different proteins are available 
as possible target 
22
. The second class of targets consists of receptors and 
enzymes which are, in general, not different from the normal population, they 
do not have any mutation. However, biological observations detected that 
their behavior differs from a normal situation. This suggests that they might be 
involved in a tumor process and by this be an interesting target 
21,23
. When an 
interesting target is found, an agent is developed towards a binding pocket in 
the target of interest and, when necessary, afterwards modified to enhance 
the pharmacokinetics and pharmacodynamics before it could be used as 
targeted contrast agent 
24
.  
The general aim of this thesis is double, first to improve image-guided surgery 
(IGS) via innovative imaging modalities in combination with targeted contrast 
agents which will lead to improved intra-operative visualization of resection 
margins during surgery. Second, for patients who undergo neo-adjuvant 
therapy, the aim is to ameliorate treatment response monitoring already in an 
early stage after start of treatment. Therefore, the second part of this thesis 
will focus on detecting the amount of necrosis, as biomarker, after 
chemotherapy and/or radiotherapy. The background information of each part 
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Part I: Image-guided Surgery 
 
As mentioned above multiple imaging modalities have proven to be essential 
for cancer diagnostics, providing much information about the tumor before 
surgery 
25,26
. However, during surgery, when the anatomy changes due to 
manipulation, the surgeon relies on palpation and visual inspection to 
accurately determine whether the resection margins are tumor free 
27-29
. In 
oncologic surgery, clean and clear demarcation of the tumor boundaries is 
essential for proper removal of the tumor. There is a fine balance between 
achieving tumor free resection margins and sparing healthy tissue and organ 
function. Therefore, visualization of the tumor borders with a high sensitivity 
is essential for an optimal and safe removal of the cancer lesion 
30,31
. The eyes 
and hands of a surgeon are useful, but cannot determine the boundaries of a 
tumor at a microscopic level 
29
. Therefore, the risk remains of an irradical 
resection of the tumor, also known as an R1 resection. For instance, in breast 
cancer patients, undergoing breast sparing surgery, the percentage of R1 
resections is around 20% 
27,28,32,33
. To improve cure rates, it is important to 
decrease local recurrence rates as well as complication rates. To reach this 
goal, intra-operative assistance, using additional visualization tools could be 
helpful. Nowadays, during oncologic surgery intra-operative ultrasound or x-
ray fluoroscopy are the only two modalities which provide real-time 
visualization. Drawbacks of these modalities are the necessity of direct contact 
with the body, the use of ionizing radiation and the current lack of availability 
of targeted contrast agents 
27
. The details about the imaging systems are 
discussed more in depth in Chapter 2. 
Up to now, in clinical trials, tumor specific optical IGS is already performed 
with several agents, such as 5-ALA for gliomas
34
, folate-near infrared (NIR) 
fluorophore for ovarian cancer 
35,36
 and bevacizumab-IRDye800CW (in 
combination with hyperthermic intra-peritoneal chemotherapy (HIPEC)) for 
peritoneal carcinomatosis 
37
. Results obtained from these trials are two-sided 
with promising results and hurdles which need to be overcome for a broader 
clinical implementation. These studies demonstrated that fluorescence 
imaging did not interfere with the standard surgical procedure, showed real-
time identification of the tumor and was able to reduce overtreatment, due to 
a higher number of R0 resections. The two main problems encountered are 
the high amount of false-positive findings of lymph nodes in particular and the 
limited penetration depth of optical imaging 
34,35,37,38
. For the development of 
new IGS approaches, there is a need for dedicated targeted contrast agents 
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with high tissue specificity and a high tumor to background ratio (TBR) for a 
more detailed visualization of the tumor (Chapter 3) in combination with 





Part II: Necrosis Imaging 
 
Treatment evaluation 
Most systemic anticancer therapies are effective only for a subgroup of 
patients. Unfortunately, up to now there are only limited possibilities to 
stratify patients for specific treatments. Therefore, it is difficult to predict 
upfront which patient will benefit from a certain treatment and which one will 
not 
39
. Currently, the treatment regimen is based on population based 
statistics, which have limited value for the individual patient. Evaluation of the 
treatment is nowadays generally based on measuring tumor shrinkage at a 
late stage during and after treatment mostly based on the RECIST criteria; 
Response Evaluation Criteria in Solid Tumors. Those criteria are generally used 
as end points in clinical trials or for routine clinical decision making in order to 
decide to stop, continue or switch to another treatment 
40-42
. Nevertheless, 
monitoring the anti-cancer efficacy of a therapy at an early stage of treatment 
would have multiple advantages 
39
. Existing methods for the determination of 
tumor markers in blood lack the accuracy for a broad routine application for 
treatment response monitoring 
43,44
. Early evaluation of the therapy efficacy 
would facilitate the growing interest for individualized cancer treatment, 
allowing the clinician to adjust the therapy based on tumor response and 




As discussed above, morphologic changes often can only be detected several 
weeks to months after the start of treatment. Functional and molecular 
alterations, on the other hand, occur much faster, already in the first weeks 
after start of treatment. Most of those molecular alterations are in a way 
related to restoring homeostasis and creating cell death. For this reason cell 
death is a biological process which can also be used as biomarker of tumor 





Cell death is a process that is reversible until the first irreversible step is made. 
Different steps could represent this phase but a cell is considered death when 
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the cell has lost its membrane integrity, undergone complete fragmentation 
and when the cell corpse is engulfed by an adjacent cell. This diversity leads to 
a high variety of types of cell death which are classified according to its 
morphology, enzyme involvement, functional aspects and immunological 
characteristics 
48
. Nevertheless, it is possible to narrow it down to the two 
fundamental and most well-known types of cell death; apoptosis and necrosis 
39,45,48,49
. In general, apoptosis is required to maintain homeostasis and the 
main mechanism by which cells die in the human body 
39,49
. Necrosis is the 
result of metabolic failure and usually occurs in response to acute hypoxic or 
ischemic injury
49
. Based on the facts above, it implies that the process of cell 
death in apoptosis and necrosis are clearly distinct from each other. However, 
when the number of cells in apoptosis is too high for the phagocytes to 
eradicate them, this will lead to secondary necrosis. Secondary necrosis is also 




In part II of this thesis, the value of intra-tumor necrosis, as unique biomarker, 
is investigated. Necrosis is used to monitor the anti-cancer efficacy of a 
treatment at an early stage after start of treatment. Necrotic cell death plays a 
prominent role in multiple pathological and physiological disorders; especially 
in cancer as tumor necrosis is associated with tumor aggressiveness and 
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Chapter overview 
In Figure 3 a graphical overview of the thesis is visualized, when comparing 
this figure to Figure 1 a close comparison can be found between a cancer 
treatment and this thesis. 
 
In Chapter 2, an overview is provided of the state of the art imaging modalities 
which can be used intra-operatively. Next to the imaging modalities, 
mentioned in this thesis, several applications of molecularly IGS will be 
discussed. The image quality of most of these techniques can be improved by 
using a dedicated contrast agent. Targets upregulated at the cell surface, 
abundantly present on tumor cells and absent on surrounding healthy cells are 
the best candidates to be used for IGS.  
In Chapter 3, two proteins, the transmembrane receptor tyrosine kinase 
EphA2 and EphB4, are evaluated as possible targets for IGS in colorectal 
cancer on a tissue microarray. In this chapter, EphA2 is derived from the 
National Cancer Institute (NCI) prioritization list and is known to be highly 
overexpressed on a high variety of tumor types, including colorectal cancer. 
EphA2 is compared to the family member EphB4 from another class 
21
. EphB4, 
a member of the B class of the same family is upregulated in many solid 
tumors. However, for both EphA2 and EphB4 their expression in healthy tissue 
has not been investigated. In this chapter, the TBR of both proteins will be 
 
Figure 3: Thesis outline. 
(FLI=Fluorescence imaging, FGS=Fluorescence guided surgery, MSOT=Multispectral 
optoacoustic tomography, SPECT=Single-photon emission computed tomography, 
OA=Optoacoustic imaging). 
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In Chapter 4 the additional value of a new imaging modality, multispectral 
optoacoustic tomography (MSOT) is assessed. MSOT uses light as a source and 
acoustics for signal detection to create images which enables the visualization 
of optical absorbing agents at a high resolution similar to optical imaging. 
However, the main advantage of MSOT compared to optical imaging is the 
accurate spatial localization within deep tissue since the detection is not 
limited by photon scattering enabling a higher depth penetration 
57,58
. In this 
chapter, the additional value of MSOT is compared to a couple existing 
fluorescence imaging modalities. The value and the results obtained with 
MSOT and the other modalities are validated both in and ex vivo by using an 
orthotopic pancreatic ductal adenocarcinoma (PDAC) mouse model targeted 




The second part of the thesis will focus on different imaging techniques to 
visualize tumor necrosis.  
In Chapter 5, two novel optical necrosis avid contrast agents, IRDye800CW 
and HQ5 are identified and evaluated. Those contrast agents both belong to 
the group of carboxylated cyanine dyes which are in general mentioned as 
non-reactive and control compounds. In addition, IRDye800CW and HQ5 both 
belong to the group of near-infrared dyes. Their necrosis avidity is validated in 
vitro and in vivo in mouse breast cancer tumor models of spontaneous 
necrosis or necrosis induced by chemotherapy. 
In Chapter 6, one of the family members of HQ5, HQ4, is equipped with a 
radioactive moiety to facilitate the clinical translation in the future. Near-
infrared dyes have a tissue penetration of up to a centimeter. However, a 
tissue penetration of one centimeter still limits a broad clinical application. By 
using radioactivity the penetration depth is unlimited. In addition, with the 
use of radioactivity, quantitative biodistribution studies were performed to 
get more insight in the behavior of the agent. 
In Chapter 7, the knowledge gained in the previous two chapters is further 
extrapolated by evaluating HQ4 for monitoring tumor cell death induced by 
radiation therapy in a clinically relevant MCF-7 human breast cancer mouse 
model. Furthermore, the multimodal imaging properties of the necrosis avid 
contrast agent were assessed with the addition of a third imaging modality, 
optoacoustic or photoacoustic imaging. Optoacoustic imaging is similar to 
MSOT with the only difference that MSOT uses a multispectral illumination 
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approach in order to differentiate even more specific spectral signatures of 
exogenous or endogenous contrast agents
62
. This modality is tested because it 
has the benefit of a higher tissue penetration as compared to optical imaging 
and it overcomes the drawbacks associated with the use of ionizing radiation.  
 
Finally, in Chapter 8 a general discussion is provided, including a summary and 
the future perspectives of multimodal image-guided interventions are 
addressed.  
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Surgery is the cornerstone of treatment for many solid tumors. Whereas a 
wide variety of imaging modalities are available before surgery for staging, 
surgeons still primarily rely on visual and haptic cues in the operating 
environment. Image- and molecular-guidance  might improve the adequacy of 
resection through enhanced tumor definition and detection of aberrant 
deposits. Available intra-operative modalities for image- and molecular-guided 
cancer surgery are reviewed here. 
  
Procedures 
Intra-operative cancer detection techniques were identified through a 
systematic literature search selecting peer-reviewed publications from January 
2012 to January 2017. Modalities are reviewed, described and compared 
according to twenty-five pre-defined characteristics. To summarize the data in 




Our search identified ten image- and molecular-guided surgery techniques, 
which can be divided in four different groups: conventional, optical, nuclear 
and endogenous reflectance modalities.  The conventional modalities are the 
most well-known imaging modalities unfortunately have the drawback of a 
defined resolution and long acquisition time. Optical imaging is a real-time 
modality, however, the penetration depth is limited. Nuclear modalities have 
excellent penetration depth, however, their intra-operative use is limited by 
the use of radioactivity. The endogenous reflectance modalities provide high 
resolution, although with a narrow field of view. 
  
Conclusions 
Every modality has its own strengths and weaknesses, not one single modality 
will be suitable for all surgical procedures. Strict selection of modalities per 
cancer type and surgical requirements is required as well as combining 
modalities in order to find the most optimal balance.  
 
  




Over the last decades, multiple imaging modalities have emerged as essential 
tools in cancer diagnostics, providing information about the molecular and 
functional processes in normal and diseased tissues 
1
. New technologies have 
been developed to enhance our understanding of the diversity and behavior 
of cancer in vivo 
2
. Despite these resources, surgeons still primarily rely on 
their eyes and hands as tools during surgeries 
3-5
. In oncologic surgery, clean 
and clear demarcation of the tumor boundaries is pivotal to determine the 
balance between excising too little or too much tissue. Therefore, a careful 
examination of the tumor borders is essential 
6,7
. Preoperative imaging does 
not always correlate well with intra-operative images due to tumor growth, 
deformation of soft tissue, shifting of organs or misalignment of the image 




As Rosenthal et al. discussed for breast, melanoma and head-neck cancer 
patients, surgical excision requires 3 detection steps: initial assessment before 
resection;  initial assessment during incision including detection of regional 
metastasis as well as lymph nodes; and post resection margin analysis by the 
pathologist
9
. Eyes and hands cannot detect the exact boundaries of a tumor or 
create a clear 3D morphologic or functional overview of the operative site 
5
. 
As a result, histologic tumor involvement of the resection margins may be 
observed in  patients with breast cancer at least 20% of the time 
3,4,9,10
. In 
order to improve cure and complication rates, the use of intra-operative in 
vivo and real-time tools would be useful. To achieve this requires spatial 
resolution better the human eye, minimal interference with daily practice, 
operator friendly instrumentation that is time efficient 
11
. To go beyond 
visualization of anatomic boundaries, real-time molecular information would 
provide additional information to optimize surgical resection.  
 
 The focus of this review was intra-operative modalities for image- and 
molecular-guided cancer surgery.  
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Twenty-five characteristics were selected to evaluate and compare the ten 
different IGS modalities reviewed here (Table 1-6). As Weissleder and Pittet 
state: “for imaging technologies to be adapted more widely and to be 
complementary to other types of imaging the read-outs need to meet certain 
criteria; they need to be quantitative, high resolution, longitudinal, 
comprehensive, standardized, digital and sensitive” 
2
. This statement refers to 
cancer imaging in general but the requirements apply equally well to image- 




The chosen characteristics are based on relevant articles, which were found 
through PubMed searches (January 2012-January 2017) using one or more of 
the following keywords; “surgery,” “cancer,” “oncology,” and the specific 
names of the (imaging) modalities. Further searches were carried out for 
specific performance characteristics, e.g., resolution. Abstracts were reviewed 
and  full-text articles obtained where possible. References and linked articles 
from included papers were  studied to identify further relevant information.  
 
To summarize the data in a comparable way, a three-point rating was applied 
to quantitate image-guided surgery (IGS) characteristics. These ratings are 
detailed as footnotes to the tabulated results. User friendliness was 
determined from discussions with end-users but differ from user to user, 




Our study identified ten modalities which could be used for image guidance 
during surgery. Example imaging systems for each modality, along with a 
representative clinical image, are visualized in Figure 1-3. In general, the 
modalities can be classified into four groups: conventional, optical, nuclear, 
and endogenous reflectance.  Each modality is discussed below, and the 
characteristics of each are tabulated for comparison (conventional in Table 1 
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Figure 4: Graphical representation of the IGS modalities, with respect to optimal resolution 
(x-axis) maximum penetration depth (y-axis) and average acquisition time (icon). 
Comparison between modalities 
Modalities within each group are compared in tables below, and it is also 
possible to compare between groups (across multiple tables). 
 
Table 1 provides information for conventional modalities already familiar to 
many practitioners, the imaging modalities are described along with the type 
of information that is obtained together with the surgical interference and 
associated risks. Table 2 and Table 3 provide the same information for optical 
and nuclear, and endogenous reflectance techniques respectively.  
 
The same groupings are used for Tables 4, 5 and 6, which compare the 
performance of each modality during surgery, including the criteria that 
Weissleder and Pittet mention as being essential 
2
. Tables 4-6 additionally 
provide information about the clinical potential and major challenges for 
clinical implementation of each of the ten modalities.  
Figure 4 provides a fast comparison of all ten modalities based on 
characteristics most interesting in clinical practice - penetration depth, 
resolution and acquisition. This clearly demonstrates a common trade off in 
image-guided surgery, a greater penetration depth often coincides with a 
degradation of resolution. 
32 │ Modalities for IGS                                                                      Chapter 2 




The use of non-invasive imaging for disease diagnosis has become a standard 
operating procedure and these conventional modalities are widely available. 
The current golden standard consists of conventional imaging modalities that 
yield anatomical and macroscopic structure information. The images and 
information obtained with any new technologies must be compared with 




iMRI (intraoperative Magnetic Resonance Imaging) 
To be able to use an MRI intraoperatively, MR compatibility of surgical 
equipment needs to be guaranteed together with special policies for safety 
and staff training. The implementation of these special policies can be 
prohibitively expensive although the costs are dependent on the field strength 
of the system. High field systems (>1.0 T) require far more investment as 
shielding of the operating room is essential but provide high resolution images  
within a shorter acquisition time. Low-field systems (< 0.3T) are cheaper since 
no additional requirements for the operating room (OR) are necessary and so 
they can be integrated into existing ORs
17
. Another advantage of using a low-
field system is the availability of open systems, which is more useful during 
surgery. Nevertheless, the lower the field strength the lower the image quality 
or the longer the scan time 
21,26
.  
Figure 1: Conventional image-guided surgery systems and examples of image output.  
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The main reason to still make use of an MRI during surgery,  despite these 
limitations, in neurosurgery it has been proven that the maximum amount of 




iCT (intraoperative Computed Tomography) 
In general CT offers high throughput with high-resolution imaging, however, 
this is not the case when used as an intraoperative imaging modality. 
Acquiring a CT during surgery takes 10-15 minutes, partly due to the 
interference caused by the shape of the gantry, as using a bore will cause 
more interference compared to a C-arm. When using the CT for assessing 
surgical specimens instead of the cavity, a micro-CT can be used in this way 
there is less interference of the surgery and a high spatial resolution of <1 µm. 
Nevertheless, the accuracy of margin assessment is variable due to specimen 
orientation and there can be a high rate of nonspecific findings due to dense 
parenchyma and architectural distortion due to the surgery 
36
.   
 
ioUS (intraoperative Ultrasound) 
Of the conventional imaging modalities ultrasound is the easiest technique to 
incorporate intraoperatively as it does not cause interference with surgery or 
logistical challenges, gives real time information and surgeons are already 
used to interpreting the images obtained. In addition, ioUS is one of the most 
sensitive imaging modalities for assessing small lesions due to the high 
frequency transducer which can be used. In addition to sensitivity, the 
specificity of discrimination between healthy tissue and residual disease is a 
benefit of this technique 
25
.  As ioUS can be used in an iterative mode one, 
should be aware of an essential drawback - surgical manipulation can cause 





Optical imaging techniques such as fluorescence guided surgery (FGS) and 
multispectral optoacoustic tomography (MSOT) can provide real-time 
feedback with limited workflow disruption. They require a targeted probe 
which consists of a fluorophore belonging to the near infrared window 
(~700 nm to 900 nm) which has the largest penetration depth in tissue of 
optical light. In this window, penetration is one centimeter for FGS or a few 
centimeter with MSOT compared to only a couple of millimeters for 
wavelengths below 700 nm 
3,4,6,19
. There is also a window above 900 nm, the 
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so called second-window near infrared light (NIR2) ranging from 900 nm-1450 
nm. This window has the advantages of even deeper tissue penetration and 
low tissue auto fluorescence signals which will lead to higher tumor to 
background ratios (TBRs). Animal study in vivo testing has shown a 
penetration depth of up to 18 mm, and simulations suggest that this might be 
increased to up to 10 cm 
31-33
. To make use of this NIR2 window new 
instrumentation will be required. Specific probes for use in this range goes 
beyond the scope of this review, however single-walled carbon nanotubes or 




FGS (Fluorescence Guided Surgery) 
FGS has the advantage of providing real-time, relatively cheap, user friendly, 
and not interfering the surgical area. However, also several disadvantages 
exists, such as the limited penetration depth of maximum 10 mm and 
challenges in quantification due to other processes that are associated with 
the use of light, such as photobleaching, transmission and reflection changes. 
Light in general is attenuated by absorption and scatter in tissue, the total 
attenuation (the sum of attenuation from absorption and scatter) has an 
exponential relationship with depth. This means practically that less than 
0.0001% of the photons transmitted into tissue can be detected and that of 
this amount only 10-25% of the photons generated in tissue will be really 
recovered. This is due to the relatively small quantum yield of most 
fluorophores and especially NIR fluorophores. Another limitation for 
quantification are absorption and scatter as those characteristics are highly 
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variable in tissue. Full correction, by measurements of the absorption, scatter 
and anisotropy of tissue, can lead to quantitative measurements, however this 
is still in its infancy 
3
. Another limitation for a full clinical translation is the lack 
of specific contrast agents. So far only 3 tumor specific agents are registered 
for clinical use. Several tumor-specific agents are in the process of clinical 





MSOT (Multispectral Optoacoustic Tomography) 
In general, MSOT deals with the same advantages and disadvantages as FGS 
with the difference that MSOT has a greater penetration depth. In addition, 
both FGS and MSOT are based on photon delivery but in optoacoustic 
tomography low frequency ultrasonic pulses are also detected. Those pulses 
are generally unaffected by tissue absorption and scattering, essentially 
removing a large component of the limiting factor in development of 
quantitative methods for fluorescence based imaging at depth. Given that the 
strength of an optoacoustic signal within a pixel is a function of both the 
diffusive light reaching that pixel and the concentration of absorber present, it 
is apparent that by determining or modeling the light propagation through the 
tissue, the concentration of a local chromophore can be determined. Work by 
both Tzoumas et al and Brochu et al has recently demonstrated that this result 
can be achieved both in phantoms and more importantly in vivo, giving a 






Nuclear modalities use a radioactive tracer to generate images with, in general 
although dependent on the tracer of choice, a high sensitivity and specificity 
34
. However, the use of radioactive material requires special biosafety permits, 
additional training, and safety procedures both for personnel and patients. 
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CLI (Cherenkov Luminescence Imaging) 
CLI is actually a combination of optical and nuclear imaging as the radioactive 
tracer in CLI is used to create optical photons. A drawback of this is that CLI 
has a similar tissue penetration as optical imaging of only a centimeter. On the 
other hand, the advantage is that the resolution is also similar to optical 
imaging which means that this is higher than any other nuclear imaging 
modality. Nevertheless, the intensity of the optical photons generated is 
about a billion times lower than the illumination in an operating room which 
makes it hardly suitable to use for open surgery, endoscopic applications 
would be favorable 
41
. This low light level negatively influences the sensitivity 
which can be improved by injecting a higher amount of radioactivity. The 
amount of radioactivity is well correlated with the light output, radiance, 
though an increase in radioactivity will also lead to an increase in radiation 
burden. 
 
SGCs (Small Gamma Cameras) 
Gamma cameras, like single-photon emission computed tomography (SPECT) 
can be considered a conventional modality. However, those systems face 
similar drawbacks as MRI and CT in that the size and shape of the machine 
causes a lot of surgical interference and actually need a dedicated scanning 
room.  To circumvent this, a handheld gamma probe is already used in clinical 
practice for sentinel lymph node detection. Although useful, these probes can 
only indicate the amount of activity within their field of view and do not have 
imaging capabilities. Innovative radiation detector design allow the generation 
of compact gamma cameras, small gamma cameras (SGCs) 
42
.  The differences 
between SPECT imaging  and SGCs is that with gamma imaging the sensitivity 
is dependent on the tracer but independent of the depth of the tumor and for 
SGCs there is a tradeoff between sensitivity and spatial resolution dependent 
on the imaging distance. In addition, the field of view (FOV) is smaller but 
dependent on the detector design.  
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Endogenous reflectance 
The last group of techniques encompasses a variety of endogenous 
reflectance/signals modalities. The advantage of this group is that no 
additional contrast agents are necessary to generate relevant and very 
detailed information based on the characteristics of the tissue itself. 
Nevertheless, creating high resolution output may require substantial 
acquisition times.  
 
RS (Raman Spectroscopy) 
In general, RS uses intrinsic properties of molecules to generate contrast 
which means RS is not limited to a certain tissue type although it requires a 
more specialized approach for skin pigments such as in melanoma. To create 
additional contrast, plasmonic particles or organic polymers coupled with 
antibodies could be used. Stimulated Raman scattering can be used to 
monitor dynamic changes, alterations in tissue cellularity, axonal density and 
protein / lipid ratio 
22
.   
 
A possible limitation of translating RS into clinical practice is the question of 
how small fields of view could be applied to the validation of a tumor bed, 
which is relative large. A clinical trial using this technique has detected low-
grade gliomas instead of the tumor bed. For this an image-resect-image 
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technique was used in which the arm movement was predefined. This method 
led to an additional operation time of 10 minutes for image acquisition which 




OCT (Optical Coherence Tomography) 
OCT has the advantage of being analogous to US which makes the images easy 
to interpret for a surgeon as they are already used to those types of images. 
Instead of sound, OCT uses the reflections of light. This means that OCT does 
not need direct contact with the surgical area however, due to differences in 
refractive index direct contact is desirable 
11,43,44
. Similarly to RS, OCT does not 
require a contrast agent but can use the same agents as used in optical 
imaging to generate additional contrast if needed. This opportunity to image 
without a contrast agent shortens the pathway towards full clinical translation 





REIMS (Rapid Evaporative Ionization Mass Spectrometry) 
Intra-operative molecular diagnostics based on mass spectrometry have 
recently gained attention from the medical field as it offers the possibility of in 
vivo, in situ, and real-time mass spectrometric analysis of tissue 
13,14
. In 
combination with electrosurgical devices 
15
, REIMS  promises to guide and 
optimize surgical resection in real-time as it is performed within a couple of 
seconds. Within this timeframe, the smoke generated by electrocautery is 
aspirated through tubing and a chemical analysis takes place, followed by real-
time data processing and finally quasi-instant visual feedback.  Nevertheless, 
to keep this speed there is the need for validated tissue-specific databases 
which require time to generate and a large clinical cohort to account for inter-
individual variability. It is expected that when this database is available any 
tissue can be analyzed 
12,13,28
. In addition, complex molecular  signatures can 
be identified which can increase the specificity over a single biomarker 
12
. 
Although it is not truly an ‘imaging’ technique, REIMS has the potential to 
improve surgical margins by molecular sampling of them 
16
 comparable to 
Mohs surgery for skin cancer in which, during surgery, the removed specimen 
is examined for cancer cells 
46
.   
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Table 1: Description of conventional image-guided surgery modalities and interference with surgical workflow. 
 iMRI iCT ioUS 
Principle MRI is based on the different 
spin relaxation rates of atoms 
within tissue under a static 
magnetic field and 
radiofrequency pulses via the 
excitation of hydrogen nuclei47. 
X-rays pass through the 
patient, are attenuated and 
subsequently measured by 
detectors which rotate around 
the patient48. 
The US probe transmits 
ultrasound waves, which are 
(partially) reflected and/or 
scattered by tissue 
inhomogeneities and interfaces 
and sent back to the probe49. 
Type of 
information 
Soft tissue discrimination and a 
multiplanar visualization26. 
Structural differences due to 
differences in absorbance36, 48. 
Contrast is based on 
scattering/ reflectance 
differences between different 
types of tissue: soft tissue, fat, 
and fluid43, 49. 
Anatomical 
information 
Yes, what, is dependent on the 
sequence17. 
Yes36. Yes, although orientation is 
limited due to the different 
planes27, 37. 
2D/3D 3D. 3D. 2D, 3D with specialized 




Not necessary  discrimination 
between two types of tissue 
can be improved17, 21. 
Not necessary  discrimination 
between two types of tissue 
can be improved23.  
Not necessary  discrimination 
between two types of tissue 
can be  improved and real time 
vascular phase images18, 25. 
Cost 
machine&facility 
€€€17. €€€24. €27, 37. 
Acq. Cost €€€




Max 2h21, 27, not real time. 10-15min23, 27, 36, not real time.  Real time interactive 
information 25, 27. Delay is 
dependent on the operator  
(max. a few minutes)37.  
Interference of 
surgery 
Yes, highly interfering. Position 
wise maybe even impossible17. 
Yes,  dependent on the 
modality and the possibility of 
a sliding gantry on a railtrack23, 
27. 
Not in general and it gives no 
logistical challenges37.  Yes, it 




No. No. Yes.  
Safety No, it can even detect 
complications in an earlier 
stage17, 21, 26. 
No complications or infections 
related to iCT and surgical 
complications were directly 
recognized23. 
Relatively safe and well 
tolerated25.  
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Table 2: Description of optical and nuclear image-guided surgery modalities and interference with surgical workflow. 
 FGS  MSOT CLI SGCs  
Principle An injected/ endogenous 
fluorophore is excited at 
a specific wavelength 
and the emitted 
fluorescent photons are 
detected6. 
Light is used as input 
energy and acoustics for 
signal detection, similar 
to US. Molecules 
absorbing light undergo 
transient thermos-elastic 
expansion which 
generates US waves11.  
Charged particles emit-
ted from radionuclides 
transfer energy as they 
move through a medium. 
If they travel faster than 
the speed of light, the 
transferred energy is 
released, through 
relaxation, as light 41.   
Radionuclides introduced 
to the patient emit 
gamma radiation. 
Gamma photons have 
sufficient energy to pass 
relatively unimpeded 
through tissue to be 




Presence of a 
fluorophore or specific 
tissue properties in a 
certain area6, 9 . 
The differences of optical 
absorption inside tissue 
is visualized11. 
Functional images based 





images based on the 









about tissue properties9.  
Yes, by strong endo-
genous absorbers like 
blood and melanin11. 
Interleaved with US 
images for mechanical 
contrast. 
No. No. 
2D/3D 2D. 2D and 3D.  2D
41. 2D or 3D depending on 
the detector system used 
Need for 
contrast agent 
Yes typically, however 
when using endogenous 
fluorescence signal a 
contrast agent is not 
necessary4, 9.  
Yes/no, detects 
endogenous tissue 
absorbers or exogenous 
contrast agents4. 
Yes, a particle-emitting 
radiotracer41. 




€4. €€. €41. €€. 
Acq. Cost €. €. €€




Real time, in the 
millisecond range, and 
related to the surgical 
field3, 4. 
Image generation is in 
real time. Possible to 
perform advanced 
analysis post process. 
Several minutes41, 53. Depends on the amount 
of activity vs SNR. In 
general, one minute is 
sufficient 29, 53. 
Interference  
of surgery 
No, as there is no direct 
contact with the speci-
men as the optimal wor-
king distance is between 
5-45cm19. A dark envi-
ronment is beneficial7. 
Not in general but yes, it 
needs to be contact 
based, similar to ioUS. 
Yes. Complete darkness 
is required for imaging.  
 
In addition, the use of 
radioactive tracers may 
have implications for 
working practice41. 
Not in general, there is 
no direct contact neces-
sary with the specimen.  
However, the use of 
radioactive tracers, may 
have implications for 
working practice.  
Endoscopic 
options  
Yes, with the Cellvizio® 
system56. 
Yes.  Yes57.  No. 
Safety NIR imaging is a safe 
technique only laser 
illumination levels needs 
attention 3. 
Similar to US in 
technique, so relative 
safe. Only the direct 
contact can cause 
problems. 
Radiation exposure for 
both patients and 
surgeons4. 
Radiation exposure for 
both patients and 
surgeons4. 
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Table 3: Description of endogenous reflectance image-guided surgery modalities and interference with surgical workflow. 
 RS OCT REIMS 
 Principle Monochromatic light from a 
certain wavelength illuminates 
tissue and scatters light with new 
wavelengths. The energy related 
to the wavelength shift is a 
function of the vibrational 
energies of molecular bonds in 
tissues22, 30.  
Is analogous to US, only reflections 
of  near-infrared light are detected 
instead of sound 45, 58, the 
information is obtained by 
differences in reflected energy and 
scattering intensity 43.  
An ambient ionization 
technique. Connected to an 
unmodified surgical 
handpiece, the system directly 
aspirates and analyses the 
smoke created by the electro-
surgical device from the 
surface of the tissue.  
 Type of 
 information 
Cellular structures can be 
distinguished based on the 
chemically specific Raman 
spectrum of metabolites, lipids, 
proteins, DNA30. 
Cross-sectional images are 
generated mimicking 
the intensity of optical backscatter 
of light passed through tissue58.  
 The identification is based on 
tissue-specific libraries 
(molecular profiles or 
fingerprints) to identify the 
tissue type 12. 
 Anatomical 
 information 
Yes, dependent on the 
technique30. 
Yes43, 58,tomographic images of 
biological tissue are generated 
(morphology)11, 30, 44. 
No, it is based on tissue-
specific molecular 
signatures28.  
 2D/3D 2D, 3D is possible by using stacked 
images or measure on a different 
depth. 
2D and 3D depending on the 
detector used45. 
There is a spectrum generated 
and not an image13, 15, 59. 
 Need for 
 contrast  
 agent 
No, it is a label-free method as it 
uses intrinsic properties of 
molecules 22.  
No, depends on the optical 
scattering and reflectance of tissue 
to generate contrast30, 44, 45. 
No, it is a label-free technique 
13, 15, 59. 
 
 Cost    
machine&facility 
€. €. €€28. 
 Acq. Cost €. €. €. 
 Time 
 acquisition&   
 reconstruction 
Short (1-10 min) 30. Spontaneous 
Raman scattering : acq time of 
0.05 second for a single high 
quality spectrum. Coherent Raman 
imaging is faster (µs/pixel)22, 30, 
with limited spectral quality. 
Real time11, 45, an image can be 
taken every 5s43, 58. Total 
acquisition time can be up to 
5min30, 44.  
A couple of seconds (< 3s) 13, 
28. The use of a real-time 
recognition algorithm allows 
for rapid identification of 
tissue being analyzed.  
 Interference   
 of surgery 
There is no direct contact needed. 
30. 
Yes/No, does not require direct 
contact with the specimen 11, 43, 44, 
rapidly scan large areas of tissue58.  
No, no modification of surgical 
procedure is required13. 
The tissue which is measured 
is destroyed during this 
process but this is the tissue 
that the surgeon is cutting12, 15.  
 Endoscopic  
 options  
Yes Yes43, 45, 58.  Yes 59. 
 Safety Reasonable, due to the weak 
signal high levels of light energy 
and exposure times are often 
needed60.  
Relative safe, similar to ultrasound 
and fast image acquisition43, 58. 
Relative safe 12. For the mass 
analyzer system, European 
norms have to be complied 
with.  
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Table 4: Performance and clinical potential of conventional image-guided surgery modalities. 
 iMRI iCT ioUS 
Resolution  Resolution around 0.3-1.3 mm
61, 
62. Improves with the scan time, 
and field strength17, 21, 62.  
Spatial resolution of 0.4-0.6mm4, 
27. 
For micro-CT <1um36. 
High spatial and temporal 
resolution around 0.3-1mm4, 25, 27, 
43. 
Field of View 
(FOV) 
Up to 20cm, although the 
distortion increases with the 
FOV63.  
14cm36. Dependent on the transducer  
curved transducer > linear 
transducerin the range 10-
60mm4. 
Iterative Yes, but mostly one scan is 
obtained21. 
Yes. Yes37. 
When to use 
during 
surgery. 
Can be used for surgical (re-) 
orientation and as quality 
control of the resection cavity17, 
21, 26. 
Can be used for surgical (re-) 
orientation and the micro-CT for 
lump margin assessment23, 36. 
Used for real-time surgical 
guidance in all stages25, 37, 52. 




Medium 17. Low. High18, 27, 52. 
User friendly  -/+, depends on the familiarity of 
the surgeon with MR image 
interpretation9.  
+ +27, 37, 52. 
Availability  -/+, Due to the high price and 
requirement, limited 17. 
+, For CT and limited use of 
Micro-CT36.  
++, Widely available27, 37, 52. 
Status 
Machine  




Non-tumor specific are available. Non-tumor specific are available. Three agents available in 
Europe18, 27. 
Quantification 
of size/ signal 
Yes, absolute2. Yes, absolute2. Yes, absolute2. 
Cancer type Neuro
4, 9, 17, 21, 26 . Lump margin assessment36, 
neuro23, spinal20. 




-Vascularized tumors will lead to 
poorly visualized operation fields  
- hematomas that produces 
imaging artifacts17. 
-Dense parachyma and 
architectural distortion making 
margin assessment difficult36.  
-Bone anatomy is well visualized 
but limited on the lesion itself20. 
- Radiation exposure24. 
-Cirrhosis, can be improved by 
using CA25. 
-Steatosis (induced by chemo)18. 






Increases with the field 
strength21, 26, 34. 
. The specificity is > 90% but 
sensitivity only 60%36.  
Both the sensitivity and 
specificity are high25. 
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Table 5: Performance and clinical potential of optical and nuclear image-guided surgery modalities. 
 FGS  MSOT CLI SGCs  
Resolution  10um
4, dependent on 
the camera system19. 
Dependent on the 
detector. Typically higher 
resolution is achieved 
with a depth trade off 
15um till 3mm, 200-
300um up to 3cm11. 
Fundamental spatial 
resolution limit of 
0.3mm, further degraded 
by scattering in tissue41, 
64.  
Spatial resolution can range 
from 3mm – 30mm4, 29, 53.  
Field of View 
(FOV) 
Dependent on the 
camera system between 
20-250mm19. 
Similar to ioUS, when the 
resolution increases the 
FOV is decreasing. 
Typical endoscopic FOVs. 
An open field FOV is 
80×80mm 65. 
Dependent on the camera 
system, between 40-120mm 
is typical. Can vary with  
pinhole cameras 29, 53. 
Iterative Yes. Yes. Yes, though limited by 
the half-life of the 
radiotracer used. 
Yes, though limited by the 
half-life of the radiotracer 
used. 
When to use 
during surgery. 
Used for tumor 
margin/SLN localization 
and quality control of the 
resection cavity3,4,19. 
Usage is similar to FGS 
but with more 
anatomical 
information11, 66. 
Mostly used for quality 
control of the resection 
cavity and lump 
assessment41, 67. 
Used for SLN detection, for 
surgical orientation and as 
quality control of the 
resection cavity29, 68. 
Depth 0.5-2cm
3, 4. Several cm4. 1 cm, dependent on the 




Low. Medium. Low. Low. 
User friendly  +, NIR light does not alter 
the appearance of the 
surgical field 3, 30. 
+ +, does not alter the 
appearance of the 
surgical field.  
-, Radiation burden.  
-, exclusion of all 
ambient light. 
+, does not alter the 
appearance of the surgical 
field.  
- , Radiation burden. 
Availability  +, Available
3. -/+, Available in limited 
centers.  





Clinical3, 19. Clinical trials ongoing. Clinical trials, some 
systems available for 
clinical use41.  
Some systems available for 





Only 3 tumor a-specific 
CA are registered for 
clinical use3. 
Likely that the agents 
under investigation for 
FGS will also be studied 
for MSOT4. 
Clinically available for 
the available PET tracers 
and more tumor-specific 
tracers are in clinical 
development. 
Clinically available for the 
available SPECT tracers more 
tumor-specific tracers are in 
clinical development. 
Quantification 
of size/ signal 
Relative, absorption and 
scatter limit the ability 
for absolute 
quantificantion2.  
Yes, via the amount of 
signal in an area38-40. 
Relative absorption and 
scatter limit the ability 
for absolute 
quantification41.  
Absolute or relative 
depending on camera 
design2. 
Cancer type Primary tumor, lymph 
nodes, vascularization, 
metastases3.  
Hollow organs for 
endoscopic else all solid 
tumors11. 
Broad range of solid 
tumors. 
For numerous cancer types; 




of the excitation light can 
help with target detec-
tion, over-compensation 
can  cause false-
positives3.  
- Penetration depth3, 19. 
Requires surface contact. -High radiation burden. 
-Exclusion of ambient 
light is essential, 
endoscopic applications 
would be favorable41. 
- Scattering can cause 
signal to be visualized in 
the incorrect area64. 
-Radiation burden 
-Tradeoffs between dose, 
acquisition time, sensitivity, 




Superficial tissue can be 
detected with a high 
sensitivity. Sensitivity is 
decreased with the 
depth4, 19. 
Nanomolar sensitivity 
with high specificity 
based on multispectral 
imaging. 
- Lack of sensitivity due 
to low light levels 41. 
- Specificity is depen-
dent on the tracer 34.  
- An increase in imaging 
distance degrades sensitivity 
and spatial resolution 29, 53. 
- Are dependent on the 
system and tracer34. 
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Table 6: Performance and clinical potential of endogenous reflectance image-guided surgery modalities. 
 RS OCT REIMS 
Resolution  High, in the submicron range
22.  High, 1-15um,  limited by the 
depth penetration which is, 
depending on the tissue, up to 
5mm11, 30, 43-45. 
Not applicable, as it does not 
generate an image but a 
profile.  
Field of View 
(FOV) 
~ 0.1 mm37, at highest far-field 
optical resolution 22, 30.  
Around 1cm2,30.  Around a surgical dissection 
rate of 1mm/s which leads to a 
FOV of 1mm3 13. 
Iterative Yes
30 Yes43, 45, 58. Yes, however not on the same 
piece of tissue12, 28. 
When to use during 
surgery. 
Mostly used for quality control 
of the resection cavity and 
lump assessment22. 
Mostly used for quality control 
of the resection cavity and 
lump assessment30, 45. 
Mostly used for quality control 
of the resection cavity and 
lump assessment12, 28. 
Depth Hundreds of micrometer  
22, 30. 0.2cm30, 43, 45, 58. Not applicable/ limited. 
Inter-operator 
variability  
Low, when incorporated in a 
robotics system 
High/medium45. Low as a reference library is 
used for feedback and tissue 
classification 13. 
User friendly  +, when incorporated in a 
robotics system, otherwise 
low.  
+45 +, does not change the 
procedure of electrosurgical 
dissections13. 
Availability  -/+, Available in limited 
number of centers. 
-/+, Not in routine clinical use 
for surgery  available for other 
approaches11, 44, 45. 
-/+, Available in limited centers 
for research purpose only. 
Status Machine  Mostly ex vivo studies, only 
one study in vivo so far 
published30. 
Mostly ex vivo, in vivo clinical 
trials are needed43. Handheld 
probes are in development 11, 
30. 
Clinical research, mainly on ex 
vivo tissue and few papers 
reporting in vivo tissue 
analysis12, 13, 28.  
Quantification of 
size/ signal 
Relative quantification2  Yes, absolute. Only relative, comparison 
based on different molecular 
fingerprints from one tissue 





Bladder, prostate, kidney43 
breast45, 58, melanoma, 
thyroid45, ovarium44. 




- interrogate a small region of 
tissue, 
- SNR can be a limiting factor 
- the intrinsic weak signals can 
be partly solved by high quality 
instruments 22, 30.  
-limited penetration depth43. 
-optical scattering and 
coherent speckle artifacts from 
cellular structures limits the 
visualization of small cells58. 
-The tissue needs to be 
disrupted for analysis and 
cannot be measured again12. 
-The need for  validated tissue-
specific databases13. 
Sensitivity, specificity 
of the system. 
Accuracy, Sensitivity and 
Specificity >90% to distinguish 
normal brain from tumor 
invaded brain22. 
High, sensitivity rates between 
80-100% could be found and 
specificity 60-100% 11, 30, 45. 
 
High, >90% depends on the 
accuracy of the classification 
library  
  




Tumor removal is an incremental and iterative process so there should also be 
the possibility to obtain intra-operative images linked to those obtained by 
initial staging scans 
12
. This may require merging of more than one modality. 
US is a well-established technique for  interventional procedures but is rarely 
the choice for definitive staging. In comparison, single-photon emission 
computed tomography (SPECT) and positron emission tomography (PET) may 
be used to perform tumor staging but cannot be used during surgery due to 
size limits whereas portable SGCs may suffice 
11
.  For this purpose, a 
conventional anatomic technique (e.g. MRI, CT or US) can be combined with a 
biological imaging modality such as optical or nuclear imaging, with the use of 
a targeted tracer. Or else a technique used during surgery for (re-)orientation 
can be combined with a technique which is used for quality control of the 
resection cavity or lump assessment as mentioned in Table 4-6. Another 
option is the use of a technique with a high penetration depth but a 
somewhat lower resolution complementary to one of the imaging modalities 
of the endogenous reflectance group to compensate for the loss of resolution. 
Both options will lead to more complete overview of the actual situation in a 
patient. Figure 4 visualizes the differences between the techniques in relation 
to depth, resolution and acquisition time 
2,70
. One has to be aware that 
techniques which are further apart from each other in the figure may gain the 
most in combination. So far, the biggest challenge remains the fusion of the 
images generated by different techniques which can lead to a certain degree 
of uncertainties, the greater the distance between two modalities in Figure 4, 
the greater the challenge.  
 
Over the past decade, imaging has broadened from the conventional  
anatomical overview to state-of-the-art methods giving a molecular 
description of structure or function 
71
. The overall goal of imaging is to provide 
a better outcome. It should be noted that a “better outcome” can be 
defined—and may often differ—from different perspectives, i.e., from the 
patient, surgeon, instrument manufacturer, and society 
16
. In iMRI, for 
example, surgeons appreciate the fact that they have a better visualisation 
and a higher chance of a complete resection of the tumor but, in contrast, 
they prefer shorter procedure times and with the use of iMRI these can be 
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increased up to two hours 
21,27
. In addition, a reduction of complications, like 
tumor-bed hematoma formation may be achieved with iMRI detection 
17,21
. 
From a manufacturing standpoint, iMRI is viewed as successful due to the 





For the imaging modalities discussed above, when used in open surgery, the 
surgeon must look away from the operative field to review the images on a 
screen; this is not the most ideal situation. With augmented reality the 
imaging results are projected onto the operative field which allows the 
visualization of different types of images merged with each other. Those 
images can be obtained pre-operatively, which allow more detailed planning 
of the operation beforehand. The major limitation with this approach is the 
deformation of soft tissue during the surgical procedure and the orientation of 
the image display in relation to the surgical field. The application of 
augmented reality is most promising in the treatment of tumors associated 
with bone structures 
8
. However, the challenges for minimal invasive surgery 
are shifted to limited depth perception and haptic feedback leading to a 
disconnection between the hand and eye 
72
. With augmented reality a patient-
specific virtual model can be created for open or minimal invasive surgery to 




It should be noted that none of the modalities described provide 
comprehensive medical information. Due to improvements in conventional 
imaging modalities the expectations placed on imaging systems have 
increased and none of them are without any limitations 
74,75
. Hybrid or 
multimodality imaging is commonly employed in diagnostics (e.g. PET-CT or 
SPECT) to combine functional and anatomical information.  
 
Is it necessary to have the amount of signal intensity or contrast agent in each 
cubic centimeter or is the signal intensity/amount of contrast agent in 
arbitrary units per pixel/voxel sufficient? Surgical decisions are generally based 
on visual interpretation of data, which gives only an impression and does not 
lead to linear obtained results. What data is necessary for a particular 
medical/clinical outcome? Does an improved clinical outcome rely on absolute 
numbers during surgery? And can this data be generated in sufficient time for 
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the patient/surgeon? Most imaging modalities are unable to provide absolute 
quantification due to noise, scattering and motion, or the absence of a 
standard. All ten modalities reviewed here allow relative quantification, 
assuming that the signals are independent of the position in the sample and 
no motion artefacts are present. Although absolute quantification is preferred, 
particularly in therapy-response monitoring, relative quantification is 
sufficient in practice and for most other indications. The future of medical 
imaging is in the transfer of images to data with a high negative power and a 
focus on sensitivity.  
 
Finally, standardization is necessary to achieve reproducible and reliable 
information, which makes interinstitutional comparisons feasible and 
facilitates the implementation of new techniques from one site to another. 
Especially in case of quantification, standardization is a prerequisite. To 
achieve images which are intuitive to interpret, reproducibility and reliability 
are key parameters. Each modality requires technical standardization for both 
signal acquisition and image reconstruction, and to account for the biological 
factors of the contrast agent and the heterogeneity of every patient. The 
technical factors can be standardized relatively easily with the use of standard 
operating protocols (SOPs) and an accurate quality assurance program, 
including validated libraries or calibration curves for the contrast agent. As an 
example, the REMARK study gave recommendations for how to report results 
about tumor markers in a standardized way for assessment of the quality and 
generalizability for further research 
78
. A similar protocol should be developed 
for imaging and molecular modalities used in surgery.  
In conclusion, every modality has its own strengths and no single modality will 
be suitable for all surgical procedures and fields. Strict selection of modalities 
per cancer type and surgical requirements is required as well as combining 
modalities in order to increase visibility and decrease noise. The range of 
available modalities at differing levels of development makes comparison 
necessarily qualitative. Eventually, standardization of data across the different 
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Targeted image-guided oncologic surgery (IGOS) relies on the recognition of 
cell surface-associated proteins, which should be abundantly present on 
tumor cells but preferably absent on cells in surrounding healthy tissue. The 
transmembrane receptor tyrosine kinase EphA2, a member of the A class of 
the Eph receptor family, has been reported to be highly overexpressed in 
several tumor types including breast, lung, brain, prostate, and colon cancer 
and is considered amongst the most promising cell membrane-associated 
tumor antigens by the NIH. Another member of the Eph receptor family 
belonging to the B class, EphB4, has also been found to be upregulated in 
multiple cancer types. 
 
Procedures 
In this study, EphA2 and EphB4 are evaluated as targets for IGOS of 
colorectal cancer by immunohistochemistry (IHC) using a tissue microarray 
(TMA) consisting of 168 pairs of tumor and normal tissue. The IHC sections 
were scored for staining intensity and percentage of cells stained. 
 
Results 
The results show a significantly enhanced staining intensity and more 
widespread distribution in tumor tissue compared with adjacent normal 
tissue for EphA2 as well as EphB4. 
 
Conclusions 
Based on its more consistently higher score in colorectal tumor tissue 
compared to normal tissue, EphB4 appears to be a promising candidate for 
IGOS of colorectal cancer. In vitro experiments using antibodies on human 




Figure 1. Graphical abstract, IHC is performed on normal or tumor tissue and evaluated on the 
presence of EphB4. Based on the N/T scorings diagram EphB4 appears to be a promising 
candidate, when labeled with a fluorophore, for IGOS of colorectal cancer. 
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Introduction 
 
During oncologic surgery, there is limited information available about the 
exact boundaries between tumor and healthy tissue. Visual inspection and 
palpation are often not enough, leading to incomplete resection of the tumor 
or substantial damage of healthy tissue 
1
. Imaging of tumor tissue by targeted 
real-time near-infrared (NIR) fluorescence is a novel technique that can help 
the surgeon during an operation 
1,2
. Besides the quality of the camera system, 
the effectiveness of this technique relies mainly on the choice of targeted 
tumor protein. Receptors and adhesion molecules upregulated on the surface 
of tumor cells are the best candidates for targeted cancer imaging, but the 
ideal protein for colorectal cancer imaging has not yet been identified 
3
. Cell 
surface-associated proteins such as MUC1, EGFR, HER2, PSMA, and CEA are 
highly ranked on the National Cancer Institute (NCI) prioritization list of cancer 
antigens and are amongst the most pursued biomarkers for imaging 
4
. We 
decided to evaluate one of the next candidates on the list, EphA2, a member 
of the Eph family of receptor tyrosine kinases that is preferentially expressed 
in tumor tissue compared to normal tissue and plays an important role in 
cancer malignancy 
4,5
. Furthermore, we included the family member EphB4 
because its overexpression has also been reported in various cancer types 
6
. 
As a target for tumor imaging, a low grade of expression of both EphA2 and 
EphB4 in normal tissue is essential and has not been thoroughly investigated 
5-7
. 
EphA2 and EphB4 are known to be upregulated, particularly in the early stages 
of colorectal cancer 
5,8,9
. In those early stages, surgery without additional 
systemic therapy is the main treatment modality, which makes accurate 
recognition and removal of the tumor essential 
10,11
. Whether a protein target 
like EphA2 or EphB4 is suitable for image-guided oncologic surgery (IGOS) is 
determined by its expression pattern in the tumor in comparison with the 
surrounding normal tissue. In this study, we evaluate the expression patterns 
of EphA2 and EphB4 by immunohistochemical (IHC) staining of a tissue 
microarray (TMA) consisting of pairs of tumor and normal colon tissue. 
Furthermore, the principle of using these Eph proteins for imaging is evaluated 
in vitro using various cancer cell lines. 
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Materials and Methods 
 
Tissue Micro Array (TMA) 
Formalin-fixed paraffin-embedded (FFPE) tissue blocks of primary tumors and 
their respective normal tissues were collected from the pathology department 
of the Leiden University Medical Center (Leiden, the Netherlands). Sections 
were cut for hematoxylin-eosin staining and histopathologically representative 
tumor regions were used for preparation of TMA blocks. From each donor 
block, three 0.6 mm diameter tissue cores were punched from tumor areas 
and transferred into a recipient paraffin block using a custom-made precision 
instrument. Because the TMA was designed to evaluate the expression of 
EphA2 or EphB4 throughout the whole tumor, cores where taken from three 
different locations across the tumor tissue, plus one outside the tumor, in 
healthy looking tissue. 
 
Immunohistochemistry 
IHC staining of the TMA was performed on 4 μm sections cut from each TMA 
receiver block. TMA sections were deparaffinized and rehydrated. Endogenous 
peroxidase was blocked for 20 min in 0.3% hydrogen peroxide in water. The 
slides were treated for antigen retrieval in citrate buffer (pH 6) for 10 min at 
95 °C (DAKO PT Link, Glostrup, Denmark). Sections were incubated overnight 
with primary antibodies. The antibodies used for EphA2 staining were a 
polyclonal rabbit (34-7400, Invitrogen/Thermo Fisher Scientific, Waltham, MA, 
USA) and a polyclonal goat (AF3035, R&D Systems, Minneapolis, MN, USA). 
Antibodies used for EphB4 were a monoclonal mouse IgG1 (37-1800, Life 
Technologies/Thermo Fisher Scientific, Waltham, MA, USA) and a polyclonal 
goat (AF3038, R&D Systems). The optimal dilution for staining colon cancer 
tissue sections was optimized for all 4 antibodies. After 30 min of incubation 
with DAKO envision containing horseradish peroxidase conjugated goat 
anti-rabbit, goat anti-mouse, or rabbit anti-goat antibodies (DAKO Cytomation, 
Glostrup, Denmark), the sections were visualized using a diaminobenzidine 
solution (DAB+; DAKO kit). The sections were counterstained with 
hematoxylin, dehydrated, and mounted with pertex (Histolab). The entire 
slides were scanned with a Philips Ultra Fast Scanner 1.6 RA (Philips, 
Eindhoven, the Netherlands) for further analysis. 
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Scoring Method 
The TMA sections were semi-quantitatively scored for EphA2 or EphB4 
staining by two independent examiners (MS, HP) using Philips Digital 
Pathology Solutions-software (Philips, Eindhoven, the Netherlands). TMA 
cores were used when 50% or more was occupied by tissue. The intensity and 
percentage of positive tumor cells within each core were scored 
independently and categorized. The intensity score of epithelial staining was 
defined as 0 when there was no staining; 1 for weak staining; 2 for moderate 
staining; or 3 for strong staining. The percentage of cells stained was scored 0 
when the percentage was 0%; 1 when <25% was stained; 2 for 25%–50% 
staining; 3 for 50%–90% staining and 4 when >90% of the cells was stained. 
The two scored parameters were added up into a final score (0–7) for each 
core. Only tumors with a minimum of 2 cores were used. The median of the 
score for each tissue was used for data analysis. Only complete sets of tumor 
and normal tissue were used for further analysis, for a total of 168 tumors. 
 
Cell Culture, Flow Cytometry, and Chamber Slide Assay 
Cancer cell lines A549 (lung), BT-20 (breast), HT-29 (colon), and Jurkat 
(leukemic T-cell lymphoblast) were grown in RPMI or DMEM (Gibco, 
LifeTechnologies, Carlsbad, CA, USA) as appropriate, with 10% fetal calf serum 
and 100 IU/mL penicillin/streptomycin (Gibco) at 37 °C in a humidified 
incubator with 5% CO2. The presence of Eph2A and Eph4B on the membranes 
of these cells was determined by flow cytometry. Cells were cultured until 
90% confluence and detached with trypsin/EDTA. Viability of the cells was 
evaluated with trypan blue. The cells were incubated with 4 μg/mL polyclonal 
goat antibodies AF3035 and AF3038, against respectively Eph2A and Eph4B for 
30 minutes on ice, washed with ice cold phosphate buffered saline pH7.5 
(PBS), and incubated with anti-goat secondary antibody conjugated with 
fluorescein isothiocyanate (FITC) (A11078, Life Technologies). The cells were 
then centrifuged, washed, and suspended in PBS containing propidium iodide 
to exclude dead cells and consequently analyzed in a BD LSRII flow cytometer 
(BD Biosciences, San Jose, CA, USA) with FlowJo (Tree Star Inc., Ashland, OR, 
USA). For the plate assay, HT-29 colon cancer cells were grown in 8-well 
chamber slides (Thermo Scientific, Waltham, MA, USA) under conditions 
described above. At 75–80% confluence, the cells were fixated with 4% 
paraformaldehyde for 10 minutes. After washings with PBS, the cells were 
incubated with a rabbit monoclonal anti-EphB4 antibody conjugated with 
60│ EphA2 and EphB4 as targets for IGOS             Chapter 3   
phycoerythrine (SinoBiological Inc., LuDong Area, BDA, Beijing, P.R. China). 
The cells were washed and dried. The slides were covered with Prolong Gold 
with DAPI (Life Technologies) and visualized using a Leica DFC350 FX 
fluorescence microscope (Leica, Wetzlar, Germany). 
 
Statistical Analysis 
Statistical analyses were conducted using SPSS statistical software (version 
20.0 for Windows, SPSS Inc., Chicago, IL, USA). Scores are presented as mean ± 
standard deviation. Differences between groups are calculated using a 
Student’s paired t-test. For the difference in differentiation in relation to 
tumor stage, a chi-square test was used. All statistical tests were conducted 
two-sided, and p-values of 0.05 or less were considered significant. 
 
Results 
A total of 168 tumor/normal pairs were suitable for evaluation of both EphA2 
and EphB4. The main characteristics of the patients and the tumors are 
presented in Table 1. In a preliminary evaluation on five sets of tumor and 
normal tissue sections, two different antibodies recognizing EphA2 and two 
different antibodies recognizing EphB4 showed similar staining patterns. 
Table 1. Patient and tumor characteristics of the 168 colorectal cancer patients in this study. 
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Figure 2. Two examples of staining patterns for EphA2 and EphB4 in sets of tumor and normal 
tissue from patients with colon cancer. (A) shows the most generally found pattern, with low 
expression of both proteins in normal tissue and abundant expression in tumor tissue; (B) 
shows an aberrant expression pattern (as indicated in Figure 2), with extremely high EphA2 
expression in normal tissue and absence of staining in the corresponding tumor tissue. The 
scale bars represent 150 micrometers; (C) shows 40× enlargements of the sections indicated in A. 
Red arrows indicate membranous staining. The scale bar represents 30 micrometer.  
Therefore, only one antibody recognizing each receptor (rabbit polyclonal 34–
7400 for EphA2 and mouse monoclonal 37–1800 for EphB4) was selected for 
screening the TMA. All stained tissues were evaluated by two examiners and 
their scores showed a strong positive correlation (R
2
 = 0.86, p ≤ 0.001). 
Inter-observer agreement was obtained by re-evaluation of the respective 
sections. Staining for EphA2 and EphB4 was generally present in epithelial cells 
throughout the whole tumor area consisting of 2 or 3 TMA cores (Fig. 2). 
EphA2 staining was also widely detected in endothelial cells, whereas EphB4 
staining was only occasionally found in endothelial cells. In general, tumor 
tissue showed more staining for both Eph receptors than the corresponding 
normal mucosa, but there were a few aberrant cases in which normal tissue 
showed more staining. Consequently, EphA2 and EphB4 expression did not 
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Figure 3. N/T scorings diagram for the tissue microarray (TMA) stained for EphA2 and EphB4. 
Green = higher score in tumor than normal tissue; Red = higher score in normal tissue than 
tumor tissue; Blue = no difference in score between normal and tumor tissue. The thickness of 
the line represents the number of patients, the thicker the line the more patients. The 
numbers 0-7 represent the IHC scoring values.  
significantly correlate (R
2
 = 0.08, p = 0.165, n = 336). Figure 2A shows a typical 
example of a Stage III patient with high EphA2 and EphB4 staining in the tumor 
and low staining in normal mucosa. Figure 2B presents a particular case in 
which normal tissue showed more EphA2 staining than the corresponding 
Stage III tumor. For EphA2, the mean score for the tumors (4.3 ± 1.8) was 
significantly higher (p < 0.001) compared with the corresponding normal tissue 
(3.3 ± 2.3). For EphB4, the difference between tumor and normal mucosa was 
even more pronounced, with scores of respectively 4.6 ± 1.6 versus 2.3 ± 1.9 (p < 
0.001).  
There was no association between the clinical-pathological variables “tumor 
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Figure 4. Presence of EphA2 and EphB4 on colon cancer cells. (A) Flow cytometry of HT-29 
shows abundant presence of both EphA2 and EphB4 compared with negative Jurkat cells. (B) 
Immunofluorescence of EphB4 indicates a membranous staining on HT-29 colon cancer cells 
grown in monolayer. X-axes indicate fluorescence intensity, the scale bar represents 20 
micrometers. 
stage” or “differentiation” and the score for EphA2 or EphB4 staining.For 
imaging purposes, the over-expression of a protein target in tumors compared 
to adjacent normal tissue is more important than high tumor expression per 
se. Therefore, in the normal to tumor (N/T) scoring diagram in Figure 3, we 
show a graphical representation of the differences in EphA2 and EphB4 
expression in normal versus tumor tissue for individual patients. The IHC score 
of a normal tissue (left side) is connected by a line with the score of the 
corresponding tumor tissue (right side).  
Green lines indicate that the tumor score was higher than the score of the 
corresponding normal tissue, whereas red lines indicate the opposite. Blue 
lines indicate no difference between tumor and normal tissue. The thickness 
of the lines is proportional to the number of pairs with identical scores; the 
thicker the line, the more pairs there are. The diagram indicates that there is 
more variation in the N/T ratios for EphA2 than for EphB4. Although both Eph 
receptors show some unfavorable red lines, the majority of tissue sets (73% 
for EphA2 and 88% for EphB4) have green lines. Interestingly, the frequency of 
pairs with at least two score points difference between N and T is 46% for 
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EphA2 versus 69% for EphB4. The frequency for a three-point difference 
becomes 30% for EphA2 versus 52% for EphB4, and for a four-point difference 
it becomes 23% for EphA2 versus 35% for EphB4. 
 
The other most important characteristic for a protein to become a candidate 
target for imaging next to upregulation in the tumor cells is the availability on 
the cell membrane of these cells. Being receptors, the majority of the EphA2 
and EphB4 would be expected on the cells rather than inside. Figure 2C shows 
that in our IHC evaluation this is clearly the case for EphB4 and, to a lesser 
extent for EphA2. Because of the observed advantages of EphB4 with respect 
to upregulation and cellular localization in  
IHC, we performed in vitro experiments on various tumor cell lines to evaluate 
whether EphB4 is targetable on these cells. All cancer cell lines, i.e., lung, 
breast, and colon, showed an enhanced presence of both EphA2 and EphB4 
compared with Jurkat control cells, as shown for colon cancer cell line HT-29 in 
Figure 4A. A chamber slide assay confirmed the accessibility of EphB4 on 
HT-29 cells grown on chamber slides in monolayer (Fig. 4B). 
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Discussion 
 
In theory, any upregulated protein specifically present in cancer tissue could 
be a potential target for IGOS, but in practice the proteins expressed on the 
surface of tumor cells are the best candidates 
3
. Cheever and colleagues 
ranked EphA2 as one of the highest cell surface antigens for cancer treatment 
4
. Therefore, in this study, we evaluated whether the EphA2 receptor and the 




Our IHC evaluation of 168 sets of N/T tissue showed a statistical significant 
upregulation in tumor tissue compared with normal tissue for both EphA2 and 
EphB4 in the majority of the patients. Both Eph receptors were detected in 
tumors of various stages and grades and in tumor areas that were suitable for 
imaging. Therefore, both Eph receptors seem to be valid candidate targets for 
IGOS of colorectal cancer. However, as clearly illustrated by the patient 
specific N/T scorings diagram, the value of EphA2 as a clinically usable target is 
problematic because of the presence of high EphA2 staining in some of the 
normal tissues. This phenomenon is much less evident for EphB4, making this 
receptor the better candidate target for IGOS. The higher EphB4 expression in 
colon cancer compared to normal mucosa was previously also shown at the 
mRNA level in 62 tissue pairs, with validation at the protein level in only a few 
samples 
14
. Although we did not find a significant correlation between EphA2 
or EphB4 expression and the stage or differentiation grade of the tumors, 
earlier studies found both EphA2 and EphB4 to be preferentially upregulated 
in the early cancer stages (Stages I and II) 
5-9,15
. Over-expression in early 
colorectal cancer stages is particularly advantageous for imaging during 
surgery, given the increased difficulty in distinguishing normal and tumor 
tissue morphologically and the fact that, for early stage tumors, surgery is 
often not accompanied by chemotherapy. Interestingly, earlier studies using 
Q-PCR to analyze 53 paired normal and colorectal cancer samples showed that 
EphB4 is more significantly overexpressed in tumor tissue compared to normal 
tissue than EphA2 
5,12
. This characteristic supports the choice of EphB4 as a 
target for IGOS. 
Multiple publications have shown that EphA2 overexpression is strongly 
correlated with tumor progression; consequently, high EphA2 levels are 
associated with worse patient survival 
8,13,16
. High EphB4 expression has also 
been correlated with poor patient survival 
17-19
, although some studies have 
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also found an opposite correlation 
15
. The signaling effects of EphA2 and 
EphB4 in cancer are complex, and not only tumor-promoting but also 
tumor-suppressing effects have been reported for these receptors 
7,20-22
. 
However, neither a role in carcinogenesis nor the status as a prognostic factor 
is relevant for the use of a protein as a target for IGOS. 
The main disadvantage of our study is the use of a TMA consisting of three 
cores per tumor, which makes evaluation of the degree of intra-tumor 
heterogeneity more difficult than with the use of whole tumor sections. 
Another point of criticism could be the antibodies used for IHC. Although we 
evaluated a panel of antibodies for EphA2 as well as EphB4, the evaluation of 
the distribution, the scoring, and the calculations were performed with the 
antibody that gave the most consistent results. The selected antibodies were 
commercially available and both raised against C-terminal peptides of 
respectively EphA2 and EphB4. In general, antibodies against intracellular 
domains are well suited for IHC, but in most cases these antibodies are not 
particularly fit for flow cytometry or for determination by IHC, whether the 
staining is membranous rather than intracellular. Especially the antibody for 
EphA2 proved to be less suitable for the latter purpose. Based on these 
results, we cannot conclude that EphB4 is more suitable as a target for IGOS 
than EphA2. The flow cytometry data, performed with polyclonal antibodies 
against whole proteins rather than internal domains, indicated that EphA2 is 
at least as abundantly present on living cancer cells as EphB4. The incubation 
of these colon cancer cells with labeled antibodies against EphB4 
demonstrates the principle that targeting of this receptor could be clinically 
relevant, but this should be further elucidated in pre-clinical studies using 
relevant mouse models. 
Targeting of Eph receptors for tumor imaging purposes could be achieved 
using various agents, such as peptides or antibodies 
23,24
. Antibodies offer the 
advantage of, in general a higher specificity and affinity compared to peptides, 
and, thanks to molecular engineering, even bi- and tri-specific antibodies have 
been developed recently, which could enhance tumor specificity 
7,13,25
. 
Recently, a series of EphB4 antibodies has been evaluated for the use of 
Positron Emission Tomography (PET) in mice xenografted with human HT-29 
colon cancer and MDA-MB-231 breast cells, underscoring the value of EphB4 
as a target for tumor imaging 
23
. A recent study also developed NIR 
fluorescence probes for targeted imaging using an EphB4 antibody 
26
. While 
the use of PET for colon cancer is not suitable for routine clinical use 
27
, NIR 
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fluorescence-based imaging of colorectal cancer shows great potential, 




In conclusion, both EphA2 and EphB4 show potential as target for 
image-guided colorectal cancer surgery, but EphB4 seems to have the best 
characteristics with respect to tumor/normal mucosa distribution, as shown in 
a relatively large cohort of 168 patients. The in vitro binding data confirm the 
presence of EphB4 on the cell membrane, which is the other important 
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A crucial point for the management of pancreatic ductal adenocarcinoma 
(PDAC) is the decrease of R1 resections. Our aim was to evaluate the 
combination of multispectral optoacoustic tomography (MSOT) with 
fluorescence-guided surgery (FGS) for diagnosis and perioperative detection of 
tumor nodules and resection margins in a xenotransplant mouse model of 
human pancreatic cancer. As MSOT and FGS are novel technologies which can 
be used to improve visualisation of specifically labeled tissue. 
 
Procedures 
The peptide cRGD, conjugated with the near infrared fluorescent (NIRF) dye 
IRDye800CW and with a transcyclooctene (TCO) tag for future click chemistry 
(cRGD-800CW-TCO), was applied to PDAC bearing immunodeficient nude 
mice. 27 days after orthotopic transplantation of human AsPC-1 cells into the 
head of the pancreas, mice were injected with cRGD-800CW-TCO and imaged 
with fluorescence-  and optoacoustic imaging devices before and 2h, 6h and 
24h after injection, before they were sacrificed and dissected with the 
guidance of a FGS imaging system.  
 
Results 
Fluorescence imaging of cRGD-800CW-TCO allowed detection of the tumor 
area but without information about the depth, whereas MSOT allowed high 
resolution 3D identification of the tumor area, in particular of small tumor 
nodules. Highly sensitive delineation of tumor burden was achieved during 
FGS in all mice. Imaging of whole-mouse cryosections, histopathological 
analysis and NIRF microscopy confirmed the localization of cRGD-800CW-TCO 
within the tumor tissue. 
 
Conclusion 
In principle all imaging modalities applied here were able to detect PDAC in 
vivo using one NIRF probe. However, the combination of MSOT and FGS 
provided detailed spatial information of the signal, and achieved a complete 
overview of the distribution and localization of cRGD-800CW-TCO within the 
tumor before and during surgical intervention which could lead to a reduction 
in R1 resections in PDAC surgery. 
 




Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis 
which is ascribed to the asymptomatic early phase of the disease and its 
aggressive tumor biology. The challenge in the management of operable 
pancreatic tumors is an achievement of R0 resections, i.e. complete removal 
of all tumor nodules. Unfortunately, 80% of pancreatic cancer surgeries are R1 
resections, resulting in a further decreased overall survival
1,2
.  
Although surgeons still mostly rely on their visual perception and palpation, 
novel imaging methods such as fluorescence-guided surgery (FGS) are evolving 
to assist the differentiation of healthy and tumor tissue. FGS, typically based 
on near infrared (NIR) fluorescent probes visualises the desired structures in 
real time
3
. The application of planar NIR fluorescence imaging for non-invasive 
detection of tumors is restricted to approximately one cm deep structures
3,4
. 
Furthermore, the strong influence of tissue microenvironment and the light 
scattering hamper signal quantification
5,6
. Moreover, the detected 
fluorescence is projected onto the photographic image of the body surface in 
2D and attribution to specific organs and structures within the body is not 
warranted. Nevertheless, planar fluorescence imaging is widely used in 
preclinical settings and increasingly applied in the clinic as it is non-invasive, 
easy-to-use, economic and possible in real-time.  
Optoacoustic (also called photoacoustic) imaging is an emerging technology, 
which uses pulsed laser light to excite absorbing molecules. Those molecules 
undergo thermoelastic expansion leading to the release of acoustic waves
7,8
. 
With multispectral optoacoustic tomography (MSOT), tissue can be 
sequentially illuminated at different wavelengths and images can be 
processed using spectral unmixing algorithms in order to distinguish and 
quantify the contribution of different chromophores in tissue which can be 
spatially resolved and back-projected to reconstruct a three-dimensional (3D) 
image
9
. MSOT delivers anatomical and functional information simultaneously, 
with a high spatial resolution and up to 5 cm penetration depths, making it 
suitable for imaging deeper tissues and tumors within the body
10,11
. 
Nevertheless, the depth is dependent on the ultrasound frequency, with lower 
frequencies allowing for greater imaging depth but with a lower spatial 
resolution
12
. MSOT has been shown to address a number of clinically relevant 
aspects such as tissue oxygenation or tumor spreading and can potentially 
overcome a number of other shortcomings in current surgical practice
13-15
.  
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Both optoacoustic and fluorescence imaging are relying on tumor specific 
probes
4,16
. Although there are numerous fluorescent dyes in every desired 
wavelength, currently, only very few of them are approved for the routine use 
in patients
17
 IRDye800CW is one of the most promising new generation NIRF 
dyes, which can be detected by both, fluorescence and optoacoustic imaging 
and is currently widely tested in clinical trials
18
. Clinical evaluation is possible, 
as biocompatibility studies of 800CW did not show evidence of toxicity
19,20
.  
Here, we decided to use a cyclic arginine–glycine–aspartic acid (cRGD) peptide 
to target integrins, which are overexpressed in various cancer types and are 
playing a key role in the early phase of tumor angiogenesis and in tumor cell 
migration
21
. The cRGD peptide contains only one labeling site, for the 800CW 
dye, in contrast to other targeting molecules, like antibodies, which usually 
contain multiple labeling sites and can therefore vary in dye to protein ratios. 
Therefore quenching effects from dye–dye interactions caused by multiple 
labeling are avoided. In the clinic, several RGD constructs are already applied 
for tumor detection using PET or SPECT
22
. 
The combination of cRGD and IRDye800CW has already been tested in several 
preclinical studies, e.g. to specifically target integrins in a transgenic mouse 
model of glioblastoma or to provide high precision delineation of tumor tissue 
during fluorescence-guided glioblastoma resection
23
. In an orthotopic head 
and neck cancer model cRGD-800CW was efficiently combined with a unique 
handheld spectroscopic device for sensitive detection of integrin 
overexpression on infiltrating tumor cells for intraoperative visualization of 
not only invasive tumor margins but also metastatic lymph nodes
24
. In a 
subcutaneous PDAC model cRGD-800CW allowed for visualization of the 
tumor up to 24h post injection using fluorescence tumor imaging
25
.  
For future pre-targeting possibilities with a radiolabel to irradiate left over 
tissue a trans-cyclooctene (TCO) tag is already added. This system is based on 
the tumor-binding of a tagged molecule, cRGD-800CW, and the subsequent 
binding of a small fast-clearing radiolabeled molecule to cRGD-800CW. This 




In this study we evaluated cRGD-800CW-TCO as a potential tool for FGS and 
more importantly as a tool to compare the diagnostic values of planar 
fluorescence imaging techniques with MSOT for in vivo preclinical imaging of 
deep seated tumors. 
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Figure 1. Synthesis of c[RGDyK]-IRdye800CW-TCO (cRGD-800CW-TCO)  
(a) N,N’-Disuccinimidylcarbonate, triethylamine, acetonitrile, r.t., 70 h, 58 % (b) 1, N,N-
diisopropylethylamine, DMF / H2O, r.t., 2 h, 62 % (c) i. 2,3,5,6-tetrafluorophenol, pyridinium-
p-toluenesulfonate, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, 
dichloromethane, r.t., 3 h, 83 %; ii. c[RGDyK]-NH2, N,N-diisopropylethylamine, DMF, r.t., 1 h; 
iii. piperidine, DMF, 79 % over two steps (d) IRDye800CW NHS ester, N,N-










Materials & Methods 
 
Probe preparation 
The preparation of cRGD-800CW-TCO composed of c[RGDyK]-IRDye800CW-
(trans-cyclooctene) is extensively described in the supplementary material 
section and is described in summary in Figure 1.  
Cell line and culture conditions 
The human PDAC cell line AsPC-1 was purchased from ATCC (Rockville, MD), 
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Animal studies 
All animal experiments were performed in accordance with German animal 
ethics regulations, approved by the local ethics office of Lower Saxony (license 
no. 33.9–42502-04–13/1085). Experiments were performed on male athymic 
nude mice NMRI-Foxn1
nu
 (Charles River Laboratories), housed in ventilated 
cages and allowed food and water ad libitum. 
For the subcutaneous (s.c.) transplantation 1 x 10
6
 AsPC-1 cells were 
resuspended in 100 µl of PBS and transplanted into the left flank under brief 
isoflurane gas anesthesia (Abbvie, ~2%, 0.8 l/min). For the orthotopic 
transplantation 1 x 10
6
 AsPC-1 cells were resuspended in 20 µl of PBS and 
implanted under xylazine (15 mg∕ kg) ketamine (75 mg∕ kg) anesthesia as 
described before
27




All in vivo analyses were preceded by native scans (0h). 27 days after 
transplantation, AsPC-1 tumor bearing mice received intravenously (i.v.) a 
single dose of cRGD-800CW-TCO (10 nmol in 100 µl of 0.9% NaCl) and were 
scanned under isoflurane gas anesthesia (2%, 0.8 l/min) with planar 
fluorescence imaging systems Optix MX2 (ART; timedomain system) and IVIS 
Spectrum (Perkin Elmer; epi-/trans-illumination system) as well as the small 
animal optoacoustic imaging system MSOT inVision 256-TF (iThera Medical 
GmbH) at 2h, 6h and 24h post injection (p.i.). Mice were sacrificed either 6h 
(n=3) or 24h (n=4) p.i. and one mouse per time-point was frozen (-20 °C) 
directly after sacrifice and used for whole body cryosectioning
28
, the other for 
fluorescence-guided dissection (FGD) with the Artemis (Quest Diagnostics; epi-




Spectrometer  measurements 
The  probe  was  diluted  in  a  solution  of  10%  BSA  in  saline  with  a  final  
optical  density  of  0.17.  The  absorbance  spectrum  was  measured  in  a  96-
well  plate  between  680  nm  and  900  nm  at  equidistant  intervals  of  10  
nm  using  SpectraMax™  M2e  (Molecular  Devices).  The  probe  spectrum  
was  normalized  to  the  maximum  peak  absorbance  value. 
Phantom  measurement 
The  same  diluted  probe  sample  was  then  inserted  inside  3  mm  wide  
tubes  at  the  center  of  a  scattering  cylindrical  agar  phantom  (1.5%  agar  
and  1%  intralipid  (Sigma);  2  cm  diameter).    MSOT  acquisition  was  
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performed  in  five  imaging  planes  (~800  μm  cross-section)  with  a  2  mm  
step  size.  Images  were  reconstructed  and  ROIs  were  drawn  around  the  
insertions  to  retrieve  the  mean  signal  intensities  for  each  measured  
wavelength  (680-900  nm).   
 
In  vivo  NIRF  imaging 
In  Optix  MX2,  730  nm  excitation  laser  and  770  nm  LP  emission  filter  
were  applied  for  all  scans.  In  vivo  whole  body  scans  and  ex  vivo  
imaging  of  organs  were  performed  with  1.5  mm  step  size  and  0.2  sec  
integration  time  per  scan-point  whereas  the  high-quality  scans  over  the  
tumor  area  with  1.0  mm  step  size  and  1.0  sec  integration  time.  Optix  
2.02.01  and  OptiView  2.01.00  software  (ART)  were  used  to  acquire  and  
analyze  the  Optix  MX2  data,  respectively. 
IVIS  scans  were  performed  with  an  excitation  filter  of  745  nm  with  30  
nm  bandwidth,  emission  of  800  nm  (range  780-840  nm),  field  of  view  
(FOV)  C  for  the  whole-body  scans  and  FOV  B  for  the  focused  tumor  
area  scans,  medium  binning.  Living  Image  software  4.4  (Perkin  Elmer)  
was  used  for  IVIS  Spectrum  image  acquisition  and  analysis. 
 
Optoacoustic  imaging  &  reconstruction   
For  optoacoustic  imaging,  the  MSOT  inVision  256-TF  small  animal  imaging  
system    (iThera  Medical,  Munich,  Germany)  was  used
30
.  Briefly,  a  tunable  
optical  parametric  oscillator  (OPO)  pumped  by  an  Nd:YAG  laser  provides  
excitation  pulses  with  a  duration  of  9  ns  at  wavelengths  from  680  nm  
to  980  nm  at  a  repetition  rate  of  10  Hz  with  a  wavelength  tuning  speed  
of  10  ms  and  a  peak  pulse  energy  of  100  mJ  at  730  nm.  Ten  arms  of  a  
fiber  bundle  provide  even  illumination  of  a  ring-shaped  light  strip  of  
approx.  8  mm  width.  For  ultrasound  detection,  256  toroidally  focused  
ultrasound  transducers  with  a  center  frequency  of  5  MHz  (60%  
bandwidth),  organized  in  a  concave  array  of  270°  angular  coverage  and  
a  radius  of  curvature  of  4  cm,  are  used.   
For  scanning,  isoflurane  anesthetized  mice  were  covered  with  ultrasound  
gel  (Parker),  gently  and  tightly  wrapped  in  cling  film  and  placed  in  a  
warm  water  container.  Anesthesia  was  maintained  throughout  the  
procedure. 
MSOT  images  were  acquired  at  six  different  wavelengths:  715  nm,  730  
nm,  760  nm,  775  nm,  850  nm  and  900  nm.  For  each  wavelength,  10  
consecutive  frames  were  recorded  and  averaged.  Data  was  fluence-
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corrected  (µs  =  10  cm-1,  µa  =  0.022  cm-1  at  800  nm)  to  compensate  
for  spectral  coloring.  Image  reconstruction  with  standard  backprojection  
and  spectral  unmixing  were  done  using  ViewMSOT™  software.  
Multispectral  processing  was  performed  using  linear  regression  on  the  
probe  spectrum  measured  in  the  phantom.  Probe  signals  were  pseudo-
colored  in  jet  and  overlaid  on  the  corresponding  anatomical  images  (800  
nm  single  wavelength)  displayed  in  grey  scale.  Maximum  intensity  images  
were  generated  using  the  3D  ViewMSOT™  software  tools.  Any  
adjustment  to  brightness,  color,  or  contrast  has  been  made  to  the  entire  
image  and  applied  to  all  images.   
For  quantification  of  probe  signals,  ROI  analysis  was  performed  on  single  
image  sections  of  the  spectrally  unmixed  probe  signals  with  the  ROI  
analysis  tool  of  ViewMSOT   
 
Fluorescence-guided  dissection (FGD) 
Quest  Spectrum  clinical  system  for  in  vivo  FGS  supported  by  Artemis  
Capture  Suite  1.1.2  software  (Quest  Diagnostics)  was  used  for  the  
dissection  guidance  applying  settings  of  both  visible  and  NIR  light.  For  
the  visible  light  of  low-pass  filter  of  <640  nm  was  used.  The  NIR  light  
was  excited  with  a  wavelength  of  785  nm,  emission  was  done  with  a  
high-pass  filter  of  >808  nm.  In  addition,  reflected  excitation  light  was  
blocked  by  a  750-800  nm  filter.  The  raw  data  could  be  saved  as  
individual  snapshots  or  a  real-time  movie  for  data  analysis.  
Representative  movie  frames  were  selected  and  FIJI  software  was  used  
to  produce  color-coded  images
31
.   
Excised  organs  were  first  imaged  with  both,  the  Optix  MX2  and  IVIS  
systems  and  afterwards  fresh  frozen  and  stored  at  -80°C. 
 
Cryoslicing  with  fluorescence  imaging 
The  samples  were  cut  at  equidistant  intervals  of  0.5  mm  throughout  the  
thoraco-abdominal  level.  For  fluorescence  imaging  of  the  cryosections  a  
Leica  cryostat  (CM  1950,  Leica  Microsystems,  GmbH,  Wetzlar,  Germany)  
was  retrofitted  with  a  self-made  fluorescence  imaging  system  with  
excitation  at  740  nm  and  emission  captured  with  a  780  nm  long  pass  
filter.  The  exposure  time  was  2.5  seconds
28
.   
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Tissue  staining 
Frozen  tissues  were  sectioned  at  2.5  µm  slices  slice  thickness  and  fixed  
for  10  min  with  acetone.  For  anti-Integrin  αν  staining,  slides  were  
incubated  for  1h  with  rabbit  monoclonal  anti-Integrin  αν  antibody  
(ab179475,  Abcam)  diluted  1:10.000  in  1%  BSA  in  PBS  followed  by  30  
min  incubation  with  goat  ant-rabbit  Alexa  Fluor  546  (1:400;  Mol.  
Probes).  For  staining  of  ανβ3  integrins,  mouse  monoclonal  anti-integrin  
αν/β3  antibody  (sc-7312)  was  transferred  to  PBS  using  a  Superdex  75  
size-exclusion  column  (500  ml  bed  volume,  GE  Healthcare),  brought  to  
pH  8.5  before  and  directly  conjugated  with  Alexa  Fluor  488  for  2h  
slowly  rocking  in  the  dark.  Slides  were  incubated  for  1h  with  the  labeled  
anti-integrin  αν/β3  antibody  diluted  1:200  in  1%  BSA  in  PBS.  Three  
washing  steps  with  PBS,  5  min  each,  were  performed  after  each  
incubation  steps.  Tissues  were  mounted  with  ProLong  Gold  Antifade  
Reagent  (Thermo  Fisher)  with  DAPI.  Haematoxylin  and  Eosin  (HE)  staining  




Tissue  imaging  and  fluorescence  microscopy 
Tissue  imaging  was  performed  on  10  µm  tumor  cryosections  obtained  
from  PDAC  bearing  mice  that  received  10  nmol  cRGD-800CW-TCO,  using  
the  Odyssey  flatbed  scanner  (Licor  Biosciences)  and  analyzed  with  the  
respective  software.  Fluorescence  microscopy  was  performed  with  an  
Axiovert  200  M  inverted  microscope  (Carl  Zeiss  Microscopy  GmbH)  
equipped  with  a  NIR-sensitive  ORCA-ER  digital  camera  (Hamamatsu).  708  
+/-37.5  nm  excitation  and  809  +/-40.5  nm  emission  filter  was  used  for  
the  detection  of  800CW. A filter  was  used  for  the  detection  of  Alexa-
Fluor  546  fluorescence  and  365  +/-  12.5  nm  excitation  and  445  +/-25  
nm  emission  filter  was  used  for  the  detection  of  DAPI. 
Image  generation  and  processing  were  performed  with  the  software  
AxioVision  Rel.4.6  software  and  FIJI
31




Spectral  features  of  the  cRGD-800CW-TCO-derived  signals  measured  with  
MSOT  in  vivo  in  the  subcutaneous  tumor  were  compared  to  MSOT  
measurements  of  the  same  probe  embedded  in  a  phantom  and  to  
spectroscopic  characteristics  of  the  probe  in  vitro.  As  shown  in  Figure  
2A,  the  in  vitro  cRGD-800CW-TCO  spectrum  was  clearly  red-shifted  when  
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Figure 2. Characterisation of cRGD-800CW-TCO in a subcutaneous PDAC mouse model 
(A) Spectral analyses of in vitro, on phantom and in vivo data sets. The spectrum of cRGD-
800CW-TCO measured with the spectrophotometer is clearly red-shifted in comparison to the 
spectra recorded in inVision 256-TF using i) cRGD-800CW-TCO dissolved in BSA and 
measured in a phantom and ii) the subcutaneous tumor. (B) Fluorescence intensity maps of 
the same tumor bearing mouse recorded 6h post injection (p.i.) of cRGD-800CW-TCO with 
Optix MX2 and (C) IVIS show clear accumulation of the probe in the subcutaneous (s.c.) AsPC-
1 tumor (white circle). Fluorescence intensities are displayed in normalized counts. (D) 
InVision 256-TF scans show cRGD-800CW-TCO-derived optoacoustic signals in the transversal 
plane inside the subcutaneous tumor with a heterogeneous distribution pattern. D1 = 
anatomical visualization, D2 = distribution of cRGD-800CW-TCO.  
compared  to  MSOT  scans  in  vivo  and  in  the  phantom.  Based  on  these  
results,  spectral  unmixing  was  performed  in  all  further  in  vivo  
experiments,  using  the  absorption  spectrum  found  with  the  MSOT  
phantom  instead  of  using  the  spectrophotometer  absorption  spectrum. 
The  binding  of  cRGD-800CW-TCO  and  the  specificity  of  the  MSOT  signals  
were  first  confirmed  in  mice  bearing  subcutaneous  AsPC-1  tumors  (n=3)  
6h  after  i.v.  probe  injection  in  comparison  to  planar  fluorescence  
imaging.  In  both  planar  optical  imaging  systems,  Optix  MX2  (Figure  2B)  
and  IVIS  (Figure  2C),  strong  probe-derived  fluorescence  signals  were  
observed  over  the  palpable  tumors.  Interestingly,  NIR  fluorescence  signals  
detected  with  Optix  MX2  were  almost  exclusively  co-localized  with  the  
tumor  region,  whereas  with  the  IVIS  system  additional  relatively  strong   
 
background  fluorescence  was  observed,  especially  in  the  area  
surrounding  the  subcutaneous  tumor  and  along  the  spine.  Optoacoustic  
tomography  revealed  comparably  strong  probe-derived  signals  within  the  
subcutaneous  tumors  but  less  background  signals  than  planar  
fluorescence  imaging,  presumably  coming  from  the  remaining  cRGD-
800CW-TCO  circulating  in  the  bloodstream  (Figure  2D).  Notably,  the  
transversal  scans  obtained  with  the  MSOT  system  revealed  
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heterogeneous  distribution  of  the  probe  within  the  tumor  (Figure  2D1),  
suggesting  areas  with  a  different  degree  of  cRGD-800CW-TCO  
accumulation  (Figure  2D2).   
 
MSOT  allows  in  vivo  3D  visualization  of  deeply  located  tumor  nodules  
in  the  orthotopic  PDAC  mouse  model 
To  validate  the  applicability  of  cRGD-800CW-TCO  as  a  contrast  agent  for  
fluorescence-  and  optoacoustic  imaging  of  deeply  located  tumors,  an  
orthotopic  mouse  model  of  human  PDAC  was  used  in  which  AsPC-1  cells  
were  transplanted  into  the  head  of  the  pancreas  of  nude  mice.  At  the  
time  of  the  imaging  experiments  -  ~3.5  weeks  after  the  transplantation  -  
all  mice  had  developed  nodular  primary  tumors  widely  spread  within  the  
pancreas.  The  tumors  generally  showed  invasion  into  the  stomach  and  
duodenum,  and  massive  tumor  spread  to  different  distant  sites  and  
organs  adjacent  to  the  pancreas  such  as  the  liver,  spleen  or  mesentery  
as  well  as  growth  of  a  tumor  mass  at  the  site  of  surgical  incision  (Fig.  
3A-D). AsPC-1  tumor-bearing  nude  mice  (n=7)  were  imaged  with  the  
OptixMX2,  IVIS  and  MSOT  before  and  2h,  6h  and  24h  after  i.v.  injection  
of  a  single  dose  of  cRGD-800CW-TCO  (10nmol). 
As  shown  in  Figure  3E,  OptixMX2  detected  a  strong  fluorescence  over  
the  upper  abdomen,  where  both,  the  primary  PDAC  tumor  and  the  
tumor  mass  at  the  site  of  surgical  incision  are  located.  The  fluorescence  
intensity  was  highest  at  2h  p.i.,  decreased  at  6h  p.i.,  but  was  still  clearly  
detectable  at  24h  p.i..  Heterogeneous  background  fluorescence  was  
detectable  at  all  scan  time-points,  which  was  presumably  due  to  the  
presence  of  the  circulating  probe  as  well  as  a  strong  fluorescence  signals  
from  the  excreted  probe  within  the  bladder.  The  highest  tumor  to  
background  ratio  (TBR)  of  1.8±0.3  was  measured  with  the  OptixMX2  at  
2h  p.i.  and  decreased  over  time  to  1.4±0.3  at  6h  and  1.5±0.3  at  24h  
p.i..  A  comparable  fluorescence  distribution  pattern  (Figure  3F)  was  
obtained  with  the  IVIS  system  with  TBRs  of  1.7±0.2  at  2h  p.i.,  2.0±0.2  at  
6h  p.i.  and  2.2  ±  0.2  at  24h  p.i..   
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Figure 3. In vivo visualization of cRGD-800CW-TCO in an orthotopic PDAC mouse model  
(A)-(D)  Representative  morphological  and  histological  appearance  of  an  AsPC-1  tumour  
model.  (A)  Image  of  an  AsPC-1  tumour  bearing  mouse  taken  during  the  dissection  
and  showing  the  typical  appearance  of  the  primary  tumour  and  extent  of  tumour  
spread  within  the  abdomen  (arrows:  yellow  =  primary  tumour,  red  =  abdominal  
metastasis  and  green  =  tumour  mass  at  the  surgical  scar  ).  (B)  Excised  widely  spread  
and  nodular  primary  tumour  (arrows)  invading  stomach  (s)  and  duodenum  (d).  (C)  HE  
staining  of  the  primary  tumour    and  (D)  of  the  tumour  mass  at  the  site  of  surgical  
incision.  (E)  Representative  ventral  fluorescence  whole  body  images  of  a  mouse  
bearing  an  orthotopic  AsPC-1  tumour,  obtained  before  (pre-scan)  and  2h,  6h  and  24h  
p.i.  of  cRGD-800CW-TCO  with  Optix  MX2  or  (F)  IVIS.  Note  the  strong  fluorescence  
signals  from  the  excreted  probe  within  the  bladder.  Fluorescence  intensities  are  
displayed  in  normalized  counts. 
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Figure 4. Detection of cRGD in relation to the tumour mass developed at the site of 
surgical incision.  
Two representative mice showing (A) large and (B) small tumour mass at the laparotomy site 
are shown. Upper panels show photographic images (left) together with epifluorescence 
scans over the abdominal area (right) performed 2h and 6h post cRGD-800CW-TCO injection. 
Lower panels show HE histological staining of the corresponding area of the scar. Yellow 
dotted lines edge tumour areas. Scale bars: 1000 µm  
We  observed  that  mice  which  developed  a  large  tumor  mass  at  the  
surgical  scar  at  the  abdominal  wall  also  showed  higher  cRGD-800CW-
TCO-derived  fluorescence  intensities  (Figure 4).  These  findings  suggest  
that  the  epifluorescence  signals  detected  over  the  abdominal  area  are  
the  sum  of  the  fluorescence  from  the  probe  bound  to  the  primary  
tumors  and  to  the  tumor  mass  grown  at  the  surgical  scar.     
 
 
Next,  we  used  MSOT  (Figure  5)  to  visualize  the  position  of  the  primary  
tumor  and  tumor  nodules  in  3D,  and  to  analyze  the  biodistribution  and  
clearance  of  the  probe  over  time  (see  Supplementary  Material).  Figure  
5A  shows  representative  MSOT  transversal  single  slices  through  the  
mouse  body  at  the  level  of  the  liver  (1),  the  kidneys  (2)  and  the  
bladder  (3)  and  corresponding  maximum  intensity  projections  (MIPs)  at  
6h  p.i.  of  the  cRGD-800CW-TCO  probe.  The  virtual  positions  of  the  slices  
are  schematically  depicted  in  Figure  5B  in  relation  to  the  planar  
fluorescence  image.   
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Figure 5. 3D in vivo visualization of PDAC by MSOT using cRGD-800CW-TCO 
(A) Representative MSOT scans of an orthotopic PDAC bearing mouse are shown as 
transversal spectrally unmixed single-slice images and maximum intensity projections (MIPs). 
A1) represents the liver level, (A2) the primary tumor level (orange solid line = scar tumor, 
yellow arrows = tumor nodules) and kidney level (green solid line), and (A3) the bladder level 
(red dotted line). (B) The corresponding location of the planes 1-3 of Figure 5A is 
schematically depicted on a whole body scan of the same tumor bearing mouse taken with 
the IVIS system. 
Using  MSOT  we  could  not  only  detect  a  clear  accumulation  of  cRGD-
800CW  in  the  primary  tumor  but  also  in  several  deeply  located  tumor  
nodules  (Figure  5A),  which  were  clearly  distinguishable  from  the  primary  
tumor.  Interestingly,  we  detected  only  very  low  background  signals  from  
the  circulating  probe,  reflected  in  high  TBRs  of  29.5±0.9  at  2h,  33.5±0.9  
at  6h,  and  TBRs  of  49.3±2.8  at  24h  p.i.. 
Furthermore,  using  MSOT,  we  could  clearly  confirm  the  renal  excretion  
pathway  of  cRGD-800CW-TCO  which  is  typical  for  small  molecules:  both,  
MSOT  images  (Figure  5A)  and  biodistribution  results  (see  Figure 6),  
revealed  a  strong  detection  of  probe-derived  signals  in  the  kidneys  
(plane  2;  green)  and  in  the  bladder  (plane  3;  red  dashed  line),  but  not  
in  the  liver  (plane  1). 
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Figure 6. Analysis of in vivo biodistribution of cRGD-800CW with MSOT  
(A) shows signal intensities for cRGD-800CW in kidney, liver, xenograft tumor, orthotopic 
tumor and bladder before and at several timepoints after injection. (B) shows raise of TBR 
signal in single representative deep seated orthotopic tumors before and  at several 
timepoints after injection. In mean, a ~50 fold raise was determined. 
 
cRGD-800CW-TCO  enables  FGD  of  PDAC 
Finally,  FGD  was  performed  in  the  orthotopic  PDAC  model  with  the  
guidance  of  the  clinical  system  Artemis  (Quest  Spectrum;  epi-
illumination),  in  order  to  assess  the  value  of  cRGD-800CW-TCO  for  the  
delineation  of  the  margins  between  normal  and  PDAC  tissue  during  
surgery.  At  both,  6h  (Figure  7A)  and  24h  (Figure  7B)  after  cRGD-800CW-
TCO  injection,  strong  fluorescence  signals  over  the  central  abdomen  were  
detected  with  the  open  field  camera  even  through  the  skin  (frame  1).  
Following  median  laparotomy  and  removing  the  skin,  the  fluorescence  
detectable  through  the  peritoneum  became  more  prominent  (frame  2).  
Opening  the  peritoneum  revealed  that  the  fluorescence  was  mainly  
located  over  the  primary  tumor  area  (frames  3-5)  as  well  as  over  the  
tumor  mass  at  the  site  of  surgical  incision  (data  not  shown).  In  addition,  
a  strong  fluorescence  was  detectable  over  the  kidneys  and  bladder,  
especially  at  6h  p.i.,  which  most  likely  corresponds  to  excreted  cRGD-
800CW-TCO.  Lower  fluorescence  was  also  detectable  over  organs  known  
to  have  a  high  integrin  expression  such  as  the  intestine  and  the  uterus.  
As  shown  in  Figure  7C  FGS  allowed  a  clear  delineation  of  the  tumor  
margins.  In  addition,  ex  vivo  imaging  shows  an  increased  signal  at  both,  
the  tumor  and  scar  thereby  confirming  the  findings  mentioned  above  
and  with  MSOT.  The  real-time  images  taken  before  and  directly   
  
88│ Pre-operative MSOT in combination with FGS                     Chapter 4                        
 
Figure 7. FGD of an orthotopic PDAC bearing mouse model  
(A) Representative images of an orthotopic PDAC bearing mouse at 6h and (B) 24h p.i. of 
cRGD-800CW-TCO. Selected frames of representative movies (frame 1-6) recorded with the 
Artemis during different steps of the dissection are shown. At both time-points strong 
fluorescence intensities are detectable over the primary tumor area (yellow line). In addition, 
strong fluorescence is detectable over kidneys and bladder, especially at 6h p.i. and lower 
fluorescence over the intestine and uterus. Red arrows mark strong fluorescence over the 
tumor mass at the peritoneum. (C) Photographic  and  cRGD-800CW-TCO-derived  
fluorescence  images  recorded  directly  before  (left)  and  after  (middle)  the  resection  of  
a  primary  tumour  attached  to  the  stomach  and  duodenum  are  shown.  The  margins  of  
the  primary  tumour  detected  with  FGS  are  delineated  with  red  line.  Note,  that  the  
fluorescence  signals  over  the  sternum  and  kidneys  is  still  detectable  after  the  
resection.  Panels on the right  show  the  fluorescence  signals  over  the  resected  primary  
tumour  attached  to  the  stomach  and  over  the  tumour  mass  at  the  surgical  scar. 
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Figure 8. Histological analyses of cryosections in comparison to the fluorescence and 
optoacoustic images of whole mice 
Representative transversal cryoslices (Cryo) of a PDAC bearing mouse sacrificed 6h p.i. of 
cRGD-800CW-TCO and the matching  MSOT MIPs  show almost identical distribution of the 
fluorescence (Fluo) and optoacoustic signals (MSOT) in the tumor pointed out by the yellow 
arrows. The yellow dotted lines outline the kidneys (K), the white lines the stomach (S) and 
the white dotted lines the bladder (B).  
after  the  resection  of  the  pancreatic  tumor  tissue,  together  with  
stomach  and  duodenum,  clearly  confirmed  that  the  resection  bed  is  
empty  of  the  tumor-derived  fluorescent  signals  upon  removal  of  the  
cRGD  labeled  tissue,  with  only  the  background  fluorescence  remaining. 
 
Ex  vivo  validation  confirms  accumulation  of  cRGD-800CW-TCO  in  an  
orthotopic  PDAC  mouse  model 
To  verify  the  accumulation  of  cRGD-800CW-TCO  within  the  tumor  and  to  
validate  the  results  from  the  in  vivo  fluorescence-  and  optoacoustic  
imaging,  we  performed  various  ex  vivo  analyses. 
Two  mice  with  orthotopic  PDAC  were  sacrificed  and  frozen  directly  after  
their  last  scan  (one  at  6h  p.i.  and  one  at  24h  p.i.)  followed  by  
cryosectioning  of  the  entire  body.  Fluorescence  distribution  in  the  
transversal  cryosections  with  respect  to  the  mouse  anatomy  was  then  
compared  to  the  signals  obtained  by  spectral  unmixing  of  MIPs  of  MSOT  
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data.  Figure  8  shows  representative  transversal  slices  at  the  level  of  the  
bladder,  the  tumor  and  the  kidneys  for  the  PDAC  mouse  sacrificed  at  6h  
p.i..  In  both  tested  mice  the  ex  vivo  fluorescence  measurements  revealed  
a  similar  distribution  pattern  as  the  optoacoustic  signals  obtained  in  vivo  
with  MSOT  (Figure  8,  yellow  arrows).   
 
Finally,  excised  samples  of  tumor  tissue  attached  to  the  stomach  and  
liver  were  cryosliced  and  analyzed  with  a  flatbed  fluorescence  scanner  
before  HE  staining  was  performed.  As  shown  in  Figure  9A-B,  strong  
cRGD-800CW-TCO  fluorescence  was  predominantly  found  at  the  tumor  
margins  allowing  for  a  clear  delineation  of  the  tumor  nodules  (Figure  
9A),  with  lower  but  still  well  detectable  fluorescence  within  the  central  
tumor  mass.  On  a  cellular  level,  co-staining  of  the  tumor  sections  with  
antibodies  targeting  different  integrins  was  
performed,  in  order  to  visualize  the  distribution  of  the  in  vivo  injected  
probe,  cRGD-800CW-TCO,  in  relation  to  the  target.  As  shown  in  Figure  
9C,  the  staining  pattern  of  the  anti-ανß3  integrin  antibody  (in  blue)  
showed  a  highly  similar  pattern  to  that  of  the  injected  cRGD-800CW-TCO  
probe  (in  green).  In  contrast,  anti-αν  integrin  antibody  (in  red)  
homogenously  stained  the  tumor  tissue,  however  without  any  correlation  
to  the  cRGD-800CW-TCO  binding  sites.  The  same  staining  pattern  was  
observed  on  high  resolution  images  (Fig.  9D). 
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Figure 9. Histological analysis of PDAC samples obtained from FGD  
(A) Representative fluorescence scan of a cryoslice of the primary PDAC tumor attached to 
the stomach and liver and (B) corresponding HE staining of the same section demonstrating 
a strong accumulation of cRGD-800CW-TCO especially at tumor margins/invasion front 
(arrows). (C,D) Fluorescence microscopy of the tumor cryoslices shows co-localisation of 
cRGD-800CW-TCO only with anti-ανß3 integrin antibody but not with anti-αν integrin 
antibody staining. Scale bars in A and B: 2000 µm, C: 500 µm and D: 250 µm 
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To our knowledge, this is the first study showing the potential and feasibility 
of MSOT as a pre-operative imaging modality for the detection of deep-seated 
orthotopic pancreatic tumors in mice with an integrin targeting probe 
33
. Using 
cRGD-800CW-TCO as a probe, we were able to distinguish the primary tumor 
and several small tumor nodules from healthy tissue non-invasively, with high 
specificity and by notably higher resolution than with planar fluorescence 
imaging. Finally, during FGD, which we used to mimic PDAC surgery, we not 
only confirmed the localisation of the tumor nodules detected by MSOT but 
could also clearly delineate tumor margins with high sensitivity.  
 
In the first part of our study we analyzed the spectral characteristics of cRGD-
800CW-TCO and found a clear red-shifted absorbance spectrum of the 
spectrometer compared to the in vitro and in vivo results by MSOT. This shift 
can be assigned to differences in relaxation times of probe molecules as they 
are excited with light pulses of different lengths
34
. In vivo, spectral coloring, 
the phenomenon by which light propagating through tissue undergoes 
wavelength specific fluence attenuation
35
 or interactions with proteins might 
occur and cause wavelength shifts. Spectral unmixing of MSOT was performed 
after fluence correction using a linear regression algorithm and using the 
spectrum measured from the MSOT phantom in order to maximize the 
specificity of the unmixed results for cRGD-800CW-TCO. As this was closely 
correlated with the spectrum derived from the subcutaneous tumor we were 
confident that using the retrieved spectrum was an appropriate choice.  
 
Using planar in vivo fluorescence imaging in cRGD-800CW-TCO injected 
orthotopic xenotransplants we were able to detect diffuse fluorescence 
signals over the upper abdomen, indicative of signal emanating from the 
primary tumor and/or from the tumor mass at the site of surgical incision. This 
however, did not allow for the precise localization of particular tumor nodules 
nor did it contain any information about the depth. In contrast, scanning the 
same mice with the MSOT resulted in high-resolution cross-sectional images 
from the abdominal area, which enabled the detection and localisation of the 
primary tumor and several deeply located small tumor nodules. In addition, by 
applying planar fluorescence imaging we obtained strong background signals, 
especially at early timepoints p.i. which were much lower in MSOT 
measurements, resulting in about 15-fold higher TBRs. This can be explained 
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by the fact that with planar fluorescence imaging all the fluorescence which 
reaches the object surface from different sources and depths after being 
subjected to absorbance and scattering, is collected and merged on the 
intensity maps. Consequently, the fluorescence of deeply located tumors 
appears less intense and more spread. Furthermore, the fluorescence from 
the circulating probe, especially in the surface-near areas can appear more 
intense, increasing the background signal and thereby decreasing the TBR. In 
this context, one advantage of MSOT over planar fluorescence imaging is the 
possibility to quantify signals in single slices (see SI) which leads to more 
reliable TBRs. Nevertheless, similar to fluorescence imaging, MSOT only allows 
a relative quantification of the signals. In both methods absolute 
quantification can only be achieved by a full correction for the absorption, 
scattering and anisotropy of the tissue, the technology to achieve this is still in 
its infancy
36,37
. Other methods such as gamma spectroscopy or mass 
spectrometry could be considered to be applied in future studies if absolute 
quantification of signals is needed.  
 
Detection of pancreatic tumors with MSOT has previously been described 
33
. 
Various probes have been used before, e.g. targeting Syndecan-1
33,38
 or  EGFR  
39
  and  all  of  them  allowed  a  clear  and  specific  detection  of  probe  
derived  optoacoustic  signals  over  the  primary  tumors.  However,  in  all  
these  studies,  pancreatic  tumor  cells  were  orthotopically  transplanted  
into  the  tail  of  the  pancreas  which  resulted  in  the  development  of  only  
locally  restricted  tumors  that  grew  on  the  left  side  of  the  abdomen  next  
to  the  spleen  and  close  to  the  body  surface  and  were  therefore  
relatively  easy  to  localise.  By  contrast,  in  our  study  we  transplanted  
PDAC  cells  into  the  head  of  the  pancreas  which  resulted  in  the  
development  of  nodular  primary  tumors  widely  spread  within  the  
pancreas  and  located  deep  in  the  abdominal  cavity,  invading  into  the  
stomach  and  duodenum  and  accompanied  with  tumor  mass  growing  at  
the  site  of  surgical  incision  as well as  multiple  abdominal  metastasis,  as  
described  by  us  and  others  
27,40
.  This  is  a  much  more  relevant  model,  as  
in  humans  about  65%  of  the  pancreatic  tumors  arise  in  the  head  of  the  
pancreas  and  only  15%  in  the  body  and  tail  
41
.  Despite  of  this  much  
more  challenging  model,  we  could  clearly  detect  optoacoustic  signals  
over  the  spread  tumor  nodules,  showing  that  MSOT  is  highly  suitable  for  
the  detection  and  discrimination  of  particularly  deeply  located  and  
disseminated  tumors. 
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Finally,  by  performing  FGD  of  cRGD-800CW-TCO  injected  tumor-bearing  
mice  we  could  confirm  that  the  signals  detected  by  the  fluorescence  
camera  during  the  surgery  revealed  similar  patterns  than  those  detected  
with  MSOT  before  surgery.  This  shows  that  MSOT  can  provide  a  specific  
overview  of  the  distribution  and  localization  of  the  fluorescence  signal  at  
the  tumor  sites  and  therefore  represents  an  ideal  complement  to  the  
FGS.  In  contrast  to  planar  fluorescence  imaging  -  which  has  excellent  
sensitivity  for  superficial  targets  but  becomes  strongly  limited  by  
absorption  and  scattering  of  the  incident  and  emitted  light  with  
increasing  depth  -  MSOT  is  not  susceptible  to  the  scatter  of  emitted  
light.  This  makes  MSOT  more  sensitive  for  imaging  of  deeply  located  
tissue,  as  confirmed  by  the  higher  TBRs  obtained  with  MSOT.  
Nevertheless,  despite  the  clear  advantages  over  planar  fluorescence  
imaging  such  as  high  spatial  resolution  and  increased  penetration  depth,  
MSOT  still  has  its  limitations.  The  work  flow  of  MSOT  is  much  slower  
than  that  of  planar  fluorescence  imaging  and  includes  i.e.  multi-
wavelength  acquisition,  reconstruction,  spectral  unmixing,  and  further  3D  
reconstruction,  which  can  require  additional  post-processing  and  makes  
operation  in  real-time  not  always  possible.   
 
The  development  of  MSOT  instrumentation  arose  from  the  need  for  
translational  imaging.  Although  handheld  optoacoustic  devices  are  
emerging,  which  can  be  handled  similarly  to  classical  ultrasound  scan-
heads,  the  current  clinical  translation  of  optoacoustic  systems  is  still  
restricted  to  the  detection  of  intrinsic  absorbers  such  as  haemoglobin,  
melanin  or  lipids  or  FDA  approved  unspecific  contrast  agents  
13,42,43
.  
Several  clinical  trials  using  MSOT  have  already  been  performed  
44
,  
showing  a  powerful  potential  of  the  technique.  However,  without  the  
availability  of  clinical  available  targeted  probes,  the  full  translation  of  
optoacoustic  imaging  to  the  clinic  is  limited.  Our  study  may  support  a  
progression  in  this  direction. 
 
Overall,  we  have  demonstrated  that  cRGD-800CW-TCO  can  be  used  as  a  
targeted  probe  to  visualize  orthotopic  PDAC  tumors  with  several  optical  
imaging  modalities.  The  TCO  tag  within  the  probe  was  designed  for  
future  therapeutic  approaches  based  on  the  two  step  “click  chemistry”  
principle,  aiming  future  pre-targeting  possibilities  with  a  radiolabel  to  
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irradiate  left  over  tumor  tissue.  This  would  involve  a  two-step  system  
with  tumor-specific  binding  of  cRGD-800CW-TCO as the first step and the 
subsequent binding of a small fast-clearing radiolabeled molecule to the TCO 
tag as the second step of the treatment. Click chemistry via TCO tag has 
already been shown to improve tumor specificity 
26
.   
 
Nevertheless,  in  addition  to  the  signals  at  the  disseminated  primary  
pancreatic  tumors,  we  detected  both,  fluorescence-  and  optoacoustic  
signals  at  the  abdominal  wall.  We  ascribed  these  signals  to  the  tumor  
mass  developed  at  the  scar  of  the  laparotomy  site,  as  the  fluorescence  
intensity  was  in  accordance  with  the  size  of  the  tumor  mass  present  at  
the  scar.  Furthermore,  we  detected  relatively  high  background  signals  
from  the  circulating  probe,  as  well  as  relatively  high  fluorescence  from  
healthy  tissue  with  a  high  cellular  turnover  such  as  intestine  or  uterus.  
This  is  not  very  surprising,  as  integrins  in  general  orchestrate  cell-cell  
and  cell-extracellular  matrix  adhesive  interactions  from  embryonic  
development  to  mature  tissue  function.  In  addition,  the  ανβ3  integrin,  
which  is  the  major  target  for  cRGD,  is  connected  with  angiogenesis,  
wound  healing  and  cell  migration  
45
.  We  thus  cannot  exclude  that  some  
tissue  remodelling  processes  involving  integrins  still  take  place  at  the  
scar  tissue,  which  could  be  a  source  of  part  of  the  cRGD-derived  signals  
over  the  upper  abdomen.  Taken  together,  this  indicates  that  the  RGD-
targeting  probe,  although  sufficient  for  the  perioperative  detection  of  
tumor  nodules,  is  not  ideal  for  the  improvement  of  the  specificity  of  
therapeutic  approaches.  Therefore,  for  clinical  use,  the  choice  of  the  
target-ligand  combination  should  be  further  optimised. 
 
 Altogether  we  showed,  that  MSOT  has  the  unique  ability  to  give  an  in  
vivo  whole-body  3D  overview  of  the  distribution  of  the  probe  and  its  
clinical  pre-surgery  application  might  provide  surgeons  with  information  
about  the  tumor  distribution  and  its  interactions  with  the  
microenvironment  and  surrounding  organs  and  structures.   
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Necrosis is a unique biomarker in cancer patients. Quantification of tumor 
necrosis in cancer patients is of diagnostic value as the amount of necrosis is 
correlated with disease prognosis and it could also be used to predict early 
efficacy of anti-cancer treatments. The purpose of this study was to show the 
strong necrosis avid properties of two near infrared fluorescent (NIRF) 
carboxylated cyanines; HQ5 and IRDye800CW (800CW). 
 
Procedures 
Several in vitro and in vivo mouse models were used, in combination with 
quantitative structure activity relations (QSAR) modeling, to confirm the 
necrosis avid properties of HQ5 and 800CW. 
 
Results 
In vitro studies showed that both dyes selectively bind to cytoplasmic proteins 
of dead cells that have lost membrane integrity. Affinity for cytoplasmic 
proteins was confirmed using quantitative structure activity relations 
modeling. In vivo results, using NIRF and optoacoustic imaging, confirmed the 
necrosis avid properties of HQ5 and 800CW in a mouse 4T1 breast cancer 
tumor model of spontaneous necrosis. Finally, in a mouse EL4 lymphoma 
tumor model, already 24h post chemotherapy, a significant increase in 800CW 




We showed, for the first time, that the NIRF carboxylated cyanines HQ5 and 
800CW possess strong necrosis avid properties in vitro and in vivo. When 
translated to the clinic, these dyes may be used for diagnostic or prognostic 
purposes and for monitoring in vivo tumor response early after the start of 
treatment. 





Cell death by necrosis merely occurs under pathological conditions, as a result 
of physiochemical damage or sudden metabolic failure and is involved in 
cancer development and treatment 
1,2
. The amount of tissue necrosis is of 
diagnostic value in many cancer types, since a high degree of necrosis is an 
indicator of rapid and aggressive tumor growth and is often correlated with 
poor prognosis 
3-10
. Moreover, necrosis can also be induced by injury caused to 
tumor tissue by anti-cancer treatments. Finally, therapeutic approaches that 
initially induce apoptotic cell death often result in secondary necrosis, as a 
natural outcome of the complete apoptotic program 
11
. Accurate 
quantification of the amount of tissue necrosis has great potential for pre- 
clinical and clinical applications, especially in monitoring anti-cancer efficacy 
at an early stage of treatment instead of at the end of therapy. However, the 
existing modalities and methods as for example standardized uptake 
values (SUVs) of FDG-PET, determination of tumor markers or of specific 
tumor mRNAs all lack the accuracy for a broad and routine application 
12,13
. Therefore, the long lag- time in determining therapy outcome causes 
loss of valuable treatment time in non-responding patients that will receive 
expensive treatment and are unnecessarily exposed to side effects. Early 
evaluation of the therapy efficacy would therefore facilitate the growing call 
for individualized cancer treatment, allowing the clinician to adjust the 




In vitro, cell necrosis is often measured using dyes such as Eosin, Propidium 
Iodide (PI), TO-PRO-3 and Trypan Blue, which enter necrotic cells upon loss of 
membrane integrity and cannot permeate living cells. PI and the cyanine TO-
PRO-3 subsequently intercalate into DNA 
14-16
 rendering them potentially 
mutagenic, which has hampered their clinical use. Perfetto et al. showed that 
amine-reactive cyanines could also be employed to discriminate between 
living and dead cells in vitro 
17,18
. The amine-reactive group on such cyanines 
can covalently interact with free amino moieties that are available on every 
protein. Because these amine-reactive compounds are incapable of passing 
intact cell membranes, only extracellular membrane proteins of living cells are 
labeled. However, as soon as cells lose their membrane integrity, cytoplasmic 
proteins become available for dye binding, leading to an accumulation of 
these agents in dead cells. Though, this principle cannot be employed in vivo, 
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as immediately after injection, these reactive cyanines will non-specifically 
interact with all proteins accessible. 
In vivo, MRI in combination with non-specific contrast agents, such as 
Dotarem, have been employed to visualize necrosis. However, with this 
procedure it was impossible to reliably distinguish healthy from necrotic tissue 
or neoplastic growth 
19
. Consequently, the focus shifted towards the 
development of compounds that could selectively target necrotic tissues. 
Already in 1988, Epstein and colleagues developed monoclonal antibodies 
against nuclear antigens, allowing specific targeting of necrotic tissue present 
in solid tumors 
20
. However, the use of antibodies is limited due to their size, 




Necrosis avid contrast agents (NACAs) are another class of compounds that 
specifically accumulate in necrotic tissue, these are categorized in porphyrin 
or non-porphyrin-based compounds. NACAs, such as the well-known 
compound hypericin, are assumed to specifically bind proteins, peptides and 
nucleotides that become available upon loss of cell membrane integrity 
22,23
. 
However, most of these compounds have poor solubility, high tendency to 
aggregate, are photo-toxic and lack specificity, which are the main reasons 
why there are currently no clinically approved NACAs available 
23,24
. Therefore, 
there is an unmet need for non-toxic, small-molecule based probes that can 
target necrosis with high specificity for diagnostic imaging and treatment 
follow-up.  
 
In the present study, using several in vitro, cell death, assays, we identified the 
near infrared fluorescent carboxylated cyanines, HQ5 and 800CW as new non-
toxic water soluble NACAs. These NACAs bind to intracellular cytoplasmic 
proteins of cells that have lost membrane integrity. We employed quantitative 
structure activity relations (QSAR) modeling to predict the overall trajectory of 
these dyes to their cellular localization sites. In contrast to amine-reactive or 
maleimide containing cyanines, used for protein labeling, carboxylated 
cyanines cannot covalently interact and are therefore indicated as non-
reactive. Next to in vitro studies, we also characterized the necrosis avid 
properties of HQ5 and 800CW in an in vivo 4T1 mouse breast cancer  
model of spontaneous tumor necrosis and in an EL4 lymphoma model in 
which cell death was induced by chemotherapy. In these animal models, due  
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to their small size, whole body imaging using NIRF imaging, or multi-spectral 
optoacoustic (OA) imaging, is well suited as a light penetration depth of 
several cm can be obtained in this part of the spectrum 
25
. The actions of the 
cyanines were compared to those of the blood pool agent 800CW-PEG.  
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Materials and Methods 
 
QSAR modeling 
Estimation of the structure parameters for carboxylated HQ5 and IRDye 
800CW (800CW) and the integration of the parameters with appropriate QSAR 





HQ5 carboxylate was obtained from Ilumicare BV (Rotterdam, The 
Netherlands). The dyes 800CW, 800CW-2-Deoxyglucose (800CW-2DG), 
800CW-epidermal growth factor (800CW-EGF) and 800CW-polyethylene glycol 
(800CW-PEG) were obtained from LI-COR Biosciences.  
 
Cells and culture conditions 
4T1-luc2 murine mammary cancer cells (PerkinElmer) was cultured in 
complete RPMI-1640 medium (Life Technologies, Inc.). EL4 murine lymphoma 
cells were cultured in complete Iscove’s Modified Dulbecco’s Medium (Life 
Technologies). Cells were transduced with a lentivirus for the expression of 
CBG99 luciferase under the control of the constitutive promoter PGK as 




Dry ice dead cell assay 
In vitro, cell death was studied using a cryo-induced cell death assay, which 
detailed procedures have been described previously 
29
. Briefly, a bar of dry ice 
was applied to the underside of the culture well confluent with 4T1-luc2 cells 
for 15sec. Subsequently, the cells were incubated with HQ5, 800CW or 
800CW-PEG, respectively (100nM, 15min, room temperature (RT), in the 
dark). After gentle washing with PBS, the samples were scanned for 
fluorescence imaging (FLI) using an Odyssey Infrared Imager 9120 (LI-COR). For 
bioluminescence imaging (BLI), D-luciferin solution (25µg/µl; SynChem Inc.) 
was added for 10min incubation. BLI measurements were then acquired using 
an IVIS Spectrum imaging system (PerkinElmer).  
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FACS analyses  
The detailed procedures for flow cytometry of cells after inducing cell death 
have been described previously 
29
. Briefly, 4T1-luc2 cells were incubated in the 
presence or absence of gambogic acid (GA, 4µM, 24h, Calbiochem) or 
Staurosporine (Sta, 3µM, 24h, Sigma-Aldrich). Cells were then collected and 
re-suspended in 100µl PBS. The cell suspensions were incubated in the dark 
for 15min at RT with one of the cyanines (200nM). Alternatively, cells were 
stained with the commercially available cell death probes AVF and PI 
(PromoKine) in accordance with the manufacturer’s protocols. Flow cytometry 
was performed using a BD LSR II or Canto II Flow Cytometer (BD Biosciences). 
The data was analyzed using FlowJo software. 
 
Confocal microscopy 
4T1-luc2 cells were cultured in a glass bottomed culture dish (MatTek Corp.) 
until 80% confluent. Cell death was induced by incubation with GA (3µM, 1h). 
Subsequently, the cells were washed gently with PBS and incubated in the 
presence of 80nM HQ5 in the dark for 15 min at RT. AVF and PI were used in 
accordance with the manufacturer’s protocols. Afterwards, samples were 
imaged using a Leica TCS SP5 confocal microscope (Leica). 
 
SDS-PAGE analysis 
Cytoplasmic and membrane protein samples of 4T1-luc2 cells were prepared 
using a subcellular protein fractionation kit (Thermo Scientific) according to 
the manufacturer’s protocol. Samples of protein extracts (2µg per lane) were 
incubated with either HQ5 or 800CW (1µM) for 15min at RT in the dark. For 
Bovine serum albumin (BSA) commercial preparations of BSA (5µg per lane, 
Life Technologies) were incubate with either HQ5 or 800CW (0.1, 0.5 and 
2µM, respectively) for 15min at RT in the dark. Subsequently, samples were 
mixed with SDS-PAGE sample buffer without indicative blue dye and loaded 
onto reduced 12.5% SDS polyacrylamide gel. The precision plus protein marker 
(BIO-RAD) was loaded to one extra lane. After running SDS-PAGE, the gel was 
processed for FLI using the Odyssey Infrared Imager 9120 scanner. Finally, 
protein samples were stained with Coomassie brilliant blue staining (BIO-RAD) 
and photographed. 
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Animals 
Female athymic mice (BALB/c nu/nu, 6weeks old) were acquired from Charles 
River Laboratories (L'Arbresle Cedex, France). All experimental procedures 
were performed under isoflurane gas anesthesia (3% induction, 1.5-2% 
maintenance) in 70% pressurized air and 30% O2, unless stated differently. 
Animals were sacrificed by cervical dislocation at the end of the experimental 
period. The animals were housed per 4-5 animals in individually ventilated 
cages with ad libitum access to food and water. All animal experiments were 
assessed for animal health & ethics and approved by the Animal Welfare 
Committee of Leiden University Medical Center, the Netherlands. All mice 
received humane care and were kept in compliance with the Code of Practice 
Use of Laboratory Animals in Cancer Research (Inspectie W&V, July 1999). 
 
Spontaneous tumor necrosis model 
Mice (n=5) received orthotopic inoculations of 2x10
4
 4T1-luc2 cells beneath 
the upper mammary fat pad. Trypan Blue (Sigma-Aldrich) exclusion was used 
to examine the viability of the tumor cells before injection. After three 
weeks, tumors were formed, containing a spontaneous necrotic core. Whole 
body BLI and FLI measurements were performed using the IVIS Spectrum, with 
either 10min post D-luciferin (150mg/kg) per intraperitoneal (i.p.) injection or 
24h post HQ5 (2nmole per mouse) per i.v. injection.  
3D fluorescent cryomicrotome imaging of a tumor was reconstructed 
according the previous published methods 
30
. In brief, tumor samples were 
immersed in carboxymethylcellulose sodium solvent (Brunschwig Chemie, 
Amsterdam, The Netherlands) mixed with 5% Indian ink (Royal Talens, 
Apeldoorn, The Netherlands) and frozen for at least 24hrs at -25°C. After each 
cut, tumor epi-illumination outline images were acquired at an excitation 
wavelength of 440nm/20nm (central wavelength and bandwidth) and an 
emission wavelength of 435nm/25nm, with 300ms illumination time. Images 
of tumor fluorescence were acquired at an excitation wavelength of 
640nm/50nm and an emission wavelength of 712nm/75nm, 5000ms 
illumination. All tissue samples were imaged in one session with camera 
binning set at 2048x2048 pixel resolution, with a corresponding in-plane 
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MSOT imaging  
A group (n=3) of female athymic nude-Fox1nu mice was inoculated with 4T1 
cells and subjected to MSOT measurements. MSOT measurements were 
performed using the inVision 256-TF system (iThera Medical GmbH, Munich, 
Germany) according to the protocol described previously 
31,32
. In brief, the 
mice were anesthetized and placed in supine position in the animal holder 
throughout the entire imaging process. Cross-sectional multispectral OA image 
datasets were acquired through the tumor at eight different wavelengths in 
the NIR window (690, 700, 710, 740, 760, 780, 800 and 900nm). MSOT 
datasets are reconstructed using the interpolated model-matrix inversion. 
Afterwards, linear spectral unmixing is applied to each set of multiwavelength 
images to resolve biodistribution of the different tissue chromophores and the 




Chemotherapy of murine lymphomas 
Two randomized groups mice (n=3) received a subcutaneous (s.c.) inoculation 
with 1x10
5
 EL4-CBG99-luc murine lymphoma cells on the upper back. 11days 
after inoculation, the animals either received chemotherapy consisting of i.p. 
injection of a combination of cyclophosphamide (CTX, 100mg/kg; Baxter BV, 
The Netherlands) and etoposide (ETO, 70mg/kg; Pharmachemie BV, The 
Netherlands) or remained untreated. After 24h, all animals received an i.v. 
injection of 800CW (5nmole per mouse). FLI measurements were performed 
another 24h after injection using the IVIS spectrum. Whole body BLI 
measurements were performed, before and 24h after injection of the 
chemotherapeutic agents, 10min after i.p. administering D-luciferin 
(150mg/kg). After FLI, all mice were sacrificed and the tumors were surgically 
excised for ex vivo FLI and processed for histological analysis. Image analyses 
were performed using the Living Image software. For quantitative analysis, 
regions of interest (ROI) from acquired images were selected to cover the 
tumor regions. Statistical analysis of the average fluorescent radiant efficiency 
in ROIs was performed using a Student’s t-test. 
Histopathology analysis  
4T1-luc2 and EL4-CBG99-luc tumors were fixed in 4% formaldehyde and 
embedded in paraffin. 5µm sections were prepared and imaged for FLI using 
the Odyssey Infrared Imager 9120 scanner. Afterwards, the consecutive 
sections were subjected to TdT-mediated dUTP Nick-End Labeling (TUNEL) 
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staining (Promega) to validate accumulation of the NIRF probes in dying and 





Figure 1A shows estimates of the most widely used numerical structure 
parameters, amphiphilicity index (AI), conjugated bond number (CBN), 
lipophilicity (logP) and charge (Z), applied to QSAR modeling of the 
carboxylated cyanines HQ5 and 800CW.  
 
In vitro characterization of necrosis avid cyanines 
Using a newly developed in vitro cell death assay, based on local killing of cells 
by freezing 
29
, we identified the carboxylated cyanines HQ5 and 800CW to 
exhibit strong necrosis avid and imaging properties. Figure 1B shows a 
schematic representation of the central, dry ice induced, area of dead 4T1-
luc2 cells (D) and the rim of living cells (L) in the periphery. Moreover, BLI 
measurements, indicated that no bioluminescent signals were obtained from 
the dead cells in the center of the well while the surrounding living cells 
produced strong signals. In contrast, HQ5 or 800CW incubated wells showed a 
strong fluorescent signal in the area of dead cells, but not in the area of living 
cells. The non-specific contrast agent 800CW-PEG, however, showed minimal 
affinity for dead cells. 
 




Figure 1. Physicochemical characteristics and in vitro examination of the necrotic avid 
properties of the near infrared fluorophores (NIRF) HQ5 and 800CW. 
(A) physicochemical characteristics of HQ5 and 800CW; λabs=absorbance wavelength; 
λem=emission wavelength; Mw=molecular weight; AI=amphiphilic index; CBN=conjugated 
bond number; logP=log octanol-water partition coefficient; Z=electric charge. (B) In the dry 
ice cell death assay an area of necrotic cells was induced in the center of a confluent 
monolayer of 4T1-luc2 murine breast cancer cells by applying dry ice for 15sec to the 
underside of a culture well. Cells in the periphery of the culture well remained alive 
(schematically represented as, D=dead cells, L=living cells). Cell viability was confirmed by 
bioluminescent imaging (BLI). After 15min incubation of the cells with HQ5 or 800CW and 
subsequent washing, a strong fluorescent signal was obtained from the area of dead cells. 
The 800CW-PEG signal was almost absent both in the areas of living and dead cells. (C) FACS 
analyses performed with viable 4T1-luc2 cells and 4T1-luc2 cells treated with GA (4uM) or 
Sta 3uM) treatment, followed by staining with HQ5 or 800CW. The fluorescence intensity of 
HQ5 or 800CW stained dead cells was significantly increased compared to that of viable 
cells. FACS analyses were also performed with viable and GA treated cells, subsequently 
stained with 800CW-EGF, 800CW-2DG and 800CW-PEG. The fluorescence intensity of both 
800CW-EGF and 800CW-2DG, in dead cells, was increased compared to viable cells. Using 
800CW-PEG, there was no detectable difference in fluorescence intensity between viable, 
dead and unstained cells. 
 






Figure 2. Confocal microscopic images of the localization of HQ5 in gambogic acid treated 
4T1-luc2 cells. 
(A) The bright-field view (BF) image shows the morphology of GA treated cells undergoing 
cell death. After treatment with GA, cells were stained with HQ5 (red), AVF (green) and PI 
(blue). A large number of cells stained positive for AVF. The merged image depicts a 
fluorescence overlay of HQ5, AVF and PI staining, indicating that cells stained with HQ5 were 
also positive for PI. (B) At the level of a single necrotic cell it was shown that HQ5, appearing 
as a granular cytoplasmatic staining, did not co-localize with membrane AVF nor with PI 
nuclear staining. (C-D) The granular HQ5 staining was further shown to have a great extent 
colocalization with Mitotracker (Mito) but not with Lysotracker (Lyso) in GA treated 4T1-luc2 
cells. The scale bar represents 20µm. 
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The results obtained from the dry ice assay were confirmed by FACS analysis 
(Fig. 1C). 4T1-luc2 cells which were killed by the cytotoxic agents gambogic 
acid (GA) or Staurosporine (Sta) stained highly positive for HQ5 and 800CW, 
this in contrast to living cells. Moreover, our FACS experiments showed that 
the commercially available NIRF imaging probes 800CW-2DG and 800CW-EGF 
in which 2-Deoxyglucose (2-DG) or epidermal growth factor (EGF) are 
conjugated to the side chains of 800CW, also specifically accumulated in dead 
4T1-luc2 cells However, the non-specific contrast agent 800CW-PEG did not 
accumulate in dead cells. 
 
Figure 2A depicts a confocal microscopic image of a GA treated 4T1-luc2 cell 
culture stained with HQ5, Annexin V-FITC (AVF) and Propidium Iodine (PI). The 
bright-field (BF) image shows the morphology of GA treated cells undergoing 
cell death. Most cells stained AVF positive and a few were positive for HQ5 
and PI. The HQ5 positively stained cells coincided with PI nuclear staining and 
not with AVF phosphatidylserine (PS) staining, as visualized in the merged 
image. The intracellular distribution of HQ5, PI and AVF staining in a single 
necrotic 4T1-luc2 cell is shown in Figure 2B. PI selectively stained the cell 
nucleus whereas AVF membrane staining was spread unevenly over the entire 
cell surface leaving the nucleus unstained. The uneven distribution of the stain 
may be explained by the loss of membrane integrity. HQ5 showed a more 
uniform granular staining pattern and did not co-localize with the nuclear stain 
PI or AVF. Furthermore, Figure 2C-D shows that the granular HQ5 staining to a 
great extent co-localizes with Mito-tracker but not with Lyso-tracker. 
Moreover, HQ5 also reveals a unique perinuclear staining. Confocal 
microscopy could not be performed using 800CW as our system is not suitable 
for the detection of 800nm fluorescence. Specific cyanine affinity towards 
membrane and cytoplasmatic proteins was examined on SDS-PAGE using 
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As shown in Figure 3A, HQ5 and 800CW strongly stained several protein bands 
in the cytoplasmatic fraction, but not in the membrane fraction. There was 
some overlap in the staining pattern of the two dyes. Coomassie blue staining 
indicated that proteins were abundantly present in both fractions.  
Furthermore, also affinity of the cyanines towards serum albumin was 
examined using SDS-PAGE analysis. As depicted in Figure 3B, HQ5 shows a 
stronger dose-dependent binding to BSA compared to 800CW, although 
binding only occurred at micromolar concentrations. 
  
Figure 3. SDS-PAGE analyses of HQ5 and 800CW protein binding. 
(A) SDS-PAGE gel electropherogram of cytoplasmatic- and membrane fractions of 4T1-luc2 
cell lysate, incubated with HQ5 or 800CW. Protein binding of HQ5 and 800CW was observed 
in the cytoplasmic but not in the membrane fraction. Coomassie blue staining confirmed the 
presence of proteins in both fractions. HQ5 and 800CW staining showed a different pattern, 
albeit with some common features. (B) Binding of HQ5 or 800CW, at different concentrations 
(0.1, 0.5 and 2µM), to bovine serum albumin (BSA).  
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Animal model with tumor necrosis  
The necrosis avid properties of the cyanines were evaluated in an animal 
model of 4T1-luc2 breast tumors, which, during growth, spontaneously 
develop a necrotic core during progression. As shown in Figure 4A, the BLI 
signal obtained from these tumors has a lower intensity in the center 
compared to the periphery of the tumor, which is indicative of the presence of 
a necrotic core. As expected, FLI of the cyanine HQ5 showed strong 
accumulation of fluorescence in the necrotic center of the tumor. Localization 
of HQ5 fluorescence in the necrotic core of the tumor was confirmed in 3D 
reconstructions of cryo-sections (Fig. 4B) and showed co-localization with 
TUNEL staining in parallel paraffin tumor sections (Fig. 4C). As shown in Figure 
4D, 800CW and bio-conjugated receptor targeting probes 800CW-2DG and 
800CW-EGF also strongly accumulated in the necrotic areas of tumors, 
indicated by a co-localization with TUNEL staining. In contrast, 800CW-PEG did 
not co-localize with TUNEL staining and most of its fluorescence signal was 
localized in the tumor periphery.  
 
Furthermore, we employed 3D Multi-Spectral Optoacoustic Tomography 
(MSOT) imaging to visualize the location of HQ5 in the tumor in vivo. As shown 
in Figure 5, the HQ5 OA signal co-localized with the deoxygenated hemoglobin 
signal present in the center of the tumor and not with the oxygenated 
hemoglobin signal present in the viable rim of the tumor, confirming necrotic 
core localization. 
  




Figure 4. In vivo and ex vivo imaging of spontaneous 4T1-luc2 tumor necrosis with HQ5, 
800CW, 800CW-EGF, 800CW-2DG and, 800CW-PEG. 
(A) Representative in vivo whole body BLI and FLI images of a 4T1-luc2 tumor injected with 
HQ5. The BLI signal originated from the periphery of the tumor (red ring), whereas the HQ5 
FLI signal mainly originated from the necrotic core (red spot). (B) 3D reconstruction of the 
localization of HQ5 in a tumor using an automated fluorescence camera mounted on a cryo-
microtome. (C) Images of a HQ5 and corresponding TUNEL stained tumor section. (D) Images 
of a 800CW, 800CW-2DG, 800CW-EGF and a 800CW-PEG and their corresponding TUNEL 
stained tumor sections. In contrast to HQ5, 800CW, 800CW-2DG and 800CW-EGF, 800CW-
PEG did not co-localize with TUNEL staining. 
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Monitoring early therapeutic response in tumors 
We investigated early therapeutic responses in tumors treated with a 
combination of the chemotherapeutic agents Cyclophosphamide (Cy) and 
Etoposide (Et) in EL4-CBG99-luc lymphoma bearing mice. For this, control 
tumor bearing mice and mice treated with Cy/Et were injected with 800CW 
24h after chemotherapy.  
After another 24h, fluorescence intensity of the tumors was measured. We 
observed a 2.4-fold higher fluorescence intensity in the tumors of chemo 
treated mice compared to those of untreated animals (p<0.001). Vice versa, 
the mean BLI intensity of untreated tumors was 2.8-fold higher than that of 
chemo treated tumors (p<0.05) (Fig. 6A-B). Histological examination of the 
tumors showed a large area of TUNEL positive tissue in the tumors treated 
(Fig. 6C) with chemotherapy which co localized with 800CW staining, whereas, 
no TUNEL or 800CW positive tissue was present in control tumors (Fig. 6D). 
Figure 5. In vivo opto-acoustic imaging of necrosis of spontaneous 4T1-luc2 tumor necrosis 
with HQ5. 
MSOT measurements showing the single wavelength anatomical image and unmixed signals 
of oxygenized hemoglobin (oxi-Hb), deoxygenized hemoglobin (deoxi-Hb) and HQ5. Detail of 
HQ5 targeting of the necrotic core in the center of the tumor. 





Figure 6. Monitoring anti-tumor efficacy in a EL4-CBG99-luc lymphoma mouse model of 
chemotherapy. 
(A) Representative whole body FLI images of tumor bearing mice treated with a combination 
of CTX and ETO and 24hr later injected with 800CW. After another 24h, in vivo whole body 
and ex vivo tumor FLI and BLI images were acquired and signal intensities were quantified. 
(B) The BLI signals obtained from the treated animals were significantly lower as compared 
to those of the untreated controls (*p<0.05). In contrast, the 800CW signals from the treated 
animals were significantly higher as compared to those of the untreated controls 
(***p<0.001). (C-D) Images of 800CW containing and a TUNEL stained tumor section of an 
(C) untreated tumor and a (D) treated tumor. The fluorescent signal obtained from a section 
of a treated tumor co-localized with TUNEL staining of the same section. Negligible 800CW 
fluorescence and TUNEL staining was observed in the untreated tumor. T=treated; 
U=Untreated. 





Reagents that can monitor necrosis in vivo have potential diagnostic and 
prognostic value in staging of cancer as well as for monitoring early efficacy of 
anti-cancer therapies 
1,34
. Compared to apoptosis, relatively few studies have 
addressed the possible role of necrosis as a biomarker for clinical applications. 
As a result, clinical probes that specifically image or target necrosis are 
currently unavailable. Consequently, we present two near infrared fluorescent 
carboxylated cyanines that display necrosis avidity in vitro and in vivo. Our dry 
ice cell death assay showed a selective staining of dead cells using the 
carboxylated cyanines HQ5 and 800CW. However, no dead cell staining was 
observed with the macromolecule, 800CW-PEG (25-60kDa). Nevertheless, the 
smaller 800CW-conjugated probes, 800CW-EGF (6kDa) and 800CW-2DG 
(1kDa), also selectively stained dead cells. The results obtained in the dry-ice 
assay were confirmed by FACS analyses. The difference in necrosis avidity 
between 800CW and its PEG conjugated form might be due to the relatively 
large size of PEG which may cause steric hindrance, as 800CW is maximally 4% 
of the mass of the conjugate. In line, de Boer et. al. recently showed that 
macromolecule cetuximab-IRDye800CW was also unable to accumulate in 
tumor necrosis 
35
. The binding to dead cells of the carboxylate forms of 800CW 
and HQ5 might be unexpected since these compounds, in contrast to the NHS-
ester and maleimide forms, do not contain a reactive group and mainly serve 
as “dye-only” control to examine potential retention of the compound. In 
addition, for 800CW it has been shown that after i.v. injection it does not 
retain in the body and is rapidly cleared via the kidneys 
36
.  
Confocal microscopy showed no uptake of any stain in living cells. 
Nevertheless, after GA treatment we observed HQ5 staining coincided with PI 
but not with AVF staining. As PI selectively targets cells that have lost 
membrane integrity, this characteristic is most likely also involved in the dead 
cell targeting of HQ5. This indicates that HQ5 does not stain apoptotic cells but 
specifically targets necrotic cells. On a single cell level HQ5 staining showed 
not to co-localize with either AVF or PI staining and the granular HQ5 staining 
pattern appeared to be cytoplasmic. The cellular localization of 800CW could 
not be examined due to the absence of specific 800nm microscope settings. 
We confirmed the cytoplasmatic protein binding of our cyanines by SDS-PAGE 
analyses using isolated cell membrane and cytoplasmic protein fractions of 
4T1-luc2 cells. These fractions were incubated with each dye and we observed 
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that both bound to cytoplasmic and not to the membrane protein fractions. 
The pattern of protein binding of HQ5 and 800CW to cytoplasmic proteins 
partly overlapped and also showed preference for a different subset of 
proteins. This is most likely due to the different physical-chemical properties 
of these compounds.  
Using a QSAR model 
26,27
, which is based on the chemical characteristics of 
HQ5 and 800CW, the expected cellular localization was further explored. The 
selective accumulation of these dyes in dead cells requires consideration of 
both dye and cell properties; the former being summarized in Table 1. The 
major species of both HQ5 and 800CW under physiological conditions are 
anionic (Z values of 1- and 4- respectively). Moreover, both dyes have 
conjugated systems of moderate size (CBN values of 34 and 31). Consequently, 
the QSAR model predicts both dyes will bind to proteins, albeit not extremely 
strongly, affinity being due both to ionic attractions with cationic protonated 
amines and to various non-ionic interactions (van der Waals forces). However, 
in other respects the dyes differ markedly. Whilst 800CW is extremely 
hydrophilic (logP=-9.4) and lacks amphiphilicity (AI=0), HQ5 is lipophilic and 
extremely amphiphilic (logP=5.0 and AI=12.5). Necrotic cells have two 
characteristic features, which are significant in this context. Their membranes, 
including those of the plasmalemma and mitochondria, are permeabilized, 
permitting the passage of impermeable dyes 
37,38
. As a result, the 
mitochondrial hydrophobic proteins are more easily accessed by dyes entering 
the necrotic cell. Moreover, protein denaturation will have increased the 
number of protein molecules with surface hydrophobic domains 
39
. 
The hydrophilic character of 800CW renders it membrane impermeable 
27
 and 
so it can only enter permeabilised cells. Once within them, its accumulation 
will be favored by the enhanced dye-binding commonly found with denatured 
proteins 
40
. As this dye is not amphiphilic, is does not bind significantly to 
serum albumin. HO5, however, is a lipophilic dye which based on our 
calculations could possibly enter cells by passive diffusion 
27
. The reason that 
we do not find this in our in vitro assay and confocal analyses is most probably 
due to the fact that HQ5 is very amphiphilic and will bind to serum albumin. It 
has been shown that amphiphilicity is correlated with serum albumin affinity 
27,41
. Binding to serum albumin of HQ5 was confirmed by us using SDS-PAGE 
analysis. Once the cells have lost membrane integrity, HQ5 bound to albumin 
will enter the cells and will bind to proteins with hydrophobic domains, such 
as those common in mitochondria, or those which are denatured 
42
. This is in 
line with the confocal microscopy data showing that HQ5 for a large part co-
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localizes with Mitotracker. From the QSAR model it is clear that, although HQ5 
and 800CW have different chemical characteristics, both can bind to proteins 
but probably using different mechanisms. This is also reflected in the 
difference in binding patterns of the two dyes on SDS-PAGE, showing that they 
target similar and partly different cytoplasmic proteins. Further detailed 
studies are needed to elucidate the exact mechanism of binding of the dyes to 
necrotic cells. 
Dyes with large conjugated systems (CBN>40), but lacking amphiphilicity, such 
as Coomassie Blue and Evans Blue, are predicted by the QSAR model to bind 
strongly to all proteins 
27
. Such dyes are therefore not expected to show 
selective uptake into necrotic cells, but will bind to whatever proteins are first 
contacted. 
The question that remains is if, in vivo, 800CW and HQ5 specifically target 
necrotic tissues or that these compounds non-specifically localize in and 
around necrotic sites because they comprise blood pool characteristics? For 
example, previous studies indicated that blood pool contrast agents can be 
employed to indicate tissue injury, due to their passive leakage from blood 
vessels at sites of tissue damage. In addition, blood pool agents are employed 
to detect tumors because of their ability to accumulate in tumor tissue, as a 
result of a process known as the enhanced permeability and retention (EPR) 
effect 
43
. This process is characterized by the ability of macromolecules (>20 
kDa), or small molecules bound to serum albumin, to accumulate in tumors as 
a result of their passive leakage from abnormal tumor vasculature. In contrast, 
small molecules (<20 kDa), which possess no affinity for blood proteins, do not 
retain and rapidly penetrate the interstitial space of tumors and subsequently 
diffuse freely back into the blood pool or the lymphatic system. Therefore, the 
increased retention of blood pool agents at or in the vicinity of tissue damage 
sites or in tumors is not due to a specific interaction with necrotic tissue, but is 
merely the result of reduced diffusion velocity of large molecules out of the 
tissue compartment.  
Previous studies and our study show that 800CW possesses very low affinity 
for blood proteins and consequently rapidly extravasates after i.v. injection 
44
. 
This indicates that the small molecule 800CW is not a blood pool agent and, 
therefore, will retain in tissue because of a specific binding to intracellular 
proteins of necrotic cells. The in vivo specificity of 800CW for necrotic tissues 
is strengthened by the observation that this compound strongly co-localizes 
with TUNEL staining, a feature that is not observed with the blood pool agent 
124│ NACAs for imaging cell death                                                Chapter 5 
 
800CW-PEG. Similar to 800CW, HQ5 also shows a strong co-localization with 
TUNEL staining in necrotic areas in tumors. However, in contrast to 800CW, 
HQ5 can bind to serum albumin and thus potentially serves as blood pool 
agent. Similarly, the photosensitizer Hypericin, which is currently under pre-
clinical investigation because of its necrosis avid properties, also possesses 
affinity for albumin 
45
. In contrast, the well-known blood pool agent Evans 
Blue, which also strongly binds to serum albumin, has been shown to target 
the viable rim of tumors rather than the necrotic core 
46
. Moreover, based on 
the observation that of the albumin binding compounds Gadophrin-2 and 
MP2269, only the first possessed NACA properties Ni et al. 
23
 stated that 
necrosis-avidity is an outstanding feature beyond the general pharmacological 
process of albumin-binding mediated drug transportation. Combined, it might 
be concluded that the role of blood protein binding in the mode of action of 
this particular group of NACAs needs, to be established.  
In our 4T1-luc2 tumor necrosis model, HQ5 and 800CW showed co-localization 
with TUNEL staining, and the same was true for the 800CW-EGF and 800CW-
2DG conjugated probes and not for 800CW-PEG. Therefore, it is important to 
note that 800CW-EGF and 800CW-2DG, that are specifically designed and have 
been extensively used to target the EGF receptor (EGFR) and the Glucose 
receptor-1 (GLUT) 
47,48
, also have strong necrosis avidity due to the presence 
of CW800 which can direct these probes towards necrotic cells. This new 
finding has to be taken into consideration when interpreting experimental 




The necrosis avidity of HQ5 and 800CW was further investigated in a well-
known model of chemotherapy. We showed that 800CW could be used to 
monitor early treatment efficacy. This feature is of great significance since in 
current clinical practice the efficacy of anti-cancer treatment can only reliable 
be established late during treatment or after completion of the treatment. 
Therefore, currently non-responding patients receive an expensive 
treatment and are unnecessarily exposed to side effects 
1,2
. Finally, it is worth 
mentioning some of the limitations of the present study, which include the 
use of athymic mice, the use of transplanted and not spontaneous tumors 
and the usage of only one type of anti-cancer treatment, namely 
chemotherapy.   
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Future perspectives and clinical relevance 
Opto-acoustic imaging, a technique in which a pulsating light signal is 
transformed into an ultrasound wave, provides much deeper tissue 
penetration (approximately 5 cm) and higher resolution than other optical 
imaging modalities currently available. This technology can revolutionize 
medical imaging in clinical practice. With the development of a handheld 
MSOT scanner, with applications in breast and melanoma imaging, the clinical 
translation of opto-acoustic imaging is already materialized and may also ease 
the translation of our necrosis probes to the clinic especially since we have 
shown that HQ5 can be detected using MSOT 
52-55
. 
However, for detection of tumors deep within the body, when measurements 
beyond the maximal optical or Opto-acoustic penetration depth are required, 
the dyes have to be radiolabeled in order to allow their visualization with 
standard clinical imaging modalities like SPECT or PET. Our preliminary results 
show that radiolabeling of a structural analogue of HQ5 with Indium-111, 
using the chelate DTPA is feasible and that this probe still specifically 
accumulates in necrotic cells in vitro and in necrotic cores of tumors 
(unpublished data). Moreover, from an economical point of view it is worth to 
mention that the production costs of the cyanines, especially when 
synthesized in bulk amounts are low and that the rates for radio labeling and 
subsequent SPECT/PET scanning will be comparable to those of other clinically 
used SPECT/PET probes. 
 
The concept of employing tissue necrosis, as a biomarker for diagnostic and 
prognostic purposes of disease, is not new. With the objective to target and 
image necrotic tissue, already back in 1988 Epstein and colleagues developed 
several so called TNT antibodies 
20
 and more recently Ni and colleagues 
22,45,56,57
 reported on the specific necrosis avid properties of the 
photosensitizer Hypericin in small animals. However, both compounds were 
examined not just for their potential as contrast agents, but also for their 
possible usage in cancer treatment by coupling of Iodine-131 used for local 
radiation therapy. In this way, when the necrosis avid agent has accumulated 
in the necrotic core of the tumor, the cancer is selectively irradiated and killed 
from the inside. After showing proof of concept, in animal studies 
58
, the TNT 
antibodies even reached clinical phase I and II studies 
59
. However, for both 
TNT antibodies and Hypericin, full clinical translation is hampered because of 
increased concern about adverse effects and other drawbacks based on their 




. No such concerns are expected with the 
employment of the NIRF cyanines examined in this study. NIRF cyanines are 
successfully used already for more than a decennium for experimental and 
clinical experimental purposes including fluorescence image guided surgery 
without serious side effects 
61
. In addition, toxicity studies by Marshall and 
colleagues, showed that 800CW carboxylate administrated as a single 
intravenous or intradermal dose of 20mg/kg, which is about 100-fold above 
the maximum dose utilized in our experiments, did not result in any 
pathological evidence of toxicity in rats 
36
. Therefore, our necrosis avid 
carboxylated NIRF dyes can potentially be used clinically to image necrotic 
tissue for diagnostic and prognostic purposes, to detect treatment response in 
tumors and for drug delivery.  
 
In conclusion, we have demonstrated that the carboxylated cyanines 800CW 
and HQ5, as well as 800CW-2DG and 800CW-EGF, possess strong necrosis avid 
properties. The molecular mechanism of necrosis avidity involves targeting of 
cytoplasmic proteins after loss of cell membrane integrity. Using NIRF imaging 
in different mouse models of cancer, we showed that these dyes can be 
applied to detect spontaneous tumor necrosis, which is of diagnostic and 
prognostic value. Moreover, we showed that they can be utilized to monitor 
early treatment responses in tumors after anti-cancer therapy and potentially 
they can also be used for drug delivery. Therefore, when translated to the 
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Recently we showed that a number of carboxylated near infra-red fluorescent 
(NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as 
in different mouse models of spontaneous and treatment induced tumor 
necrosis, indicating their potential use for cancer diagnostic- and prognostic 
purposes. In the previous study, the detection of the cyanines was achieved by 
whole body optical imaging, a technique that, due to the limited penetration 
of near-infra red light, is not suitable for investigations deeper than one 
centimeter within the human body. Therefore, in order to facilitate clinical 
translation, the purpose of the present study was to generate a necrosis avid 
cyanine based probe that could be used for Single Photon Emission Computed 
Tomography. For this, the necrosis avid NIRF cyanine HQ4 was radiolabeled 
with 
111
Indium, via the chelate diethylene triamine pentaacetic acid (DTPA).  
 
Procedures 
The necrosis avid properties of the radiotracer [
111
In]DTPA-HQ4 were 
examined in vitro and in vivo in different breast tumor models in mice using 
SPECT and optical imaging. Moreover, biodistribution studies were performed 
to examine the pharmacokinetics of the probe in vivo. 
 
Results 
Using optical imaging and radioactivity measurements, in vitro, we showed 
selective accumulation of [
111
In]DTPA-HQ4 in dead cells. Using SPECT and in 
biodistribution studies, the necrosis avidity of the radiotracer was confirmed 
in a 4T1 mouse breast cancer model of spontaneous tumor necrosis and in a 





In]DTPA-HQ4 possessed strong and selective necrosis 
avidity in vitro and in various mouse models of tumor necrosis, indicating its 
potential to be clinically applied for diagnostic purposes and to monitor anti-











Necrosis is a form of cell death characterized by severe cell swelling, 
denaturation and coagulation of cytoplasmic proteins and disruption of the 
cell membrane, causing the release of its intracellular content. Necrotic cell 
death is irreversible and is induced by external factors or disease, such as 
radiation, trauma and loss of blood supply, and is also involved in cancer 
development and treatment 
1,2
. In the center of most solid tumors, an area of 
ischemia and subsequent necrosis develops, as vascularization cannot keep up 
with the rapidly growing tumor mass. The size and growth rate of this necrotic 
area is positively correlated with the aggressiveness of cancer and can, 
therefore, be used as a diagnostic biomarker of cancer staging 
3-8
. Moreover, 
anti-cancer treatments like chemotherapy are utilized to induce cell death, 
increasing the total amount of tumor necrosis 
9-11
. Thus, agents that 
specifically bind to necrotic tumor tissue can contribute to a more accurate 
disease diagnosis and can be exploited to predict early treatment outcome of 
anti-cancer treatments 
12
. To this end, back in 1988, Epstein and colleagues 
13
 
developed so called Tumor Necrosis Targeting (TNT) antibodies, that are 
directed towards nuclear proteins, and labeled with radioactive Iodine for 
imaging and anti-cancer treatment purposes. Likewise, the photosensitizing 
agent Hypericin has also been shown to possess necrosis avidity and is 
currently under investigation for cancer imaging and treatment purposes 
14-17
. 
However, there are several drawbacks for the existing agents. Antibodies are 
relatively large in size, have long circulation time, could induce immune 
response and expensive to develop in Good Manufacturing Practices (GMP) 
quality, and the photosensitizer Hypericin is phototoxic, poorly soluble and 
tend to aggregate rapidly 
16,18,19
. All these issues hamper the clinical 
translation of these compounds 
14,20-22
. 
Recently, we reported on two near infrared fluorescent (NIRF) carboxylated 
cyanine dyes, HQ5 and IRDye 800CW (800CW) that also possess strong 
necrosis avid properties 
23
. Cyanines are, amongst other dyes, widely used as 
fluorescent tags for protein labeling to enable whole body optical imaging in 
small animals 
24-28
. Although the mechanism of necrosis avidity is not fully 
understood, it is independent on the Enhanced Permeability and Retention 
(EPR) effect 
23,29
. On a cellular level, increased retention of the dye may 
involve augmented accessibility to cells that have lost membrane integrity 
along with an increased affinity to denatured cytoplasmatic proteins 
30-32
. 
Using whole body optical imaging in mice, we showed that these cyanines can 
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be employed to image areas of spontaneous necrosis in solid tumors and to 




Optical imaging is successfully applied in whole body imaging for small animals 
and in imaging of superficial tissues in humans. Optical imaging is based on the 
detection of light emitted from agents and/or tags coupled to biomolecules in 
living systems. In order to obtain better tissue penetration, optical imaging 
often makes use of agents and tags that emit light in the near infrared range. 
However, even with these compounds, the maximal penetration depth is 
limited to a few cm 
33,34
. Although, this relatively small measuring range is 
sufficient for the detection of light in small animals, it is not sufficient for the 
detection of light in deep tissues such as tumors situated deep within the 
human body. Alternatively, nuclear imaging modalities such as Single Photon 
Emission Computed Tomography (SPECT) and Positron Emission Tomography 
(PET) are used clinically to image deep tissues. To enable SPECT and/or PET 
imaging for clinical translation, our previously described necrosis avid NIRF 
cyanines must be radiolabeled. Generally, this is achieved by conjugating a 
targeting moiety to a chelate that is subsequently labeled with a metal 
radionuclide 
35-38
. In the present study we employed this principle to the 
necrosis avid cyanine HQ4, a close structural analogue of the recently studied 
necrosis avid cyanine HQ5 
23
. As HQ5 has two moieties which can be 
functionalized by the chelate diethylene triamine pentaacetic acid (DTPA) we 
used HQ4, a mono-derived analogue, to avoid scrambling of the DTPA 
molecules or steric hindrance 
39
. HQ4 was conjugated to the chelate (DTPA) 




In-Cl3) was performed. In 
this study we investigated the necrosis avidity of [
111
In]DTPA-HQ4 in vitro and 
in mouse tumor models of spontaneous and chemotherapy induced tumor 
necrosis using optical imaging and SPECT. 
 
  




Material and methods  
 
Compounds 
The cyanine dyes; HQ4 carboxylate and HQ4-NHS ester were obtained from 
Ilumicare BV (Rotterdam, The Netherlands). 
 
Synthesis of HQ4-DTPA 
Synthesis of diethylene triamine pentaacetic acid (DTPA)- Polyethylene Glycol 
(PEG) –NH2, DTPA containing PEG amine link (4,7,10-trioxa-1,13-
tridecanediamine, indicated as PEG-NH2 in the formula (DTPA-PEG-NH2) was 
synthesised on Chloride-Trityl Chloride (Cl-TrtCl) resin. Thus, 
Fluorenylmethyloxycarbonyl (Fmoc)-PEG amine was incorporated on Cl-TrtCl 
resin (CTC resin) by reacting 3eq. Fmoc-PEG amine in presence of 6eq. N,N-
Diisopropylethylamine (DIEA) in Dichloromethane (DCM) overnight at room 
temperature (RT). Final loading was measured by Fmoc quantification and the 
value obtained was around 0.8 mmol/g. Fmoc group removal was carried out 
with piperidine— Dimethylformamide (DMF) (1:5)(1 x 1min, 2 x 10min). Next, 
the DTPA-(terta-tBu ester)-COOH (2eq.) was coupled using N,N'-dipropan-2-
ylmethanediimine (DIPCDI) (2eq.) and Hydroxybenzotriazole (HOBt) (2eq.) in 
DMF overnight. After coupling overnight the ninhydrin test was negative. Later 
on, DTPA-(terta-tBu ester)-CO-NH-PEG-CTC-resin cleavage and deprotection 
was performed in two steps. DTPA-(terta-tBu ester)-CO-NH-PEG-CTC-resin was 
treated with 1% Trifluoroacetic acid (TFA) in DCM 10 times for 1min each time. 
Excess DCM was removed using vacuum and side chain protecting groups 
were removed using 95% TFA, 2.5% Triisopropylsilane (TIS) and 2.5% water. 
DTPA-CO-NH-PEG-NH2 was precipitated with cold Methyl-tert-butylether 
(MTBE) after TFA removal under a N2 stream. The DTPA-CO-NH-PEG-NH2 was 
dissolved in water and lyophilized to obtain the final product. The desired 
DTPA-CO-NH-PEG-NH2 was 85.0% in yield with a purity of 90.6% as analyzed 
by High-performance liquid chromatography (HPLC) (retention time 2.28min). 
HPLC- mass spectrometry (MS), m/z calc.: 523.25 for C20H37N5O11, Found: 
524.5.28 [M+1]+ and matrix assisted laser desorption/ionisation time-of-flight 
(MALDI-TOF) analysis found 524.2 [M+1]+ 546.3 [M+Na]. 
Synthesis of DTPA-CO-NH-PEG-NH2–HQ4: HQ4-NHS (8.3x10-4mmol, 1 mg) 
dissolved in 50µL of Dimethyl sulfoxide (DMSO) was added to DTPA-CO-NH-
PEG-NH2 (2.8 x 10-3mmol, 2mg) dissolved in 200 µL of DMSO containing 5µL 
DIEA and stirred overnight at room temperature. Later on, the complex DTPA-
CO-NH-PEG-HQ4 was purified by reversed phase (RP)-HPLC. The desired DTPA-
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PEG-HQ4 was 50.5% in yield with a purity of 98% as analyzed by HPLC (tR 
5.34). HPLC-MS, m/z calc.: 1331.59 for C66H90N8O17S2, Found: 
1332.0[M+1]+ and MALDI-TOF Found 1331.9 [M+1]+ 1353.9 [M+Na]. 
 
Cells and culture conditions 
4T1-luc2 mouse mammary cancer cells (PerkinElmer, Waltham, MA, USA) and, 
MCF-7 human mammary cancer cells were all cultured in RPMI-1640 medium 
(Life Technologies Inc., Carlsbad, CA, USA) supplemented with 10% fetal calf 
serum (FCS; Lonza, Basel Switzerland), 100 units/ml penicillin and 50 μg/ml 
Streptomycin (Life Technologies Inc.). All cell lines were cultured in a 
humidified incubator at 37°C and 5% CO2, monthly checked for Mycoplasma 
infection by polymerase chain reaction (PCR) and checked routinely for 
morphologic changes. 
 
Dry ice dead cell assay 
In vitro, cell death was studied using a cryo-induced cell death assay as 
previously described
40
. In short, 4T1-luc2 cells were seeded onto 24-well tissue 
culture plates (Sigma-Aldrich) and grown until confluent. After discarding the 
medium, a bar of dry ice 3-5mm in diameter was applied to the underside of 
the culture well for 20sec. Subsequently, the cells were incubated in the dark 
for 15min. at RT with HQ4 at a concentration of 100 nM. After incubation, the 
samples were gently washed with phosphate buffered saline (PBS) and 
subsequently scanned for fluorescence using the Odyssey Infrared Imager 
9120 (LI-COR) and for radioactivity via phosphor imaging on the Typhoon 9410 
imager (GE Healthcare).  
 
In vitro viability assay 
4T1-luc2 cells were plated in a 96-well plate (Costar) in 100 µl medium at a 
density of 10.000 cells per well and left over night to adhere. The next day the 
medium was replaced with medium containing the experimental compounds: 
HQ4, HQ4-DTPA, HQ5 and Gambogic acid (GA), 3 wells per condition. After 
24h, cell viability was measured using a nonradioactive colorimetric MTS 
viability assay (Promega Benelux) according to the manufacturer’s protocol. 
Optical absorption was measured at 490 nm with a Versamax absorbance 
microplate reader (Molecular Devices).  
 
  





Female athymic mice (BALB/c nu/nu, 6weeks old) were purchased from 
Charles River Laboratories (L'Arbresle Cedex, France). Animals were housed at 
22°C and 50% humidity with free access to food and water and maintained 
under standard 12 h light/12 h dark cycles. All surgical and analytical 
procedures were performed under isoflurane gas anesthesia (3% induction, 
1.5-2% maintenance) in 70% pressurized air and 30% O2. Animals were 
sacrificed by cervical dislocation at the end of the experimental period. The 
animals were housed per 4-5 animals in individually ventilated cages with ad 
libitum access to food and water. 
All animal experiments were assessed for animal health, ethics, and research 
and approved by the Animal Welfare Committee of Leiden University Medical 
Center, the Netherlands. All mice received humane care and were kept in 
compliance with the Code of Practice Use of Laboratory Animals in Cancer 
Research (Inspectie W&V, July 1999). 
 
Subcutaneous Tumor Model 
Approximately 1*10
5
 4T1-luc2 cells, suspended in 15 µl PBS, were implanted 
bilateral and subcutaneously onto the upper back of nude mice. Tumors were 
grown until they reached a size of 6-7 mm in diameter which developed 
roughly after 1.5-2 weeks of tumor implantation. 
Similarly, 2*10
6
 MCF-7 cells, suspended in 15 µl PBS in a 1:1 mixture with 15 µl 
of Matrigel (BD biosciences, San Jose, CA, USA) were injected bilateral and 
subcutaneously onto the upper back. Tumors were grown until they reached 
6–7 mm diameter, which developed after approximately 2-3 weeks.  
Whole body FLI measurements were performed using the Pearl Impulse in vivo 
fluorescence imager (LI-COR) and/or IVIS Spectrum in vivo imaging system 
(PerkinElmer) several time points after injection. On the IVIS, an excitation and 
emission wavelength of 675nm and 720 nm was used for HQ4.  
 
Radiolabeling of HQ4-DTPA and SPECT 
To label HQ4-DTPA with 
111




In-Cl3 (35MBq; Covidien-Mallinckrodt, Dublin, Ireland) was added. 
After 30min. of incubation on the shaker, labeling was validated with high-
pressure liquid chromatography (HPLC) (Jasco Inc., Easton, MD, USA) or thin 
layer chromatography (TLC). In all cases, labeling efficacy was >90%. 
To study the specificity of the radiolabeled HQ4-DTPA versus radiolabeled 
DTPA in vivo, 10 μg [
111
In]DTPA-HQ4 (=10 nmole per mouse) or 10 μg 
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[
111
In]DTPA was injected i.v. into mice bearing 4T1-luc2 tumors (n=3 and 4, 
respectively). The total injected dose (ID) in each mouse was determined in a 
dose-calibrator (VDC101, Veenstra Instruments, Joure, the Netherlands). 
SPECT scans were conducted at several time points post injection on a 3-
headed U-SPECT-II gamma camera (MILabs, Utrecht, The Netherlands) under 
isoflurane anesthesia for 40 minutes. Radioactivity counts from total body 
scans were acquired using a 0.6mm mouse pinhole collimator with energy 
settings at 171 and 245keV with a window of 20% and background energy 
settings of respectively 4.5% and 3.5% around the tails of the energy window 
42
. Subsequently, the image was reconstructed using 20 POSEM iterations with 
4 subsets, 3D gauss 1 mm (FWHM) filtering, a 0.2mm voxel size, and with 
decay and scatter corrections integrated into the reconstruction 
43
. Images 
were generated and analyzed using PMOD software. In vivo SPECT scanning 
was followed by in vivo fluorescence imaging on the Pearl Impulse Small 
Animal Imaging System (LI-COR). 
After the last imaging time point mice were sacrificed and several tissues were 
excised, weighed, and counted for radioactivity (Wizard2 2470 automatic 
gamma scintillation counter, Perkin Elmer, USA) to determine the percentage 
of the injected dose per gram (%ID/g). The %ID/g was calculated as follows: 
((MBq measured in tissue/injected dose) *100%) /weight of tissue).  
 
Chemotherapy of MCF-7 tumors 
In two groups of mice (n=5), two weeks after tumor implantation the mice 
received either an i.p. injection of cyclophosphamide (265 mg/kg; Baxter BV, 
Utrecht, The Netherlands) 
44
 or remained untreated. After 72hr, all animals 
received an i.v. injection of radiolabeled HQ4-DTPA. SPECT scans were 
conducted 24hr later, followed by whole body FLI. After the last imaging time 
point mice were sacrificed, several tissues were excised, weighted, and 
counted for radioactivity.  
 
Ex vivo tumor imaging 
Ex vivo tumor imaging was performed to visualize the distribution of the probe 
in the tumor. Images were obtained for FLI (Odyssey Infrared Imager 9120 (LI-
COR)) and for radioactivity via phosphor imaging (Typhoon 9410 imager (GE 
Healthcare) and ImageQuant TL software). For phosphor imaging the tumors 
were manually sliced in sagittal sections and placed o/n on a phosphorscreen.  
 
  





The tumors collected for histological analysis were fixed in 4% formaldehyde 
and embedded in paraffin. 5µm sections were prepared and FLI was 
performed using the Odyssey Infrared Imager (LI-COR). Afterwards, the 
sections were subjected to TdT-mediated dUTP Nick-End Labeling (TUNEL) 
staining (Promega, Madison, WI, USA) to validate accumulation of the NIRF 
probes in necrotic cells. 
 
Statistical Analysis 
All statistical analyses was performed using Prism software (GraphPad). For 
repeated measures a student’s t-test was used in all cases. P < 0.05 was 




We selected the necrosis avid cyanine HQ4, instead of HQ5, to perform 
radiolabeling and further in vitro and in vivo investigations to demonstrate its 
potential clinical translation. The choice for HQ4 was based on the number of 
functionalized moieties present in the cyanine molecules, which is one in the 
case of HQ4 and two in the case of HQ5 (see Fig. 1A). Furthermore, as shown 
in Figure 1B, HQ4 showed slightly higher necrosis avid properties in our dry ice 
dead cell assay than HQ5. The fluorescent signal intensity, obtained from the 
area of cell death caused by freezing, was over the whole dose range (1 -100 
nM) 2.8 (+/- 1.0) -fold higher for HQ4 as compared to HQ5. A HQ4-DTPA 
hybrid complex was synthesized by covalent coupling via conjugation with a 
polyethylene glycol (PEG) linker (Fig. 2).  
 
Reversed-phase chromatography showed a clear peak indicating the high 
grade of purity (98%) of this conjugate. Mass spectrometric analysis of HQ4-
DTPA further showed the expected molecular weight (calc.: 1331.59 for 
C66H90N8O17S2 and MALDI-TOF found 1332.4 [M+1]+ 1354.6 [M+Na]), 
indicating the high grade of purity of this conjugate (see Fig. 3). Lastly, the 
HQ4-DTPA conjugate was labeled with 
111
In-Cl3 with a labeling efficiency of 
>90% (data not shown).  
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In vitro viability assay 
 
Figure 1. Structural characteristics and in vitro necrosis avid properties of HQ4 vs HQ5.  
(A) Chemical and structural characteristics of the carboxylated cyanine dyes HQ4 and HQ5. 
(B) In vitro necrosis targeting properties of HQ4 and HQ5 utilizing the dry ice assay. 
Fluorescent signal intensity was obtained from the area of dead cells in the center of a 
culture well after incubation with different concentrations of HQ4 or HQ5 (1-100 nM) and is 
subtracted by the background signal from the area of the living cells. 
 
Figure 2. Chemical and structural characteristics of HQ4-DTPA.  
Chemical structure of HQ4-DTPA. λabs=absorbance wavelength; λem=emission wavelength. 




Using the MTS cell toxicity assay, the acute in vitro toxicity of the cyanine dyes 
 
Figure 4. MTS cell viability assay of various agents. 
Confluent cultures of 4T1 cells were incubated for 24hr with various concentrations HQ4, 
HQ4-DTPA, HQ5 or the natural anti-cancer compound Gambogic Acid (GA). Relative cell 
viability (%) was expressed as a percentage relative to the untreated control. HQ4, HQ4-
DTPA and HQ5 did not affect cell viability, whereas, GA induced cell death with an IC50 of 
around 6µM. 
 
Figure 3. Reversed-phase mass spectrometry of HQ4-DTPA. 
Reversed-phase chromatography showed a clear peak indicating the high grade of purity 
(98%) of this conjugate. Mass spectrometric analysis of HQ4-DTPA further showed the 
expected molecular weight (calc.: 1331.59 for C66H90N8O17S2 and MALDI-TOF found 1332.4 
[M+1]+ 1354.6 [M+Na]), indicating the high grade of purity of this conjugate. 
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HQ4, HQ4-DTPA and HQ5 were examined in 24h cultures of 4T1 breast cancer 
cell and compared with the cytotoxic compound Gambogic acid (GA). In the 
dose range of 0 - 20 µM, none of the cyanine compounds affected cell 
viability. GA, however, dose dependently induced cell death with an IC50 of 
around 6 µM (see Fig. 4).   
 
In vitro necrosis targeting properties of [
111
In]DTPA-HQ4 
The dry ice dead cell assay was performed to examine the necrosis avid 
properties of the entire conjugate [
111
In]DTPA-HQ4 and the individual 
Figure 5. In vitro necrosis avid properties of [
111
In]DTPA-HQ4 by fluorescence and 
radioactivity measurements. 
(A) Necrotic cell death in confluent monolayers of 4T1 mouse breast cancer cells was induced 
by applying dry ice to the underside of the culture well. Cells were subsequently incubated for 







(100 nM, 10 µg). After subsequent washing with PBS, cells were imaged either for 
fluorescence imaging (FLI, upper panel) or for radioactivity (RA, lower panel). NL = not 
labeled. (B) Calculated signal-to-background (S/B) ratio (FLI and RA) of the different 
compounds obtained from the dry-ice assay. The S/B ratio was defined as the signal intensity 
obtained from the area of dead cells in the center of the well divided by the signal intensity 
obtained from an area of living cells of the same size in the periphery. 




components, HQ4 and HQ4-DTPA, respectively, in vitro. HQ4, HQ4-DTPA and 
[
111
In]DTPA-HQ4 all strongly accumulated in the area of dead cells, as shown 
by fluorescence imaging (Fig. 5A). In addition, radioactive signal was obtained 
in areas of dead cells only when incubated with [
111
In]DTPA-HQ4. In contrast, 
neither [
111
In]DTPA nor free 
111
In-Cl3 accumulated in the dead cells area, as 
indicated by RA measurements. Figure 5B shows quantifications of the 
fluorescent and radioactive signal-to-background (S/B) (dead cells vs living 
cells area) ratios for the five different compounds tested confirming that 
[
111
In]DTPA-HQ4 retains fluorescence and radioactivity, as well as necrosis 
avidity with a S/B ratio of 11.1 and 2.4 respectively. 
 
Necrosis targeting properties of [
111
In]-DTPA-HQ4 in a 4T1 mouse tumor 
model of spontaneous necrosis  
The necrosis targeting properties of [
111
In]DTPA-HQ4 were evaluated in 
subcutaneous 4T1 breast tumor bearing mice, using SPECT and optical 
imaging. [
111
In]DTPA-HQ4 (10 nmole, 30-35MBq) was injected intravenously 
(i.v.) into the tumor bearing mice, and in vivo SPECT and optical images were 
obtained 6, 24h, 48 and 72h, post injection (Fig. 6A and B). An increased 
retention of [
111
In]DTPA-HQ4 in the tumors and in the metabolizing organs 
was observed over time with both optical imaging and SPECT.  
To further assess the biodistribution of [
111
In]DTPA-HQ4 in different organs, 
mice (n=3) were sacrificed at each time-point. Subsequently, radioactivity in 
various organs and body fluids was quantified (Fig. 6C). The measured 
radioactivity across different time points confirmed accumulation of 
radioactivity in the tumors (4.8 %ID/w), liver (3.3 %ID/w) and the kidneys (7.6 
%ID/w) at 72hrs post injection. Finally, histological examination of the 4T1 
tumors confirmed the presence of a large necrotic core, see Figure 6D.  
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Figure 6. Optical imaging, SPECT and biodistribution of [111In]DTPA-HQ4 in 4T1 breast 
tumor bearing mice.  
(A) Whole body FLI (coronal view) obtained 6-72h after tail vein injection of [
111
In]DTPA-HQ4 
(10 nmole, 30-35 MBq). The white light image (WL) indicates the position of the mouse in the 
Pearl imager, from a dorsal point of view (T=tumor). The same device settings were applied 
to all FLI, rendering comparison between the different images possible. (B) Whole body 
SPECT images (sagittal view) obtained 6h-72h after tail vein injection of [
111
In]DTPA-HQ4 (10 
nmole, 30-35 MBq). The white light image (WL) indicates the position of the mouse from a 
sagittal point of view, in the µSPECT (RA); T=tumor, L=liver, K=kidney and I=intestine. Arrows 
indicate the tumor. 
(C) Biodistribution of [
111
In]DTPA-HQ4 in 4T1 tumor bearing mice. 6h, 24h, 48h and 72h after 
probe injection, mice (n=3 per time point) were sacrificed and the organs, body fluids and 
tumors were dissected, weighed and measured for radioactivity in a gamma counter. At each 
time point, the amount of radioactivity in the organs is expressed as percentage of the 
injected dose divided by body weight (%ID/w). (D) TUNEL stained histological section of a 
representative 4T1 mouse breast tumor showing a large area of necrosis (brown). 




Similarly, the biodistribution of the radiolabeled chelate [
111
In]DTPA was 
examined in 4T1 tumor bearing mice 24h after i.v. injection of [
111
In]DTPA (10 
µg, 30-35 MBq). Mice (n=4) were euthanized and the internal organs and body 
fluids were removed to quantify remaining radioactivity (see Fig. 7A). Greatest 
accumulation of radioactivity was observed in the kidneys (5.0 %ID/w) and 
only relatively low values of radioactivity could be measured in other organs, 
body fluids and tumors ( tumors; 0.5 %ID/w, liver 0.6 %ID/w).  
 
Figure 7B, shows the measured amount of radioactivity in the mouse corpus 





expressed as the percentage of the total injected doses (%ID). It was found 
that 24h and 48h after injection of [
111
In]DTPA-HQ4, respectively 38% and 35% 
of total injected dose was retained in the body, whereas, this was only 10% 
and 8%, for [
111
In]DTPA.  
Figure 7. Biodistribution of [
111
In]DTPA. 
(A) Biodistribution of the free chelate [
111
In]DTPA in 4T1 tumor bearing mice. 24h after probe 
injection (10 µg, 30-35 MBq), mice (n=4) were sacrificed and the organs, body fluids and 
tumors were dissected, weighted and measured for radioactivity in a gamma counter. At 
each time point, the amount of radioactivity in each organ and tumor is expressed as 





In]DTPA in the whole mouse body (% of ID) at the 
indicated time points 6 to 72h after probe injection. 
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SPECT and optical imaging of [
111
In]DTPA-HQ4 in a MCF-7 mouse model of 
chemotherapy induced tumor necrosis  
Using SPECT and optical imaging, we examined whether [
111
In]DTPA-HQ4 
could be employed to monitor chemotherapy induced tumor necrosis. For 
this, MCF-7 tumor bearing mice were treated with a single intraperitoneal 
(i.p.) injection of cyclophosphamide (265mg/kg) 
44
, followed by an i.v. injection 
of [
111
In]DTPA-HQ4 (10 nmole, 30-35MBq) 72h later. 24h after injection of 
[
111
In]DTPA-HQ4, whole body optical images and SPECT were obtained to 
assess its biodistribution. Both optical imaging and SPECT showed 
accumulation of [
111
In]DTPA-HQ4 in cyclophosphamide treated tumors as 
compared to untreated tumors (Fig. 8A and B). Figure 8C shows quantification 
of the fluorescent signals obtained from the tumors, 24h after probe injection. 
A significant increase in tumor fluorescent signal intensity was observed in 
mice that were treated with chemotherapy as compared to untreated controls 
(ratio = 1.8:1.0, p= 0.0011).  
 
Figure 8. Optical imaging, SPECT and biodistribution of [
111
In]DTPA-HQ4 in chemotherapy-
treated MCF-7 tumor bearing mice.  
(A - B) Representative whole body FLI (coronal) and SPECT (transversal) images of MCF-7 
tumor bearing control (a) and cyclophosphamide treated (b) mice. Mice were injected with 
[
111
In]DTPA-HQ4 (10 nmole, 30-35 MBq), 72h after injection with chemotherapy. Whole body 
FLI and SPECT were acquired 24h after probe injection. The dashed lines indicate the 
boundary of the tumors. 
(C) Mean FL signal intensity obtained from the tumors of control and chemotherapy-treated 
mice (n=5, two tumors per mouse), 24h after injection of [
111
In]DTPA-HQ4. (D) Biodistribution 
of [
111
In]DTPA-HQ4 in MCF-7 tumor bearing mice. Mice were injected with [
111
In]DTPA-HQ4 
72h after chemo-treatment, and were sacrificed 24h later and the organs, body fluids and 
tumors were dissected, weighed and measured for radioactivity in a gamma counter. At each 
time point, the amount of radioactivity in the organs is expressed as percentage of the 
injected dose divided by the weight (%ID/w). 




Biodistribution study based on quantification of radioactivity in various organs 
further demonstrated higher amount of radioactivity in chemotherapy treated 
tumors compared to untreated controls. The average %ID/w was 1.85 for the 
control tumors vs 4.02 for the chemo-treated tumors (Fig. 8D). In addition, a 
significantly higher amount (1.4-fold) of radioactivity was observed in left 
kidneys of the chemotherapy-treated mice as compared to controls. Finally, 
tumors of chemotherapy-treated and control mice, which were injected with 
[
111
In]DTPA-HQ4 (10 nmole, 30-35 MBq), were dissected and cut in half to 
perform ex-vivo fluorescence and radioactivity analysis. In addition, the 
opposite half of the tumor was processed for paraffin embedding and 
histological analysis.  As shown in Figure 9, the TUNEL stained section of the 
untreated control tumor showed very little necrotic tissue, whereas the 
chemotherapy-treated tumor contained a large area of necrotic tissue (brown 
staining). Notably, the TUNEL staining showed co-localization with both 
fluorescence and radioactivity signals in tumors, confirming the specific 
increased necrosis retention property of [
111
In]DTPA-HQ4. For comparison all 
the settings used for the different images are similar.  
 
Figure 9. Histological and ex vivo analyses of [
111
In]DTPA-HQ4 injected control and 
chemotherapy treated MCF-7 tumors.  
Tumors were dissected 24h after probe injection and were subsequently cut in half for ex-
vivo FLI and RA analyses. The opposite half of the tumor was used for paraffin embedding 
and TUNEL-staining (brown indicates the area of necrosis). FLI = Fluorescence imaging and 
RA = radioactivity. 
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Discussion 
 
Over the last two decades, several attempts have been made to exploit 
disease and/or therapy induced tumor necrosis as a diagnostic and/or 
prognostic biomarker of disease and to utilize necrotic tissue as a target for 
drug delivery. The existing necrosis imaging agents can be divided in two 
different groups; (non-) specific CT and MR contrast agents to enhance the 
natural signal and the other group consists out of mostly radiolabeled necrosis 
avid contrast agents (NACAs) that specifically target necrotic tissue. The latter 




. It is expected that the non-specific necrosis contrast 
agents will fall into abeyance when compounds with high necrosis specificity 
become clinically available. However, thus far, only the 
131
Iodine conjugated 
Tumor Necrosis Targeting Therapy monoclonal antibody (TNT-3), licensed by 
Peregrine Pharmaceuticals, reached the clinical trials for therapeutic use 
13,21
. 
This antibody, under the brand name Cotara
TM
, has been examined in clinical 
trials for treatment of Glioblastoma Multiforma. However, although 
encouraging results have been published on the website of the manufacturer 
in December 2012, no follow-up studies have been reported since 
50
. In 
addition, the necrosis avid photosensitizer Hypericin, under the brand name 
Oncocidia, is also under investigation to enter clinical trials 
14,51,52
. Although 
proof of concept has been shown for both approaches, both compounds, as 
mentioned earlier, suffer from major drawbacks which hampers their clinical 
translation.  
To overcome the limitations associated with the size and possible 
immunogenicity of antibodies, the photo-toxicity, problems with solubility and 
ability to aggregate, a simple, injectable and non-toxic agent that displays 
specific necrosis avidity is required. Recently, we demonstrated that two non-
toxic constituents of the group of NIRF cyanine dyes, IRDye800CW and HQ5 
carboxylate, the former being commonly used as an optical probe for 
biomolecular labeling 
53,54
, display strong and specific necrosis avid properties 
in vitro as well as in tumor bearing mice 
23
. In this study, the increased 
retention of NIRF cyanine dyes in tumor necrosis was examined using whole 
body fluorescence imaging. Although whole body optical imaging is suitable 
for use in small animals, it is often insufficient for assessments of deep tissues 
in the human body, due to the limited tissue penetration depth of NIRF light. 
In order to seek for potential clinical applications for our newly discovered 
necrosis avid cyanines, we examined the possibility to radiolabel it for in vivo 




nuclear imaging by conjugating to a chelator 
55,56
. To render HQ4 applicable for 
SPECT we first conjugated HQ4 to the chelate DTPA with a linker molecule, 
and subsequently radiolabeled with 
111
In-Cl3. Following the synthesis and 
purification procedures, purity of 98% was achieved. Thus, we created a 
molecule that targets necrosis and can be imaged using both NIRF and SPECT.  
 
We demonstrated in vitro that [
111
In]DTPA-HQ4, like unconjugated HQ4, 
appears to specifically bound to dead cells after washing. Our findings, in the 
dry ice assay, show that the specificity of [
111
In]DTPA-HQ4 for necrotic cells 
was solely due to the presence of the HQ4 molecule, as the radiolabeled 
chelate [
111
In]DTPA alone and free 
111
In-Cl3 did not show to bind to the dead 
cells. Although DTPA conjugation is likely to change the chemical and physico-
chemical properties of HQ4, for example by increasing its overall 
hydrophylicity 
57
, it retained its necrosis avid- and fluorescent properties. We 
observed a clear difference in the signal-to-background (S/B) ratio of 
[
111
In]DTPA-HQ4 between fluorescence- and radioactivity measurements. The 
reason for this discrepancy is unclear, but may involve environmental 
conditions that specifically affect the fluorescent properties of the molecule. 
Previously, Jiskoot et. al 
58
 reviewed the fluorescence properties of extrinsic 
dyes, which are strongly influenced by their environment 
(hydrophilic/hydrophobic or differences in pH) and/or by interactions with 
proteins. Such factors may also influence fluorescence signal intensity of HQ4 
in an environment of living cells compared to in an environment of dead cells. 
However, such environmental dependent signal intensity influences will not 
occur when a radiolabel, offering a quantitative readout, is utilized. 
Nevertheless, the observed S/B ratio of 2.5, obtained with radioactivity 
measurements, is theoretically sufficient for clinical translation 
59
. Additional 
studies that determine the relationship between time, probe concentration, 
and S/B ratio could help to optimize the sensitivity of the measurements.  
Furthermore, none of the cyanine dyes, including HQ4-DTPA, showed any 
acute in vitro toxicity in cultures of 4T1 cells. Even at the highest concentration 
of 20uM (during 24h), which is 200-fold higher compared to the concentration 
used to image dead cells in vitro, cell viability remained unaffected.  
Collectively, our in vitro study revealed that DTPA conjugation is not 
deleterious to the necrosis avid properties of HQ4 and the lack of toxicity 
encouraging further studies with the aim of its clinical translation. Further 
investigations are warranted concerning the mechanism of interaction of the 
DTPA conjugated cyanine to specific proteins in necrotic cells. In the paper of 
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Xie et. al. 
23
 we showed that HQ5, a close cyanine analogue of HQ4, specifically 
accumulated in necrotic cells and not in apoptotic cells. Moreover we have 
shown that HQ5 does not co-localize with F4/80 macrophage staining in an 
around the tumor, indicative of inflammation. Nevertheless, we did not yet 
examine these specific mechanistic properties for HQ4..  
Using in vivo whole body optical imaging, SPECT, and ex vivo analysis, we 
confirmed the observed in vitro necrosis avid properties of [
111
In]DTPA-HQ4 in 
two tumor models: 4T1 mouse breast cancer tumor model of spontaneous 
necrosis and MCF-7 human breast cancer tumor model of chemotherapy 
induced tumor necrosis. MCF-7 tumor model was selected to assess 
chemotherapy-induced necrosis due to its slow growth kinetics. MCF-7 tumor 
cells have a population doubling time (PDT) of approximately 38h in vitro 
60
, 
thus representing a slow-growing tumor. This is in contrast to 4T1-cells, PDT 
+/- 12h 
61
, which develop necrotic cores spontaneously, and to EL4-cells, PDT 
+/- 17h 
62
, used in the previous paper 
23
. Since MCF-7 cells hardly develop 
spontaneous necrosis during their growth, necrosis induced by chemotherapy 
is more evident and can be determined with higher accuracy. Moreover, MCF-




In both mouse tumor models, the acquired optical imaging and SPECT results 
over time, provided information on the pharmacokinetic profile of 
[
111
In]DTPA-HQ4. In the model of spontaneous tumor necrosis, necrotic areas 
in the tumor were clearly delineated using optical imaging and SPECT. No clear 
specific tissue interactions could be detected 6h after injection, probably due 
to high quantities of unbound circulating probe in the blood at this early time 
point. The amount of radioactivity that retained in the 4T1 tumors remained 
approximately equal over time, while, it declined in most organs and body 
fluids, resulting in a relative increase in tumor signal intensity inside the tumor 
at later time points. In the chemotherapy-induced tumor necrosis model, the 
specific targeting of [
111
In]DTPA-HQ4 to necrotic areas of MCF-7 tumors was 
confirmed histologically using TUNEL staining. In this model we also observed 
that the kidneys of the chemotherapy-treated mice retained more 
radioactivity than in untreated mice. The reason for this is unknown, but it 
might be speculated that some necrosis may develop due to 
cyclophosphamide induced renal oxidative stress which leads to perioxidative 
damage to the kidneys 
64
.  
Finally, we compared the biodistribution and clearance rate of [
111
In]DTPA-
HQ4 with that of the free labeled chelate ([
111
In]DTPA). We observed that both 




the biodistribution and the excretion rate of the two compounds were vastly 
different. 24h after probe injection, [
111
In]DTPA was mainly retained in the 
kidneys and could hardly be detected in other organs or in the tumors, 
confirming our in vitro findings of a lack of tumor necrosis specificity. The 
observed accumulation of [
111
In]DTPA in the kidneys confirms findings of 
Boswell and colleagues 
65
 who also reported predominant clearance of this 
hydrophilic compound via this excretion route. Moreover, not only the organ 
distribution of these two compounds was dissimilar, the clearance rate of 
[
111
In]DTPA was about 8-fold faster than that of [
111
In]DTPA-HQ4. Combined, 
these findings indicate that both the pharmacokinetics and the tissue 




In]DTPA are largely different 
and strengthen the notion that the cyanine HQ4 governs the overall necrosis 
avid properties of the [
111
In]DTPA-HQ4 molecule.  
 
In summary, we successfully yielded a new necrosis avid SPECT radiotracer by 
conjugating the necrosis avid cyanine HQ4 to DTPA, followed by radiolabeling 
with 
111
In-Cl3. We showed that, after DTPA conjugation, this newly synthesized 
radiotracer retained its specific necrosis targeting properties in vitro and in 
vivo in mouse models of spontaneous and therapy induced tumor necrosis. 
The advantages of the small molecule [
111
In]DTPA-HQ4 include; high water 
solubility, NIR property that enables deep penetration into tissues, lack of 
photo- toxicity, and low production costs. Therefore, the necrosis avid 
radiotracer [
111
In]DTPA-HQ4 has the potential to be clinically translated for 
diagnostic-prognostic purposes and to predict early treatment outcome of 
anti-cancer treatments.  
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Most effective antitumor therapies induce tumor cell death. Non-invasive, rapid and 
accurate quantitative imaging of cell death is essential for monitoring early response to 
antitumor therapies. To facilitate this, we previously developed a biocompatible 





In-Cl3) via the chelate diethylene triamine 
pentaacetic acid (DTPA), to enable clinical translation. The aim of the present study 
was to evaluate the application of HQ4-DTPA for monitoring tumor cell death induced 
by radiation therapy. Apart from its NIRF and radioactive properties, HQ4-DTPA was 
also tested as a photoacoustic imaging probe to evaluate its performance as a 
multimodal contrast agent for superficial and deep tissue imaging. 
 
Procedures 
Radiation-induced tumor cell death was examined in a xenograft mouse model of 
human breast cancer (MCF-7). Tumors were irradiated with three fractions of 9 Gy 
each. HQ4-DTPA was injected intravenously after the last irradiation,  NIRF and 
photoacoustic imaging of the tumors were performed at 12, 20 and 40 h after 
injection. Changes in probe accumulation in the tumors were measured in vivo, and ex 
vivo histological analysis of excised tumors was performed at experimental endpoints. 
In addition, biodistribution of radiolabeled [
111
In]DTPA-HQ4 was assessed using hybrid 
single-photon emission computed tomography-computed tomography (SPECT-CT) at 
the same time points. 
 
Results 
In vivo NIRF imaging demonstrated a significant difference in probe accumulation 
between control and irradiated tumors at all time points after injection. A similar trend 
was observed using in vivo photoacoustic imaging, which was validated by ex vivo 
tissue fluorescence and photoacoustic imaging. Serial quantitative radioactivity 
measurements of probe biodistribution further demonstrated increased probe 
accumulation in irradiated tumors.  
 
Conclusions 
HQ4-DTPA has high specificity for dead cells in vivo, potentiating its use as a contrast 
agent for determining the relative level of tumor cell death following radiation therapy 
using NIRF, photoacoustic imaging and SPECT in vivo. Initial preclinical results are 
promising and indicate the need for further evaluation in larger cohorts. If successful, 
such studies may help develop a new multimodal method for non-invasive and 
dynamic deep-tissue imaging of treatment-induced cell death to quantitatively assess 
therapeutic response in patients.   




The International Agency for Research on Cancer estimated that globally in 
2012, 14.1 million new patients were diagnosed with cancer and that this 
number will increase to more than 20 million in 2025 
1
. After diagnosis, most 
patients with solid tumors undergo surgery, radiotherapy and/or 
chemotherapy, and may be followed up with alternative treatments. 
Conventional methods for monitoring antitumor treatment response are 
based on anatomical imaging, e.g. X-ray, magnetic resonance imaging (MRI) 
and computed tomography (CT) every 6-8 weeks during the course of 
treatment as described in the Response Evaluation Criteria In Solid Tumors 
(RECIST) 
2
. Although RECIST provides a standardized guideline, assessment of 
treatment efficacy based on gross tumor size alone may be insufficient for 
certain organs and treatments 
3
. Moreover, volumetric change in tumor size 
based on conventional imaging may be a delayed indicator of treatment 
effectiveness 
4
, unnecessarily exposing patients to the side effects of 
additional ineffective treatments, and postponing treatment adjustment. 
Thus, there is a need for novel imaging methods to assess tumor response 
early and at a cellular/molecular level in order to determine treatment 
efficacy accurately and adjust the therapy based on tumor response 
5,6
. 
Ideally, such methods would be non-invasive, clinically practical, and have 
sufficient sensitivity and specificity for tumor cell death in real time. 
 
Imaging of treatment-induced tumor necrosis may facilitate quantitation of 
early treatment response in solid tumors as an alternative to the conventional 
radiological volumetric imaging. Firstly, antitumor therapies such as radiation 
therapy are known to induce several forms of tumor cell death which will 
often lead to secondary necrosis
7-9
. Secondly, necrosis is primarily induced by 
external factors that cause physiochemical damage compared to apoptosis 
which can occur in any tissues during normal development and cell turnover 
10,11
, making necrosis-based imaging method suitable to distinguish cell death 
induced by antitumor therapies. Lastly, tumor necrosis, secondary to ischemia 
and insufficient vascularization to support a rapidly proliferating tumor mass 
12
, has been positively correlated with the aggressiveness of cancer, and, 
therefore, has been used as a diagnostic biomarker for cancer staging 
13-18
. 
Thus, exogenous imaging contrast agents that specifically bind to necrotic 
tumor cells in vivo could enable accurate determination of treatment effects 
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Accurate quantification of tissue necrosis may have wide clinical relevance 
compared to conventional practice, especially in monitoring the efficacy of 
antitumor therapies at earlier stages. Existing necrosis-based imaging agents 
can be divided in two general groups: 1) MRI and CT contrast agents that 
enhance endogenous tissue necrosis contrast non-specifically by enabling 
visualization of the presence of an avascular necrotic core, and 2) positron 
emission tomography (PET) and single-photon emission computed 
tomography (SPECT) contrast agents that are specifically targeted to 
endogenous necrotic tissue 
8,13-18,20-29
. Non-specific tissue necrosis imaging 
agents will likely fall into abeyance when affordable necrosis-specific agents 
become clinically available. Thus far, only a few agents have been considered 







Iodine-conjugated Tumor Necrosis Targeting 
monoclonal antibody (TNT-3, Peregrine Pharmaceuticals, California, USA) 
24,33
. 
While clinical feasibility has been shown for both agents 
34
, several drawbacks 
may hinder their widespread clinical adoption 
27, 30, 35-37
. For example, 
Hypericin is phototoxic, poorly soluble and aggregates rapidly. Monoclonal 
antibodies are relatively large in size, have long circulation times, may induce 
host immune response, and are expensive to develop using Good 




Recognizing the biological significance of tumor necrosis as a hallmark of 
tumor response to treatment and the need for alternative imaging methods to 
measure treatment-induced solid tumor necrosis, we previously developed a 
biocompatible near-infrared fluorescent (NIRF), water-soluble imaging probe 
called HQ4. HQ4 is economical to produce, is non-phototoxic, and binds 
specifically to cells with compromised cell membrane integrity 
38
. We 
validated HQ4-DTPA as a necrosis-avid contrast agent histologically by 
demonstrating localization of HQ4-DTPA in necrotic tumors, and indicated that 
HQ4-DTPA could be made more clinically practical by addition of a radioactive 
moiety 
38
. Building on these results, in the current study, we investigated the 
utility of HQ4-DTPA as a necrosis-imaging agent in vivo to measure tumor 
response to radiation therapy. Radiotherapy is used to treat over 50% of 
cancer patients 
39
, making the translational value of HQ4-DTPA universally 
significant.  
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In this study, we examined a relatively high dose-per-fraction treatment 
scheme (3 x 9 Gy) to induce tumor cell death based on a biological equivalent 
dose (BED) that is clinically relevant to 60 Gy for 2 Gy fractions. We 
investigated a trimodal HQ4-DTPA imaging (photoacoustic, NIRF, SPECT) 
approach to measure tumor response to radiation therapy in a MCF-7 human 
breast cancer mouse xenograft model. We reasoned that the addition of 
photoacoustic imaging would overcome some of the disadvantages associated 
with SPECT and NIRF, such as the exposure to ionizing radiation emitted from 
radionuclides and the limited penetration depth
40
, respectively. Photoacoustic 
imaging may also be ideal for routine clinical use as it is easily accessible, 
minimally invasive, and technologically inexpensive compared to conventional 
imaging methods (CT, MRI). The results of this work demonstrate the 
feasibility of using the multimodal (NIRF, photoacoustic, SPECT) HQ4-DTPA 
probe in vivo for longitudinal measurement of solid tumor necrosis in 
response to clinically relevant high-dose radiotherapy.  
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Materials and Methods 
 
HQ preparation 
HQ4-DTPA was obtained from Ilumicare BV (Rotterdam, The Netherlands). 
HQ4-DTPA was synthesized as previously described
38
. For phantom studies, 
dilutions of HQ4-DTPA were prepared in phosphate buffered saline (PBS) at 
various concentrations (12.5, 25, 50, and 100 μM). For in vivo mouse studies, 
100 μl which represents 10 nmol HQ4-DTPA was injected via the tail vein. To 
label HQ4-DTPA with 
111
InCl3, HQ4-DTPA was dissolved in 0.1 M HEPES (10 
μg/100 μL) 
41
 and incubated with 
111
InCl3 (35 MBq; Nordion, Vancouver, BC). 
After 30 minutes of incubation on a shaker, labeling was validated with instant 




GFP-fluorescent MCF-7 human breast cancer cells (kindly provided by Dr. 
Shirley Wu, Leslie Dan Faculty of Pharmacy, University of Toronto) were grown 
in D-MEM Medium supplemented with 10% fetal bovine serum and 1% Pen-
Strep in a humidified incubator at 37°C and 5% CO2. Cells were trypsinized, 
counted and suspended in 10% PBS before further use. 
 
Animal Studies 
All animal procedures were conducted in accordance with appropriate 
regulatory standards under protocols AUP#2407 and #3004 approved by the 
University Health Network Institutional Animal Care Committee, and conform 
to the institutional guidelines for the proper and humane use of animals in 
research. Eight to 10-week-old female athymic nude mice (NCRNU-F strain) 
were obtained from Taconic Biosciences (Hudson, NY). 2 x 10
6
 MCF-7-GFP cells 
were injected subcutaneously in both sides of the mouse scapularis region and 
were allowed to grow for 3-4 weeks until they reached approximately 5 mm in 
diameter, as measured using a caliper. All experimental procedures were 
 
Figure 1. Experimental schedule. 
Three fractions of 9 Gy irradiation were delivered with a 5-hour interval and HQ4-DTPA was 
injected at the end of the irradiation schedule. In vivo photoacoustic and fluorescence 
imaging were performed at 12, 20 and 40 h following the injection. 
Chapter 7                       Multimodal imaging of RT-induced tumor necrosis│ 165 
 
conducted under isoflurane gas anesthesia (2-3%, 0.8 l/min).All animal 
experiments were performed following the treatment schedule shown in 
Figure 1.  
Briefly, pre-treatment images were obtained prior to irradiation to determine 
the size of the tumors based on bulk tumor GFP fluorescence. Tumor GFP 
fluorescence intensity is a delayed indicator of tumor response to irradiation 
since the GFP protein has a half-life of ~26 h 
42
, ergo, GFP fluorescence 
intensity was not used to quantify tumor response following irradiation. 
 
Radiation Treatment and HQ4-DTPA Administration 
All irradiation procedures were performed using a small animal irradiation 
system (XRad 225Cx, Precision X-Ray Inc., North Branford, CT) at a photon 
energy of 225 kVp and a tube current of 13 mA. Tumors were localized using x-
ray fluoroscopy prior to irradiation. A 1.5 cm circular collimator was used to 
irradiate tumors at a dose rate of 2.9 Gy/min. The dose rate was measured 
using radiochromic films and a solid water phantom, as described previously 
43
. After delivery of the last radiation fraction, HQ4-DTPA was injected via the 
tail vein and anesthetized mice were imaged with each modality at 12, 20 and 
40 h following injection (Fig. 1).  
 
Fluorescence Imaging 
In vivo and ex vivo fluorescence images of GFP and HQ4-DTPA signals in MCF-7 
tumors were obtained using the IVIS Spectrum imaging system (Perkin Elmer 
Inc., Waltham, MA). GFP fluorescence signal was collected with an excitation 
wavelength of 465 nm and an emission wavelength of 500 nm (+/- 20 nm). 
HQ4-DTPA NIRF signal was collected with an excitation wavelength of 675 nm 
and an emission wavelength of 720 nm (+/- 20 nm).  
 
Photoacoustic Imaging 
Tissue phantom, in vivo and ex vivo photoacoustic imaging of MCF-7 tumors 
was performed using the Vevo LAZR system (FujiFilm VisualSonics Inc., 
Toronto, ON) with a 21 MHz center-frequency transducer. To prepare the 
phantom, HQ4-DTPA samples prepared at different concentrations (12.5, 25, 
50, and 100 μM) were passed through polyethylene tubes that were placed on 
a piece of sliced turkey breast, having an approximate thickness of 2.5 mm. 
Additional layers of meat were added to simulate various thicknesses of 
tissues. Photoacoustic images were obtained after the addition of each layer. 
For all experiments, 3D photoacoustic and ultrasound images were acquired 
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simultaneously with a single wavelength of 700 nm for HQ4-DTPA, and the 
built-in Spectro mode was used to obtain the absorption spectrum from 680 
nm to 900 nm.  
 
SPECT-CT  
Mice were imaged at 12, 20 and 40 h after intravenous injection of 
[
111
In]DTPA-HQ4. Mice were anesthetized by inhalation of 2% isoflurane in 
medical grade air. Imaging was performed on a nanoSPECT/CT system 
(Bioscan Inc., Washington, DC) with four NaI(Tl) detectors fitted with 1.4 mm 
multi-pinhole collimators (resolution <1.2 mm at full-width-half-maximum). 
Cone beam CT images were acquired first (180 projections, 45 kVp), followed 
by the SPECT images. Photons were accepted from the 10% window centered 
on both the 245 keV and 171 keV photopeaks of 
111
In. A total of 24 projections 
were obtained in a 256 x 256 matrix for a total of 45 minutes. The CT slices 
were reconstructed using a filtered back-projection algorithm, whereas the 
SPECT slices were reconstructed using an ordered subset expectation 
maximization (OSEM) algorithm with four subsets and nine iterations. CT and 
SPECT images were anatomically co-registered using the InVivoScope software 
(Bioscan, Boston, MA). 
 
Three mice were sacrificed after each experimental time point. Tissues were 
excised, weighed, and counted for radioactivity (PerkinElmer Wallac 1480 
Wizard 3″ gamma-counter, Waltham, MA) along with a standard of the 
injected dose, so that the decay-corrected uptakes of HQ4-DTPA were 
determined as the percentage of the injected dose per gram (% ID/g). The % 
ID/g was calculated as follows: [(MBq measured in tissue/injected dose) * 
100%)/weight of tissue]. The total injected dose per mouse was equal to the 
difference between the pre- and post-injection syringe radioactivity, as 
measured by a CRC-15R dose calibrator (Capintec, Ramsay, NJ). 
 
Ex vivo Fluorescence Imaging and Autoradiography  
Tumors were resected at the experimental endpoints, and were either 
embedded in OCT compound and snap frozen in liquid nitrogen, or fixed in 
formalin. Frozen sections were imaged using a phosphor imager (Cyclone Plus, 
Perkin Elmer) to detect 
111
In radioactivity. The same sections were 
subsequently imaged to measure HQ4-DTPA fluorescence with an excitation 
wavelength of 650 nm using TissueScope system (Huron Technologies). 
Formalin-fixed tissue sections were subjected to Haemotoxylin and Eosin 
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(H&E) staining and TdT-mediated dUTP Nick-End Labeling (TUNEL) staining 






All statistical analysis was performed using GraphPad Prism software 
(GraphPad Software, San Diego, CA). Student’s t-test was used to compare 
two sets of data, and two-way repeated measures ANOVA with Bonferroni 
post-test was used for serial imaging data. P < 0.05 was considered significant, 




HQ4-DTPA as a photoacoustic contrast agent  
To evaluate the application of HQ4-DTPA in addition to the NIRF property that 
was described previously 
38
, the photoacoustic property of carboxylated 
cyanine HQ4-DTPA was tested in a phantom composed of transparent plastic 
tubes. As seen in Figure 2A-B, HQ4-DTPA absorption increased with increasing 
concentration, demonstrating a peak at around 710 nm excitation. The 
photoacoustic absorption spectrum was similar to its known fluorescence 
spectrum 
38
, supporting its use as an extrinsic photoacoustic contrast agent.  
 
To further characterize its performance as a photoacoustic contrast agent, 
multiple layers of meat were added over top of the tube phantoms to simulate 
a tissue thickness of up to 1 cm. After the addition of each layer of meat, 
fluorescence and photoacoustic images, as well as photoacoustic absorption 
spectra, were acquired. In this way, we represented similar scattering and 
absorption patterns to those found in the human body. The fluorescence 
signals derived from the different concentrations were indistinguishable by 
the addition of the first layer of turkey breast tissue (2.5 mm thick) (data not 
shown). The photoacoustic intensity of the agent in the tubes was, however, 
detectable with layers up to 10 mm in total thickness at the highest 
concentration of HQ4-DTPA (100 μM) (Fig. 2C). Figure 2D shows the PA 
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In vivo serial photoacoustic and fluorescence imaging of HQ4-DTPA 
accumulation in irradiated tumors 
TdT-mediated dUTP nick-end labeling (TUNEL) staining of irradiated tumor 
demonstrated over a two-fold difference in tumor cell death in tumors 
irradiated with 3 fractions of 9 Gy (27 Gy total), compared to non-irradiated 
control tumors (Fig. 3A-B). H&E staining was performed to confirm the TUNEL 
positive area as necrotic. The arrowheads in the image mark the difference in 
H&E staining between healthy and necrotic tissue. Based on those results, the 
same irradiation treatment regimen was used for all subsequent experiments.  
 
As demonstrated in Figure 4A, the photoacoustic images demonstrated 
accumulation of HQ4-DTPA inside the treated tumor mass, while some 
endogenous photoacoustic signals were observed in the outer rim of the 
Figure 2. Photoacoustic property of HQ4-DTPA.  
(A) Representative ultrasound (top) and photoacoustic (bottom) images of HQ4-DTPA in a 
tube phantom at different concentrations (from left to right: 12.5, 25, 50, and 100 μM). The 
photoacoustic image was acquired at 700 nm. (B) Corresponding absorption spectra of HQ4-
DTPA for the different concentrations. (C) Representative ultrasound (top) and photoacoustic 
(bottom) images of HQ4-DTPA in the same tube phantom as in (A), covered with 10 mm-
thick meat. The yellow circles indicate the location of tubes, and the white circle indicates the 
photoacoustic absorption of the tube containing 100 μM HQ4-DTPA. (D) The corresponding 
absorption spectra of 100 μM HQ4-DTPA with various thicknesses of meat covering the tube. 
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tumor in both control and irradiated tumors. Figure 4B demonstrated a trend 
for increased accumulation of HQ4-DTPA in irradiated tumors compares to 
control tumors, although the difference was not statistically significant. The 
fluorescence images (Fig. 4C-D) showed an approximate 1.8-fold increase in 
HQ4-DTPA accumulation in the irradiated subcutaneous tumors compared to 
non-irradiated controls, most notably at 12 h post-radiotherapy.  
 
Figure 3. Histological analysis of cell death after irradiation. 
(A) Representative images of TUNEL and H&E staining for control and irradiated 
tumor resected 40 h after irradiation. The arrowheads point to necrotic areas. Scale 
bar = 500 μm. (B) Quantified TUNEL positivity for tumors resected 40 h after 
irradiation, expressed as % positivity. (n = 7/group, *p<0.05) 
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To validate in vivo observations, control and irradiated tumors were resected 
Figure 4. In vivo photoacoustic and fluorescence imaging of tumors.  
(A) Representative photoacoustic images of control and irradiated tumors prior to 
and at 12, 20 and 40 h following injection of HQ4-DTPA. The photoacoustic image 
was acquired at 700 nm and an accumulation of HQ4-DTPA inside the irradiated 
tumor was observed. Scale bar = 2 mm. (B) Measured photoacoustic intensity at 
different time points. (n = 3/group) (C) Representative fluorescence images of the 
GFP-MCF7 tumor and HQ4-DTPA in control (C) and irradiated (R) tumors. (D) 
Measured fluorescence intensity of HQ4-DTPA at different time points. (n = 
10/group, *p<0.05, **p<0.01). 
Figure 5. Ex vivo photoacoustic and fluorescence imaging.  
Representative ultrasound, photoacoustic, GFP fluorescence (FLI-GFP) and HQ4-DTPA (FLI-
HQ4) fluorescence images of control and irradiated tumors resected 40 h after injection of 
HQ4. Scale bar = 2 mm. 
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Validation of photoacoustic and fluorescence imaging of HQ4-DTPA in ex 
vivo tissues 
40 h following injection of HQ4-DTPA and subsequently imaged by 
photoacoustic and fluorescence systems. The resected masses were 
confirmed to be tumors based on the GFP fluorescence signal. As seen in 
Figure 5, increased HQ4-DTPA accumulation in an irradiated tumor was 
observed based on photoacoustic and fluorescence images. This indicated that 
the increased accumulation of HQ4-DTPA was specific to radiation-induced 
tumor cell necrosis in tumors. Since the skin covering the xenografted tumor 
was removed during resection, there was less interference from the intrinsic 
hemoglobin signal from blood vessels in the skin.  
 
In vivo biodistribution and ex vivo validation of 
111
In radiolabeled HQ4-DTPA  
SPECT-CT was performed to quantify whole-body biodistribution of 
[
111
In]DTPA-HQ4 in MCF-7 tumor-bearing mice following the experimental 
treatment schedule shown in Figure 1. Radiolabeling efficiency of HQ4-DTPA 




In]DTPA-HQ4 in irradiated tumors was observed compared to controls in 
the same mice 40 h after probe injection (tumor-to-background ratio 
(TBR)=1.8, P40h=0.03) (Fig. 6A), thus confirming HQ4’s specificity for necrotic 
tissues and suggesting the kinetics of HQ4-DTPA accumulation. Measurements 
of radioactivity in various resected organs demonstrated that [
111
In]DTPA-HQ4 
was concentrated in the excreting organs with a peak in the kidneys, 
suggesting that the renal system was the main excreting route (Figure 6B). 
 
Figure 6. SPECT-CT of [
111
In]DTPA-HQ4-DTPA biodistribution. 
(A) Representative transversal SPECT-CT image of a mouse with control (C) and irradiated (R) 
tumor 40 h following injection. (B) Measurement of [
111
In]DTPA-HQ4 biodistribution in % 
ID/weight in different organs at various time points (12, 20 and 40 h post injection), where 
irradiated tumor (‘tumor r’) shows higher accumulation of the probe compared to control 
(‘tumor l’) (n=3, *p<0.05). 
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Lastly, the tumors were resected and imaged for [
111
In]DTPA-HQ4 using 
autoradiography and fluorescence. The autoradiographic images revealed a 
clear difference in structural characteristics between the irradiated and 
control tumors (Fig. 7A-B). The internal tissue organization of the non-
irradiated tumor was cohesive and showed a clear cellular pattern with a 
homogeneous color. In contrast, the irradiated tumor showed a high level of 
disorganization. Furthermore, the overlay (C3) of fluorescence (C1-red) and 
autoradiography (C2-green) images showed a high degree of co-localization of 
111





Figure 7. Ex vivo fluorescence and autoradiography images of tumors.  
Representative images of (A) control and (B) irradiated tumor resected 40 h following 
injection of [
111
In]DTPA-HQ4. The tumors were imaged for HQ4-DTPA fluorescence. (C) 
Overlay (C3) of HQ4-DTPA fluorescence (C1/red) and 
111
In-Cl3 radioactivity (C2/green) in a 
tumor, illustrating co-localization of the two signals. 




In the current study, we evaluated HQ4-DTPA as a multimodal necrosis-avid 
imaging agent to assess tumor response to a clinically relevant radiotherapy 
dose using a MCF-7 human breast cancer mouse xenograft model. The 
necrosis-avid property of HQ4-DTPA for detection of chemotherapy-induced 
tumor cell necrosis was previously demonstrated using NIRF imaging and 
SPECT 
38
. To extend the applicability of HQ4-DTPA to another imaging 
modality, we first assessed its photoacoustic property and demonstrated its 
distinct optical absorption peak at approximately 700 nm. Based on this result, 
multimodal imaging was performed to quantitatively evaluate the in vivo use 
of HQ4-DTPA to detect tumor response to radiotherapy using a fractionated 
irradiation scheme (3 x 9 Gy). Our in vivo fluorescence results demonstrated 
an increase in HQ4-DTPA signal in irradiated tumors compared to non-
irradiated tumors in vivo for up to 40 h after treatment, indicating specific and 
sustained accumulation of HQ4-DTPA in irradiated tumors. These data were 
supported by ex vivo NIRF and photoacoustic imaging of control and irradiated 
tumors. Lastly, we used SPECT-CT to quantitate the biodistribution of HQ4-
DTPA, demonstrating HQ4-DTPA accumulation in irradiated tumors and 
clearance of unbound HQ4-DTPA mostly via kidneys, which was visualised at 
all time points. Collectively, our data indicated that HQ4-DTPA may be used as 
a multimodal necrosis-specific imaging agent. The data also suggested that 
HQ4-DTPA may be used clinically in the future to monitor solid tumor 
response to radiation therapy in a practical time frame. 
 
Radiation therapy was selected as the treatment modality for the breast 
cancer model in the present study because of its wide-spread clinical usage. 
Breast conserving surgery is the standard treatment for localized breast cancer 
in combination with  
(neo-) adjuvant therapies 
46
, such as radiation therapy, which has been shown 
to reduce local recurrence 
47
. Radiation therapy is commonly administered in a 
conventional fractionated schedule (25 fractions of 2 Gy) on the breast with 
an additional boost of up to 10 Gy on the lumpectomy cavity 
47
. Since such 
treatment schemes cannot be easily replicated in a relevant manner in animal 
models, we selected a radiation regimen that is isoeffective to a clinically-
relevant fractionated irradiation regimen based on a BED of 60 Gy in 2 Gy 
fractions 
48,49
. Thus the rationale for 3 fractions of 9 Gy with a 5 h interval was 
based on the BED for 60 Gy, calculated using the α/β ratio of MCF-7 cells 




 and by taking into account the incomplete repair model based on 
the halftime of recovery from radiation damage in murine skin. Although the 
radiation regimen used in our study may not be used routinely or be clinically 
practical, we assumed that the regimen was appropriate to mimic the total 
radiation dose given in cancer patients as the BED is used to compare the 
relative effectiveness of different radiation protocols that vary in fraction size.  
 
The NIRF properties of carboxylated cyanine HQ4-DTPA and its radioactive 
labeled variant [
111
In]DTPA-HQ4 have been previously demonstrated by our 
group 
38
. Although nuclear imaging overcomes the limited tissue penetration 




, it has its drawbacks including radiation safety, cost 
of radioactive materials, limited temporal sensitivity, and the lack of 
anatomical detail 
53
. Photoacoustic imaging overcomes such limitations and 
offers a novel and clinically relevant means of imaging HQ4-DTPA in vivo. Since 
photoacoustic imaging includes ultrasound imaging, both anatomical and 
functional information can be obtained simultaneously in real-time. 
Photoacoustic imaging can image beyond the depth limitation of fluorescence 
imaging to more than 5 cm 
54
, making it suitable for imaging deeper tumors. In 
the current in vitro experiments, we distinguished a specific photoacoustic 
signal at a maximum depth of 1 cm, achieving 5 times the tissue depth of NIRF 
imaging. However, depth imaging beyond 1 cm could not be performed due to 
the inherent property of the high-frequency ultrasound transducer (21 MHz) 
used in our study. Photoacoustic imaging depth may be increased by using a 
lower frequency transducer, but at the expense of reduced detection 
sensitivity 
55
. Alternatively, a higher concentration of the probe may facilitate 
detection in deeper tissue.  
 
Despite the advantages of photoacoustic imaging, there are some technical 
limitations. Firstly, photoacoustic imaging may not be a suitable method for 
certain organs, such as lung and brain, where acoustic impedance is different 
between tissue interfaces 
56
. However, several preclinical studies 
demonstrated the use of photoacoustic imaging in these organs, suggesting 
future use of photoacoustic imaging in a variety of organs 
57-59
. Secondly, the 
clinical use of photoacoustic contrast must be approached cautiously, since 
photoacoustic imaging visualizes any tissue-based optical absorber at a given 
wavelength. As such, this method detects the presence of endogenous 
hemoglobin, a primary optical absorber in tissues, across a broad spectral 
range that includes 700-750 nm, corresponding to the peak absorption of 
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HQ4. Our photoacoustic imaging results indicated the presence of an 
endogenous optical absorber mostly in the periphery of control and irradiated 
tumors, suggesting the presence of vasculature around the tumor. The 
endogenous absorption limited our ability to detect HQ4-DTPA in a highly-
specific manner. To distinguish absorption by any contrast agent from that of 
endogenous absorbers, photoacoustic spectral unmixing techniques can be 
performed to obtain a clear overview of the contrast agent signal based on its 
known spectrum 
60
. Such techniques can be applied in future studies to 
visualize the accumulation of HQ4-DTPA inside the irradiated tumors in a 
specific manner. In addition, the imaging probe may accumulate inside tumors 
due to intrinsic tumor necrosis resulting in the presence of background signal 
in both fluorescence and photoacoustic imaging. In such cases, baseline 
imaging needs to be performed with the injection of HQ4-DTPA prior to 
initiation of an anticancer treatment. 
 
Although NIRF imaging is widely clinically applicable, its use as a singular 
imaging modality to assess biological activities may be suboptimal. For 
example, fluorescence properties of exogenous dyes used in vivo are strongly 
influenced by the tissue microenvironment, such as hydrophobicity and pH, as 
well as by interactions with various proteins 
61,62
. Such interactions will 
influence HQ4-DTPA fluorescence intensity differently in an in vivo 
environment of living cells, which may hamper quantification of probe 
accumulation inside necrotic tumors. These same interactions may have 
contributed to the differences in the time point of highest signal accumulation 
observed using the different imaging methods in our model, although it was 
not explicitly addressed in this study. To achieve absolute quantification of a 
probe, gamma spectroscopy or mass spectrometry should be considered 
61,62
. 
In our study, quantification of HQ4-DTPA was achieved by measurement of 
radioactivity in various organs, supporting the in vivo imaging data in a 
quantitative manner.  
 
Irradiation causes direct DNA damage and the production of reactive oxygen 
species (ROS), both leading to cell death. The amount and the type of cell 
death depends on the tumor type and the irradiation dose per fraction. For 
MCF-7 cells, the α/β ratio, a model of radiation effect, is relatively low 
compared to the higher α/β ratios for other tumors such as Tara-1/2 
(teratoma), DU145 (bladder), TSU and UNCap (prostate) (e.g. 7-20 Gy) 
51
, 
suggesting that the treatment response may be delayed in MCF-7 tumor-
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bearing animals. This delayed response can be seen by our in vivo 
radioactivity-based biodistribution results demonstrating significant 
differences of HQ4-DTPA accumulation between the treated and control 
tumor 40 h after irradiation. This discrepancy may increase even more over 
time, requiring re-injection of the probe at a later time point or at multiple 
time points following radiotherapy. In addition, radiation-induced damage 
may be more severe when high dose of radiation is used per fraction, leading 
to direct tumor cell destruction as well as secondary tumor cell death 
63,64
. 
Therefore, future studies may focus on multi-fractionated scheme with a 
lower fraction dose to assess whether the proposed necrosis-imaging 
technique is still applicable. In testing multi-fractionation schemes, the 
imaging technique could be initially tested in the same way so immediately 
after the end of the complete treatment, and later on even during the 
treatment process to assess its utility in adapting therapeutic regimen. In the 
current study, we chose to inject HQ4-DTPA immediately after the final tumor 
irradiation to detect early treatment response since the goal of this study was 
to investigate HQ4-DTPA imaging as an early indicator of radiation induced 
necrosis. Collectively, future studies are warranted with multi-fractionation 
scheme and/or injections at multiple time points to evaluate its utility in 
treatment monitoring and adaptive treatment.  
 
 
Overall, we have demonstrated that HQ4-DTPA can be used to objectively 
assess tumor response to radiation therapy. HQ4-DTPA is distinct from current 
clinically-available necrosis-avid agents given its unique in vivo specificity and 
multimodal imaging capability. The added benefit of multimodal imaging 
potentially broadens its applicability in a variety of clinical settings, where 
tissue necrosis serves as a surrogate marker of diseases as well as response to 
necrosis-inducing treatments. The advantages of the small molecule 
[
111
In]DTPA-HQ4 include high water solubility, the photoacoustic property that 
enables deep tissue penetration into tissues, lack of phototoxicity, and low 
production costs. Unlike fluorescence imaging and SPECT, photoacoustic 
imaging combines the anatomical and functional properties of tissue in a 3D 
image. Therefore, the necrosis avid radiotracer [
111
In]DTPA-HQ4 has the 
potential to be clinically translated for diagnostic and prognostic purposes, as 
well as to predict early treatment outcome of antitumor treatments such as 
radiation therapy. Additional preclinical and clinical studies are required to 
demonstrate the advantages of this novel imaging approach to assess early 
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This thesis consists of two parts addressing novel imaging technologies to 
improve the treatment of cancer patients. In part I, the additional value of real 
time image guidance during surgery is discussed and the research described in 
this part of the thesis showed that imaging performed during surgery can be 
of great value. Nevertheless, the success rate is highly dependent on the 
choice of imaging modality and biomarker to be targeted. In part II, a necrosis 
avid probe was successfully evaluated as novel method for early neoadjuvant 
treatment response monitoring. 
 
Part I: Image-guided Surgery 
 
For patients with a solid tumor, extensive diagnostic procedures are 
performed before the start of treatment as baseline and to determine the 
cancer stage
1,2
. However, during surgery, the tissue is deformed and margin 
assessment is only accessible by visual inspection and palpation
3
. In surgical 
oncology, clear demarcation of the tumor boundaries is off course essential. 
Nevertheless, the final conformation whether visual tumor resection indeed 
resulted in a complete tumor resection, can only be determined by final 
pathology assessment of which the results become available approximately 
one week after surgery
3
. The main advantage of using (molecular) image-
guidance during surgery is to enhance the visualization during the surgical 
procedure and to provide direct feedback. 
In Chapter 2, conventional imaging modalities and a variety of state-of-the-art 
image- and molecular guided surgery modalities are described and compared. 
The modalities are divided in four groups: conventional, fluorescence, 
radioactive, and endogenous reflectance. The majority of these techniques 
encountered a challenge, such as lack of functional information, limited 
penetration depth or the need for a specifically targeted contrast agent. 
Unfortunately, there is not a single modality which is able to cover all our 
clinical needs. Therefore, it is necessary to combine imaging modalities to 
obtain the best surgical outcome.  
 
Creating sufficient tumor-to-background contrast is one of the main 
challenges for advanced imaging. In general, imaging contrast is based on 
endogenous tissue contrast which is not sufficient to detect microscopic 
involvement of the tumor. The amount of contrast generated in an image can 
be increased with the use of an exogenous contrast agent. Non-specific 
exogenous contrast agents, such as gadolinium for MRI or iodine for CT, are 
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widely available, however, only specifically increase the visibility of the 
vasculature. As these contrast agents are not tumor-specific, they are only 
helpful to a certain extent 
4-7
. Therefore, there is a need for targeted 
exogenous contrast agents, which are more specific for imaging of cancer. 
Nevertheless, the difficulty will be to characterize an appropriate target which 




In general, every specifically activated, expressed or upregulated marker on 
the surface of a tumor could serve as a target for image guided surgery (IGS) 
4,9
. Many markers are in different phases of clinical development, of which 
several show positive results in preclinical investigations. However, the next 
step, the actual translation from bench to bedside is demanding. Therefore, 
most probes are not able to pass the early stages of clinical translation, often 




In Chapter 3 the molecular expression of a target was determined in a human 
tissue microarray (TMA) to determine whether this would be an interesting 
target for IGS or not. Using this approach, EphB4, a tyrosine kinase receptor 
binding the transmembrane ephrin-B2, was identified which is overexpressed 
in the majority of colorectal cancer patients. Eph receptors and their ephrin 
ligands play an essential role in cell communication and EphB4 upregulation is 
associated with cancer progression 
13
. To (semi-)quantify the expression of 
EphA2 and EphB4 in tumor tissue, compared to the expression in adjacent 
healthy tissue, a normal-to-tumor scorings diagram was developed. This 
shows that both EphA2 and EphB4 were overexpressed in the majority of 
colorectal cancer patients. Only EphB4, demonstrated a clear difference 
between tumor and normal adjacent tissue. Although EphA2 is currently on 
the prioritization list of the national cancer institute (NCI) to be used as cancer 
vaccine target, it turned out to be an unsuitable target for the determination 
of tumor boundaries during surgery 
9
. 
To overcome the drawback of low specificity rates, it is essential that there is a 
clear difference between expression of the marker in the tumor, as visualized 
in the scorings diagram, compared to adjacent healthy tissue which will lead 
to a difference in uptake of the imaging agent. In general, during surgical 
procedures, a tumor-to-background ratio (TBR) of around 2 is determined as 
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The main aim of Chapter 4 was to determine whether a combination of pre-
operative multispectral optoacoustic tomography (MSOT) and fluorescence 
guided surgery (FGS) would be able to overcome the drawbacks of limited 
depth penetration of FGS. This combination provided detailed visualization of 
an integrin targeting near infrared fluorescent (NIRF) contrast agent, which 
resulted in a complete and specific overview, both before and during surgery, 
of the distribution and localization of a pancreatic ductal adenocarcinoma 
(PDAC) in an orthotopic mouse model. Overall, this chapter clearly showed the 
additional value of 3D imaging over 2D imaging, independent of the technique 
used, and showed that MSOT might be a suitable addition or alternative for 
FGS to improve visualization at a penetration depth over 1 cm. 
 
Part I of this thesis addressed the advantages of IGS. There are, however, also 
some drawbacks. The disadvantages are related to the use of certain imaging 
modalities during surgery. The use of a nuclear imaging modality, for instance 
PET and SPECT, requires the use of radioactivity or, when using tracers with a 
short half-life, the availability of an on-site cyclotron facility 
15
. Also, the 
magnetic field associated with the use of an MRI requires additional safety 
and logistic planning requirements, which makes these techniques less 





Part II: Necrosis Imaging 
 
Cell death is a universal process in the human body and tumor cell death is in 
general an effect of anti-cancer treatment, which is necessary to cure cancer 
patients
17
. Cell death is related to the cancer hallmark “resisting cell death” 
which makes visualizing the amount of cell death via a molecular pathway an 
interesting concept instead of focusing on morphology 
18
. In general, 
morphological imaging is suitable when the tumor is clearly responding (e.q. 
shows a reduction in tumor size). However, when this is not the case, 
anatomical imaging modalities have limited value in differentiating tumor 
progression from pseudo-progression, which some neoadjuvant therapies can 
initiate 
19,20
. Patients are, in general, only selected to undergo (organ 
preserving) surgery, after neoadjuvant therapy, when the tumor is responding. 
When the surgeon is not able to distinguish non-responders from responders 
it is impossible to select the appropriate patients for surgery 
21
.  
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In the second part of this thesis the hypothesis is being explored that an 
increase in tumor cell death is a sign that a patient does respond to 
neoadjuvant therapy. Nevertheless, it is also possible that due to the therapy, 
the biological systems around a tumor are activated to release tumor 
promoting factors instead of suppressive by which the tumor can grow even 
faster 
22
. In fast growing tumors, angiogenesis cannot keep up with the size of 
the tumor which will also create an increase in cell death in the core of the 
tumor. Next to this, it is highly likely that the cell death which occurs after 
cancer treatment is a combination of several types of cell death and is not 




Imaging cell death 
Imaging of cell death nowadays can roughly be divided into apoptotic imaging 
and necrosis imaging. Apoptosis is a controlled type of cell death, visualizing 
apoptosis is based on targeting a marker in the apoptotic pathway. Caspases 
are potential targets nonetheless often difficult to reach as they reside inside 
the cell 
25
. The most well-known apoptosis targeting agent is Annexin V, which 
selectively binds, with a high affinity, to Phosphatidylserine (PS). Annexin V, 
labeled with Techneticum-99m, was used in clinical trials, though facing some 
drawbacks. Suboptimal biodistribution patterns have been found with a high 
background uptake in the abdomen. Another disadvantage is that PS as target 
is only available for a limited amount of time in the process of apoptosis. An 
alternative target is phosphatidylethanolamine (PE) targeted via duramycin. 
The major advantage of PE over PS is the higher availability of PE on the cell 
membrane. Duramycin as probe is stable with a high binding affinity and 
specificity, radiolabeled with Techneticum-99m makes it a promising probe, 
currently available for preclinical studies 
25,26
. Although apoptosis imaging will 
probably be able to reflect treatment response as the amount of apoptosis is 
relative high, it is not tumor specific as it targets a process which also is 
required to occur in a healthy multicellular environment to maintain 
homeostasis 
17
. Therefore, the accuracy to identify tumors with a marginal 
treatment response might be limited. 
 
Necrosis imaging is also not tumor specific. The chance of coexistence of a 
simultaneously ongoing pathological process of cell death in the neighborhood 
of the tumor is quite unlikely. This makes necrosis an interesting target for 
tumor treatment response evaluation. Probes targeting necrosis can be 
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divided in three groups: porphyrins, antibodies and dianthrones. The first 
group consists of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) 
derivatives which accumulate in nonviable tissue. Unfortunately, porphyrins 
are hampered for clinical use mostly due to their phototoxicity, limited 
effectiveness and difficult synthesizing procedure 
27-29
. Antibodies, the second 
group, are in general more specific. One of the antibodies, Cotara, is directed 
against the DNA histone complex which is present in dead and dying cells in 
the center of solid tumors 
30,31
. Another antibody, Myoscint, targets the 
intracellular heavy chain of myoscin. In general, the clinical translation of 
antibodies is challenging due to several reasons including their size which 




The last groups are dianthrones, Hypericin, is a natural occurring 
photosensitizer, proved to be a potent agent for photodynamic therapy in 
cancer treatment and also shows necrosis avidity. Hypericin and its derivatives 
Sennidin A and Sennoside b are labeled with Iodine for both diagnostics and 
therapeutic approaches. The main drawback of these agents is that they are 
phototoxic and difficult to dissolve 
25,33-35
.  
The carboxylated cyanine dyes tested in this thesis do not suffer from the 
drawbacks of the above-mentioned agents, as they are non-toxic small 
molecules which are easy to dissolve.  
 
Therapeutic cell death 
The most prominent process of cell death, initiated by chemotherapy and 
radiotherapy, was investigated to prove the value of our necrosis avid contrast 
agent. Chemotherapy and radiotherapy were chosen as they are the two most 




Chemotherapy induces alterations in Adenosine Triphosphate (ATP) levels, 
which is distinctive for dying cells: ATP decreases intracellularly and increases 
extracellularly. The level of decrease intracellularly will determine the switch 
between apoptotic or necrotic cell death. When cell death progresses and the 
membrane potential is completely disrupted, the intracellular ATP level is 
further decreased, finally leading to secondary necrosis. Based on this 
knowledge, apoptosis is the initial form of cell death after treatment with a 
chemotherapeutic agent, followed by (secondary) necrosis 
17,38
. However, 
some chemotherapeutic agents, such as cyclophosphamide, induces type I 
immunogenic cell death (ICD). Cyclophosphamide is used in the experiments 
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in Chapter 5 & 6, in an immunodeficient mouse model. ICD is a form of cell 
death which is closely related to the secretion and release of damage-
associated molecular patterns (DAMPs) 
39,40
. This means that molecules inside 
the cell, which under normal circumstances are not associated with 
immunological functions, will be released, secreted or exposed on the cell 
surface of damaged or dying cells. In this way, they trigger an immune 
response in the absence of infection and they stimulate immunogenicity 
through endoplasmatic reticulum stress related effects 
40
. Extracellular ATP is 
seen as DAMP and as mentioned above the amount of extracellular ATP 
determines the cell death pathway 
39
.  
Radiotherapy eliminate cancer cells by the use of ionizing radiation 
41
. Ionizing 
radiation creates DNA damage which will have a direct and indirect effect on 
cells both leading to cell death. Irradiation with a high dose per fraction (>10 
Gy) will cause, in general, more direct DNA double strand breaks and will 
result in lethal damage in a higher number of cells, as compared with 
irradiation using a lower fraction dose (<10 Gy). Nevertheless, this is 
compensated with fractionation which will cause a similar linear decrease in 
the number of surviving cells at the end of the treatment 
37,42,43
. In addition, 
fractions above 10 Gy will also cause severe vascular damage, leading to 
indirect cell death 
42
. Vascular damage causes a reduction in blood perfusion 
and has a negative influence on the oxygenation status, severe ischemia will 




The results described in Chapter 5 shows that the two identified NIRF 
carboxylated cyanine dyes, HQ5 and IRDye800CW, possess strong necrosis 
avidity. The exact molecular targeting mechanism is not clear; however, it 
involves avidity for probably a mixture of cytoplasmic proteins available after 
loss of cell membrane integrity. 
In preclinical research, the advantages of using optical modalities over 
radionuclide imaging are clear as they require less safety requirements, are 
cheap and fast. The downside of limited tissue penetration and lack of 
quantification is relatively small in early stages of research. Research closer to 
clinical translation needs quantitative pharmacokinetic and distribution 
profiles which are demanding to provide with optical imaging only. In addition, 
the limited penetration depth of only 1 cm makes the technique not feasible 
for quantitative pharmacokinetic studies in humans.  
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To enable quantification and a possible clinical translation, in Chapter 6 one of 
the members of the family of HQ5 cyanine dyes, HQ4, was conjugated with 
Indium-111 as radiolabel via the chelate DTPA. This chapter illustrates that 
also after radiolabeling the necrosis avidity was still intact and could be 
visualized both with the fluorescence- and the radiolabel. Moreover, due to 
radiolabeling, the specificity of the probe in vivo could be demonstrated. It 
was shown that the uptake was not solely due to the enhanced permeability 
and retention (EPR) effect. Latter could be caused by the positive charge of 
the HQ-compound, conceivably leading to binding to albumin. By comparing 
the radiolabel alone with radiolabeled HQ4, a significant difference in tumor 
uptake could be measured.  
 
In Chapter 7 another imaging modality, optoacoustic tomography, was 
validated. In this chapter, the performance of the probe was confirmed as a 
truly multimodal contrast agent for both superficial and deeply situated tumor 
imaging. Based on the obtained results, the necrosis avid contrast agent, HQ4, 
has the potential to be clinically translated for multiple purposes. One of those 
purposes is the evaluation of treatment (chemotherapy and or radiotherapy) 
response, which was already successfully tested in Chapter 6, by monitoring 
chemotherapy response, at clinically relevant dose levels. Chapter 7 further 
elucidates its use in monitoring radiotherapy induced tumor cell death. 
Nowadays, measuring treatment response is mostly performed with 
18
F-
fluorodeoxyglucose (FDG), the most widely available PET-tracer 
45
. In several 
tumor types, FDG-PET showed a high predictive value to assess tumor 
response early after start of treatment. The disadvantage of FDG is that it is 
taken up by cells with an increased glucose metabolism. Macrophages, often 
involved in the removal of necrotic tumor cells, also accumulate FDG. In 
addition, it is challenging, during radiotherapy, to discriminate between FDG 
uptake in tumor cells or radiation-induced inflammation, inducing an 
underestimation of the treatment response. Nevertheless, it is already proved 
for both lung and rectal cancer patients treated with chemoradiotherapy that 
the alteration in glycolysis level or standard uptake value during therapy was 
predictive for progression-free survival. In addition, scans obtained 3 months 
post-treatment showed a clear positive correlation between FDG uptake and 
patient outcome 
25,46-50
. Another promising PET-tracer is 
18
F-fluorothymidine 
(FLT) which detects cell proliferation; the uptake is positively correlated with 
cell growth. It has been found that, in preclinical research, FLT is superior to 
FDG and that it is a sensitive and early predictor of therapy response in various 





. In clinical practice, however, is found that the sensitivity of FLT 
is lower compared to FDG and that a decrease in uptake during therapy is not 
associated with a longer overall survival which makes it less suitable to use for 
treatment evaluation and adaptive therapies 
48
. As mentioned above, there 
are a couple of other promising agents in several stages of clinical 
development which can also be used for the same purpose. Unfortunately, it 
is not possible to compare these probes with the results obtained with HQ4 
(Chapter 6 & 7), since each of the probes visualizes another biological process. 
Necrosis is the only process which is in general not present in healthy tissue 
though also not solely linked to cancer.  
For longitudinal monitoring of treatment responses most probes could be 
used as an increased cell metabolism, cell proliferation, apoptosis and necrosis 
are all taking place in the tumor environment. However, the use of HQ4 is in 
this form the least favorable, as it is coupled to the SPECT isotope Indium-111, 
which has a long half-life. SPECT has a lower intrinsic resolution and sensitivity 
as compared to PET. An isotope with a longer half-life, however, is necessary 
as it takes about 24h before HQ4 reaches its most optimal TBR. Indium-111 
could be replaced by a PET isotope like Zirconium-89 to be able to image it 
with PET. However, DTPA is not the most optimal chelate to incorporate 
Zirconium-89, desferrioxamine (DFO) is a better alternative 
52
. Nonetheless, 
HQ4 can be a suitable theranostic agent, since instead of Indium-111, also 
Ytrium-90 or Lutetium-177 can be incorporated.  
 
  




Over the last years a lot of anticancer drugs have been developed. 
Unfortunately, only a small percentage reached the clinical market. The same 
is true for targeted contrast agents. Due to a high level of tumor heterogeneity 
in human cancer it will be difficult to find one suitable, personalized target 
which will target the whole tumor. Instead of using one target it is probably 
more favorable to use a variety of targets combined in one targeted contrast 
agent. In this way, one could create the potential to target and visualize 
multiple receptors at the same time. The question which markers to combine 
is difficult to answer and depends on two main points. The first point is related 
to the tumor to be imaged. Suggestions would be to combine markers towards 
targets directed to one of the biological processes mentioned in the 
“hallmarks of cancer” instead of combining highly specific markers 
downstream the cascade 
18,53
. Additionally, literature already showed that 
targeting multiple pathways is more effective compared to targeting multiple 
targets of one pathway, especially when the tumor is trying to bypass a certain 
pathway, in case of multidrug resistance 
10,54
. This also accounts for the 
development of a broadly applicable targeted contrast agent. Final suggestion 
would be to combine markers which are known to be upregulated in different 
phases of the disease development to increase sensitivity. The second point to 
take into account when combining targets is the chemical construction and 
pharmacological behavior of such probes: its physicochemical character. This 
character can be partly predicted by the use of quantitative structure activity 
relations (QSAR) modelling. Nevertheless, in general, an increase in size and 
alteration in charge will influence the clearance and biodistribution of a probe 
55-57
. In addition, some combinations of targeting moieties or imaging agents 
can interact with each other by which they could block their function or lose 




Combining imaging modalities  
As already concluded above there is not a single imaging modality which could 
be used for all purposes. Combining imaging modalities is an option to 
circumvent this problem. Unfortunately, the generation of hybrid imaging 
modalities is only feasible with a limited number of machines. Nevertheless, 
fusing of the images obtained is always an option.  Combining analysis data of 
different modalities instead of analyzing each modality separately will create a 
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high-dimensional dataset. New methods to analyze such data sets are under 
development, like t-distributed stochastic neighbor embedding (t-SNE). T-SNE 
will give more detailed information and will hopefully reveal new relationships 
which could be used to stratify patients before they start with their cancer 
treatment or during neoadjuvant treatment 
59
. However, it will be demanding, 
if ever possible, to use this during IGS, where analyses and feedback need to 
be performed fast and real-time. 
 
In Chapter 4 MSOT is introduced to overcome the limited penetration depth 
of FGS. In this chapter, the preclinical MSOT machine is used, showing 
promising results, however, it is still limited by relatively long acquisition and 
reconstruction times. These long acquisition times are necessary due to the 
limited sensitivity as compared to fluorescence only imaging systems. 
Nowadays, clinical MSOT systems, used in combination with ICG, are available 
and the time to capture single cross-sectional images is reduced to less than 1 
ms 
60
. In addition, the concentration of ICG for SLN detection in melanoma 
using either MSOT or fluorescence is relatively similar with a dose of 0.5 mg 
ICG injected around the tumor 
60,61
. Hopefully, newer generations of this 
imaging system will reach higher sensitivity, which is of importance to further 
increase the resolution, to reduce the dose of the contrast agent and/or to 
decrease image acquisition time. In addition, as it is impossible to chemically 
link a targeting agent to ICG, ICG will be replaced in the future for another 
fluorophore, such as IRDye800CW combined with a targeting agent, which will 
hopefully improve detection sensitivity even further. The future perspective 
would then be that MSOT could be used both for image guided surgery and 
for diagnostic imaging purposes, for instance for treatment monitoring of not 
only superficially located melanoma but also for deeper-located tumors. 
Nowadays, for instance, human breast cancer is already visualized via a label-
free method, reaching imaging depths of up to 2.5 cm 
62
. Nevertheless, 
reaching an imaging depth of over 5 cm, at least necessary for full clinical 
usage, will not be reached with this technique so far. However, when MSOT 
would become available as endoscopic tool, this penetration depth would be 
sufficient in for example rectal cancer Watch & Wait strategies.  
 
The Watch & Wait strategy offers a lot of opportunities for patients with a 
complete clinical response after neoadjuvant therapy for rectal cancer and 
oesophageal cancer patients. When those patients could be identified before 
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surgery, unnecessary procedures and subsequent postoperative morbidity 
could be avoided. However, for those patients it is essential to keep them 
under a strict follow-up regimen to detect possible local recurrences in an 
early stage 
63,64
. During the follow-up period the use of personalised imaging 
with targeted contrast agents is obligatory. For Watch & Wait PET-CT for total 
body imaging could be used in combination with an endoscopic modality by 
either fluorescence or MSOT. 
 
Combining therapy and diagnostics  
Theranostics combines diagnostics and therapeutics to eliminate multi-step 
procedures and increase efficacy by using the diagnostic agent to visualize 
whether the proposed treatment will arrive at the tumor site 
65,66
. By using 
click chemistry this efficacy can be even further improved as click chemistry 
combines the beneficial targeting properties of, in general, antibodies to reach 
high TBRs, with the fast pharmacokinetics of small molecules for therapeutic 
agents 
67,68
. The method relies on a two-step approach in which in the first 
step an antibody, labeled with a click label, is injected. After a couple of days, 
when the antibody is accumulated in the tumor and cleared from the blood, 
the second part is injected consisting out of a radionuclide combined with the 
opposite site of the click label. As the radiolabel is relative small it will be 
cleared fast from the blood and does not accumulate in other parts than the 
tumor 
67
. Such an approach is investigated for radioimmunotherapy, however, 
can also be used for IGS in combination with radionuclide therapy 
67,68
. 
Administer a patient a couple of days before surgery with the first agent, now 
additionally labelled with a NIR fluorophore to use during surgery. Afterwards 
the second part is injected to treat possible tumor residues with targeted 
radionuclide therapy based on the same probe.  
 
To finish, as the Chinese philosopher Lao Tzu quoted; “the journey of a 
thousand miles begins with one step”, which means in the context of the 
present thesis: “to beat a high variety of cancer types, all knowledge gained is 
a little step forward in unraveling the behavior of cancer. Each tiny little step 
will help in the fight against cancer and I hope that this thesis provided such 
tiny step forward in the right direction!” 
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Op dit moment is kanker één van de belangrijkste doodsoorzaken in de wereld 
met circa 14 miljoen nieuw gediagnosticeerde gevallen in 2012 en rond de 20 
miljoen in 2025. Dit betekent dat het risico dat iemand kanker krijgt nu al op 
18.5% ligt en alleen nog maar verder gaat stijgen. Het doel van het onderzoek 
uitgevoerd in dit proefschrift is dan ook om een bijdrage te leveren aan zowel 
de diagnostiek als behandeling van kankerpatiënten. De meest gebruikte 
behandelingen voor kanker zijn: chirurgie, systemische therapie of 
radiotherapie. Vaak zal er voor een combinatie van deze behandelingen 
worden gekozen en wanneer mogelijk maakt chirurgie daar deel vanuit. Voor 
alle combinaties geldt dat het doel is om het kankergezwel in zijn geheel te 
verwijderen. Wanneer chirurgie in eerste instantie niet goed mogelijk is, dan is 
het soms mogelijk om eerst een andere behandeling te geven om de tumor te 
verkleinen. Indien dit succesvol blijkt, dan hoopt men in tweede instantie de 
tumor alsnog operatief te kunnen verwijderen (Figuur 1).  
 
Tegenwoordig is één van de speerpunten in de behandeling van 
kankerpatiënten om deze meer patiënt- en doelgericht te maken. Op deze 
manier hopen we de nauwkeurigheid om kankercellen te vernietigen te 
verhogen en om daarnaast meer gezond weefsel te kunnen sparen. Er zijn 
meerdere manieren om dit aan te pakken en te verbeteren.  
 
 
Figuur 1: Kanker behandeling  
IGS= image-guided surgery = beeldgeleide chirurgie 
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Dit proefschrift bestaat uit twee delen, in het eerste gedeelte wordt de 
mogelijke meerwaarde van beeldgeleide chirurgie besproken en 
bediscussieerd. Het onderzoek dat in dit gedeelte is uitgevoerd, toont aan dat 
beeldvorming van grote meerwaarde kan zijn tijdens de operatie. Het 
slagingspercentage hiervan is echter afhankelijk van de keuze van de 
beeldvormende modaliteit in combinatie met het target waartegen het 
contrastmiddel gericht is. In het tweede gedeelte van het proefschrift wordt 
een stof getest die necrose, onnatuurlijke celdood, aantoont. In dit gedeelte 
wordt succesvol aangetoond dat deze stof gebruikt zou kunnen worden als 
biomarker voor een vroege evaluatie van de behandelrespons tijdens een 
kankerbehandeling.  
 
Deel I: Beeldgeleide Chirurgie 
 
Voor de start van een behandeling van een kankerpatiënt, met een solide 
tumor, worden er verschillende vormen van beeldvorming gedaan om een 
goed overzicht te krijgen van de conditie van de patiënt en voor de stadiëring 
van de tumor. Tijdens een operatie is het beeld echter veranderd doordat de 
anatomie van alle weefsels gewijzigd is. Het vaststellen van de rand van de 
tumor kan dan dus niet meer op basis van de voorafgaande beeldvorming 
adequaat gedaan worden maar moet gedaan worden door visuele inspectie 
en palpatie door de chirurg. Complete verwijdering van een tumor wordt dan 
bepaald op basis van palpabel en visueel afwezig tumorweefsel. De 
bevestiging of dit juist was wordt bepaald door histologische inspectie van het 
uitgenomen weefsel door de patholoog, echter de resultaten hiervan zijn 
ongeveer een week na de operatie bekend met alle consequenties van dien. 
Het grote voordeel van beeld- of moleculair geleide chirurgie is dat, door de 
toevoeging van deze nieuwe techniek, de chirurg een directe terugkoppeling 
krijgt over het weefsel wat hij uitgenomen heeft door een verbetering van het 
zicht.  
 
Over het algemeen kan ieder element in een tumor dat specifiek geactiveerd, 
tot expressie gebracht of overgereguleerd wordt, dienen als doelwit voor 
beeldgeleide chirurgie. Op dit moment zijn een groot aantal van dit soort 
‘elementen’ of biomarkers voor optische beeldvorming in verschillende fases 
van onderzoek, waarbij veelbelovende resultaten worden verkregen. Deze 
studies tonen aan dat de standaard chirurgische procedure niet negatief 
wordt beïnvloed door het gebruik van optische beeldvorming en dat de tumor 
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zonder vertraging “live” in beeld kan worden gebracht. De twee grootste 
problemen die gezien worden is het hoge aantal vals-positieve bevindingen en 
daarmee de overbehandeling van patiënten en de minimale penetratie diepte 
van optische beeldvorming. Voor de ontwikkeling van nieuwe beeldgeleide 
technieken zijn doelgerichte contrast middelen noodzakelijk die een hoge 
weefsel specificiteit hebben met daarbij een hoge tumor-achtergrond ratio 
voor een meer specifieke en gedetailleerde visualisatie van de tumor 
(hoofdstuk 3). Daarnaast is het zinvol om op zoek te gaan naar alternatieve 
beeldvormende modaliteiten of combinaties hiervan (hoofdstuk 2 & 4)  
 
In Hoofdstuk 2 worden tien verschillende innovatieve en beschikbare 
beeldvormende modaliteiten, die tijdens de operatie gebruikt zouden kunnen 
worden, met elkaar vergeleken vanuit een klinisch oogpunt. De conclusie die 
in dit hoofdstuk getrokken wordt, is dat geen enkele beeldvormende 
modaliteit op zichzelf in staat is om al het noodzakelijke weer te geven. Het 
gebruik van multimodale beeldvorming is vereist om op die manier de 
voordelen te laten prevaleren boven de nadelen. De betrouwbaarheid en 
beeldkwaliteit van de meeste van deze modaliteiten kan verbeterd worden 
door het gebruik van doelgerichte contrastmiddelen. Hierbij lijken specifieke 
“doelen”, die ruimschoots aanwezig zijn op het celoppervlak van tumorcellen 
en afwezig zijn bij gezonde cellen, de beste en meest kansrijke kandidaten 
voor beeldgeleide chirurgie.  
 
In Hoofdstuk 3 worden twee biomarkers; EphA2 en EphB4 met elkaar 
vergeleken. Beide worden tot over-expressie gebracht bij de meerderheid van 
patiënten met een colorectale tumor. Om de verschillen in expressie tussen 
tumor en nabijgelegen gezond weefsel in beeld te brengen werd een 
scoringsdiagram ontwikkeld. Dit gaf in één oogopslag weer dat hoewel beide 
biomarkers tot over expressie werden gebracht, alleen EphB4 een duidelijk 
verschil toonde in vergelijking met gezond weefsel.  
 
In Hoofdstuk 4 wordt de meerwaarde van multi-spectrale optoacoustische 
tomografie (MSOT) aangetoond. MSOT is vergelijkbaar aan optische 
fluorescente beeldvorming, alleen gebruikt MSOT licht als bron en geluid voor 
signaal detectie, waardoor de penetratie diepte groter is. Dit hoofdstuk toont 
de meerwaarde van 3D over 2D beeldvorming aan, onafhankelijk van de 
techniek die gebruikt wordt. Daarnaast wordt hard gemaakt dat een 
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combinatie van anatomische en functionele beeldvorming onontbeerlijk is 
voor het verkrijgen van een compleet overzicht van de tumor voor de 
operatie. 
 
Deel II: Beeldvorming van Necrose 
 
Celdood is een essentieel proces in het menselijke lichaam om in zijn geheel te 
kunnen overleven. Tumor celdood is meestal het effect van een 
kankerbehandeling en hoewel geïnduceerd van buiten het lichaam 
noodzakelijk om patiënten kanker te laten overleven. In dit gedeelte van het 
proefschrift doen we de aanname dat een verhoging van de hoeveelheid 
celdood in een tumor een teken is dat een patiënt reageert op de 
behandeling. Dit is een aanname, omdat het ook mogelijk is dat door de 
behandeling de biologische systemen rond een tumor geactiveerd worden en 
dat de tumor daardoor zelfs sneller gaat groeien. Ook dit proces zal celdood 
veroorzaken in de kern van de tumor, daar de bloedvaten niet zo snel mee 
kunnen groeien. Zowel respons op de behandeling als het sneller groeien van 
de tumor leidt tot celdood echter alleen een respons op de behandeling is een 
positief teken. De tweede aanname is dat necrose de belangrijkste vorm van 
celdood is, die plaatsvindt tijdens het behandelproces van kankerpatiënten. 
Deze aanname doen we omdat necrose geclassificeerd wordt als onnatuurlijk 
en veroorzaakt door directe onherstelbare schade aan de cel. Echter, volgens 
de internationale classificaties van celdood, zijn er 13 verschillende vormen 
van celdood te onderscheiden. Elke vorm heeft zijn eigen karakteristieken. 
Hoogstwaarschijnlijk vindt er dus een combinatie van verschillende vormen 
van celdood plaats na een behandeling.  
 
In Hoofdstuk 5 werd aangetoond dat de twee gecarboxyleerde cyanine 
kleurstoffen, HQ5 en IRDye800CW, een sterke aantrekkingskracht tot necrose 
hebben. Het exacte mechanisme waarmee ze binden op moleculair niveau is 
onduidelijk. We weten dat deze stoffen zich richten op cytoplasmatische 
eiwitten, die beschikbaar komen nadat de membraan integriteit verbroken is. 
Hiermee is de aanname uit bovenstaande alinea gerechtvaardigd, aangezien 
het eindpunt bij vele vormen van celdood het verlies van de membraan 
integriteit is. 
 
Om deze stoffen in de toekomst klinisch bruikbaar te maken en om de 
hoeveelheid celdood te kunnen kwantificeren hebben we in Hoofdstuk 6 één 
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van de leden van de HQ5 familie, HQ4, gekoppeld met een radioactief label. In 
dit hoofdstuk hebben we laten zien dat na deze koppeling er nog steeds 
binding aan necrose plaatsvindt en dat deze binding specifiek is. Hierdoor 
heeft HQ4 de potentie om gebruikt te gaan worden voor meerdere klinische 
toepassingen. Eén van de belangrijkste toepassingen is de evaluatie van 
behandelrespons. In Hoofdstuk 6 laten we zien dat dit mogelijk is in met 
chemotherapie behandelde muizen, en in Hoofdstuk 7, door muizen te 
behandelen met radiotherapie.  
 
Daarnaast testen we in Hoofdstuk 7 ook een andere beeldvormende 
modaliteit, optoacoustische tomografie, voor de detectie van necrose met 
behulp van HQ4. In dit hoofdstuk is aangetoond dat HQ4 een multimodaal 
contrastmiddel is voor de beeldvorming van zowel oppervlakkig als dieper 
gelegen weefsels. De resultaten uit dit deel van het proefschrift laten zien dat 
contrastmiddelen gericht tegen necrose de potentie hebben om in de kliniek 
gebruikt te worden voor zowel diagnostische, prognostische als 
therapeutische doeleinden.  
 
Toekomst Perspectief  
 
Kort samengevat laten de onderzoeken in dit proefschrift zien dat er meerdere 
veelbelovende technieken in ontwikkeling zijn, die mogelijk van meerwaarde 
kunnen zijn bij beeldgeleide chirurgie en behandel evaluatie van 
kankerpatiënten. Dit proefschrift toont ook aan dat het noodzakelijk is om 
modaliteiten te combineren, om de behandeling van kankerpatiënten verder 
te kunnen verbeteren. In dit proefschrift werd gekozen voor een combinatie 
van beeldvormende technieken en biomarkers. Een andere mogelijkheid is het 
combineren van diagnostiek en therapie, theranostiek. Theranostiek kan een 
combinatie zijn van diagnostiek gevolgd door therapie waarbij de diagnostiek 
gebruikt wordt om te onderzoeken of de therapie aan gaat slaan. Daarnaast 
kan theranostiek ook therapie gevolgd door diagnostiek zijn om vroege 
behandel respons vast te legen. De laatste mogelijkheid is dat diagnostiek en 
therapie tegelijkertijd worden uitgevoerd. Het doel van theranostiek is dat er 
gepersonaliseerde behandelingen gegeven worden. De juiste behandeling 
wordt dan aan de juiste patiënt gegeven. Het maakt de patiëntenzorg 
efficiënter en tevens (kosten) effectiever. Doordat patiënten minder belast 
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worden met onnodige bijwerkingen, zorgt dit tevens voor een verbetering van 
de kwaliteit van leven.  
Ik zou willen afsluiten met een citaat van de Chinese filosoof Lao Tzu; “een reis 
van duizend kilometer begint met één enkele stap”. In de context van mijn 
proefschrift heeft dit voor mij de volgende betekenis: om een hoge variëteit 
aan kankersoorten te verslaan is iedere stap voorwaarts er één. Met elke stap 
kunnen we het gedrag van kanker en het complete biologische proces 
erachter iets verder ontrafelen, met als doel kanker in de toekomst nog beter 
te kunnen behandelen. Ik hoop dat dit proefschrift bijgedragen heeft met een 
kleine stap voorwaarts in de juiste richting! 
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List of Abbreviations 
 
%ID/g Percentage injected dose per gram 











AI Amphiphilicity index 
5-ALA 5-aminolevulinic acid 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
AVF Annexin V-FITC 
BED Biological effective dose 
BF Bright-field 
BLI Bioluminescent imaging 
BSA Bovine serum albumin 
CA Contrast agent 
CBG99 Green click beetle luciferase 
CBN Conjugated bond number 
CLI Cherenkov luminesce imaging 
cRGD c[RGDyK], cyclo (Arginine- Glycine – Aspartic acid-Tyrosine- Lysine) 
CT Computed tomography 
CTX Cyclophosphamide 
DAMP Damage-associated molecular pattern 
DNA Deoxyribonucleic acid 
DTPA Diethylene triamine pentaacetic acid 
EGF Epidermal growth factor 
EphA2 Erythropoietin-producing hepatocellular carcinoma  receptor A2 
EphB4 Erythropoietin-producing hepatocellular carcinoma  receptor B4 
EPR Enhanced permeability and retention 
ERC European research council 
ETO Etoposide 
FACS Fluorescence-activated cell sorting 
FDA Food and Drug Administration 
FDG Fluorodeoxyglucose 
FFPE Formalin-fixed paraffin-embedded 
FGD Fluorescence-guided dissection 
FGS Fluorescence-guided surgery 
FITC Fluorescein isothiocyanate 
FLI Fluorescence imaging 
FOV Field of view 
FP7 Seventh framework programme 
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FWHM Full width half maximum 
GA Gambogic acid 
GFP Green fluorescent protein 
GLUT Glucose receptor-1 
GMP Good manufacturing practices 
HIPEC Hyperthermic intra-peritoneal chemotherapy 
H&E Hematoxylin and Eosin 
H&N Head and neck 
H2020 Horizon 2020, funding programme 
ICD Immunogenic cell death 
ICG Indocyanine green 
iCT Intraoperative computed tomography 
IGS Image-guided surgery 
IGOS Image-guided oncologic surgery 
IHC immunohistochemistry 
iMRI Intraoperative magnetic resonance imaging 
ioUS Intraoperative ultrasound 
logP Log octanol-water partition coefficient, Lipophilicity 
MALDI Matrix assisted laser desorption/ionisation 
MIP Maximum intensity projection 
MR Magnetic resonance 
MRI Magnetic resonance imaging 
mRNA Messenger Ribonucleic Acid 
MSCA Marie Skłodowska-Curie actions 
MSOT Multispectral optoacoustic tomography 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) 
Mw Molecular weight 
N/T Normal to tumor 
NACA Necrosis avid contrast agent 
NCI National Cancer Institute 
NHS N-Hydroxysuccinimide 
NIH National Institutes of Health 
NIR (F) Near- infrared fluorescence 
NL Not labeled 
OA Optoacoustic imaging 
OCT (1) Optical coherence tomography  
OCT (2) Optimum cutting temperature 
OR Operating room 
OSEM Ordered subset expectation maximization 
PA Photoacoustic 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
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PDAC Pancreatic ductal adenocarcinoma 
PDT (1) Photodynamic therapy  
PDT (2) Population doubling time 
PEG Polyethylene glycol 
PET Positron emission tomography 
PI Propidium iodide 
POSEM Pixel-based ordered subset expectation maximization 
PS Phosphatidylserine 
qPCR Realtime PCR 
QSAR Quantitative Structure Activity Relations 
R0 resection Radical resection 
R1 resection Irradical resection 
RA Radioactivity 
RECIST Response Evaluation Criteria in Solid Tumors 
REIMS Rapid evaporative ionization mass spectrometry 
REMARK REporting recommendations for tumor MARKer prognostic studies 
RIP-1 Receptor-Interacting Protein 1 
ROI Region of interest 
ROS Reactive oxygen species 
RS Raman spectroscopy 
RT Room temperature 
RT Radiation therapy 
S/B Signal-to-background 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SGC Small gamma camera 
SLN Sentinel lymph node 
SNR Signal to noise ratio 
SOP Standard operating protocol 
SPECT Single-photon emission computed tomography 
Sta Staurosporine 
SUV Standard uptake value 
TBR Tumor to background ratio 
TCO Trans-Cyclooctene 
TMA Tissue microarray 
TNM Tumor node metastasis classification of malignant tumors  
TNT Tumor necrosis targeting 
TOF Time of flight 
TUNEL TdT-mediated dUTP Nick-end labelling 
US Ultrasound 
Z Electric charge  
λabs Absorbance wavelength 
λem Emission wavelength 
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Yes, de dag waarvan ik op een gegeven moment dacht, dat die nooit ging 
komen, is daar en ik mag dit dankwoord schrijven! Een berg beklimmen kost 
doorzettingsvermogen en datzelfde geldt voor promoveren. Daarnaast beklim 
je een berg nooit alleen, je hebt hulp en vooral mentale ondersteuning van de 
mensen om je heen nodig. Ook hiervoor geldt dat dit vergelijkbaar is met het 
doen van onderzoek en promoveren, er moeten nu eenmaal bergen werk 
verzet worden. Vaak wordt deze ondersteuning als normaal opgevat, alhoewel 
dat volstrekt niet vanzelfsprekend is. Dat ik figuurlijk de ene voet voor de 
andere ben blijven zetten, gestaag klimmend naar het einddoel toe, is te 
danken aan de mensen om me heen, mijn figuurlijke steenmannetjes, die me 
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het woord richten.  
 
Ten eerste wil ik Clemens en Alan bedanken voor de mogelijkheid om aan dit 
promotietraject te beginnen.  
 
Lioe-Fee, ergens halverwege de rit ben je op mijn bergpad gekomen en ik ben 
je daar enorm dankbaar voor. Ik heb je meerdere malen gevraagd of je nog blij 
was dat ik op jouw pad ben verschenen, maar onder het motto; “we gaan dit 
gewoon samen aanpakken” hebben we de top gehaald.  
 
Als ik de weg weer eens dreigde kwijt te raken of er een obstakel op de weg 
lag, dat ik niet zelf kon opruimen, kon ik altijd bij jullie langs: Alex, Boudewijn 
en Kees ontzettend bedankt voor jullie steun de afgelopen jaren! 
 
Voor een bergbeklimming is niet alleen kracht maar ook techniek nodig. Wat 
betreft het onderzoek hebben Vicky, Marieke, Henny en Karien geprobeerd 
om hun laboratorium technieken gedeeltelijk op me over te brengen. Bedankt 
voor het altijd meedenken in oplossingen, in plaats van in problemen, zodat ik 
weer verder kon. 
 
Annemieke en Marieke, wat fijn dat jullie me tijdens het laatste stukje van 
mijn bergbeklimming ondersteunen, hiervoor heb je mensen nodig die je 
volledig kunt vertrouwen. Dat kan ik zonder enige twijfel. Bedankt dat ik altijd 
bij jullie terecht kon en kan, tijdens mijn verdediging.  
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Mark en Hein, samen hebben we heel wat uurtjes op E0 doorgebracht. Ook al 
ben je daar nooit alleen vanwege onze kleine vriendjes, samen is het toch 
gezelliger en gaat het werk ook sneller. In dit kader wil ik ook Fred & Ben 
bedanken voor de goede zorgen voor mijn kleine vriendjes.  
 
Pia, Judith and Jolijn, it was a pleasure guiding you with your first steps in a 
research environment. Besides, you gave me a fresh view on research and a 
lot of energy with your enthusiasm. 
 
In the past years I have seen a lot of rooms, roommates and departments 
within and outside of the LUMC. Different people in different periods have 
contributed (in) directly to this thesis. Mention a couple of them would do 
others shortage so I keep it to: Bedankt, Thanks, Danke, Merci, Grazie, Gracias, 
Domo arigatou, Terima Kasih and Xièxie.  
 
Next to the LUMC, I did spend some time abroad in both the Princess 
Margaret Cancer Center in Toronto and the University Medical Center 
Göttingen. Ralph and Azusa thanks for hosting me, doing all the experiments 
together and for taking care of me outside work hours. Frauke, Joanna, Anne 
and others thank you for your hospitality, I always felt very welcome when I 
was at your place.  
 
In general, I want to thank all the partners from the H2020 MSCA-RISE PRISAR 
project. Working together with you inside this project has widened my 
scientific view in multiple directions. I really liked the interaction with all the 
different disciplines. I also want to thank all the co auteurs for the research we 
performed together, our cooperation yielded great publications. 
 
Eline, Ellart, Gertjan, Ilse, Lianne, Lieke, Maartje, Wina en Yolanda bedankt 
voor jullie luisterend oor de afgelopen jaren, maar ook voor de gezelligheid en 
de momenten van ontspanning samen, vaak met een lekker hapje en/of 
drankje. 
 
De meiden van de handbal wil ik ook bedanken dat ze me de kans gaven om 
mijn frustraties af te reageren op de bal. Hierbij hebben vooral de keepers het 
soms zwaar te verduren gehad. Sorry hiervoor, ik beloof vanaf nu beterschap!  
 
Pap, Mam en Rick, bedankt voor jullie steun en dank dat jullie altijd achter me 
blijven staan. Soms konden jullie niet meer doen dan alleen luisteren maar nu 
kunnen jullie er ook naar kijken! 
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